Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Vaccines

  Free Subscription


Articles published in Vaccine

Retrieve available abstracts of 1329 articles:
HTML format



Single Articles


    July 2025
  1. MARANGOU J, Beaton A, Fulurija A, Carapetis J, et al
    Cardiac monitoring safety assessment framework for early phase group a streptococcal vaccine trials.
    Vaccine. 2025;60:127334.
    PubMed     Abstract available


  2. NJOH AA, Dinga JN, Kongnyuy EJ, Ndoula TS, et al
    Malaria vaccine acceptance and associated factors in cameroon: A nationwide cross-sectional survey.
    Vaccine. 2025;60:127323.
    PubMed     Abstract available


  3. STOUTEN V, Van Evercooren I, Vernemmen C, Braeye T, et al
    Averted mortality by COVID-19 vaccination in Belgium between 2021 and 2023.
    Vaccine. 2025;60:127290.
    PubMed     Abstract available


  4. PIAL RH, Capeding MR, Song KR, Park EL, et al
    Immune persistence after 5 years of vaccination by Vi-DT vaccine among children below 2 years: Result from long-term observational study.
    Vaccine. 2025;60:127304.
    PubMed     Abstract available


  5. LI H, Zhang J, Guo R, Li J, et al
    Immunogenicity evaluation of a recombinant pseudorabies virus co-expressing PCV2 and PCV3 capsid proteins in mice and piglets.
    Vaccine. 2025;60:127307.
    PubMed     Abstract available


    June 2025
  6. YI Z, Owusu-Edusei K, Elbasha EH
    Economic evaluation of PCV21 in PCV-naive adults aged 50-64 years in the United States.
    Vaccine. 2025;59:127264.
    PubMed     Abstract available


  7. MUSTAJAB T, Kwamboka MS, Khan I, Song D, et al
    Immunologic responses to an extracellular vesicle-based vaccine expressing the full suite of SARS-CoV-2 structural proteins.
    Vaccine. 2025;61:127407.
    PubMed     Abstract available


  8. PHUMRATTANAPRAPIN W, Shalash AO, Skwarczynski M, Smout MJ, et al
    Development of an efficacious oral peptide vaccine against infection with the carcinogenic liver fluke Opisthorchis viverrini.
    Vaccine. 2025;61:127400.
    PubMed     Abstract available


  9. PURCELL RA, Aurelia LC, Allen LF, Bond KA, et al
    Genetic markers of enhanced functional antibody responses to COVID-19 vaccination.
    Vaccine. 2025;61:127379.
    PubMed     Abstract available


  10. BEZELJAK U, Jerman A, Kobal T, Birsa E, et al
    Development of multivalent SARS-CoV-2 virus-like particle vaccine candidates.
    Vaccine. 2025;61:127394.
    PubMed     Abstract available


  11. HANSEN BT, Dahl J, Greve-Isdahl M, Winje BA, et al
    Low and inequitable influenza and COVID-19 vaccination coverage among pregnant women in Norway: Nationwide population-based cohort study.
    Vaccine. 2025;61:127386.
    PubMed     Abstract available


  12. PUENTE-MASSAGUER E, Vasilev K, Krammer F
    Combination of recombinant neuraminidase with cHA-based inactivated split vaccines improves the breadth of cross-reactivity and protection against influenza viruses in mice.
    Vaccine. 2025;61:127388.
    PubMed     Abstract available


  13. ESPARZA J
    The illness of empress Maria Theresa as a trigger for the adoption of variolation in Austria (1768).
    Vaccine. 2025;58:127253.
    PubMed     Abstract available


  14. LUYTEN J, van Hoek AJ
    Reasons for excluding adverse events in cost-effectiveness analyses of vaccines: A survey amongst authors.
    Vaccine. 2025;61:127341.
    PubMed     Abstract available


  15. JORDAN Z, Roderick M, Marlow R, Rowland E, et al
    "I'm not aware of anyone having died from chickenpox?": Acceptability of varicella vaccination in the UK, a mixed methods questionnaire and interview study.
    Vaccine. 2025;61:127322.
    PubMed     Abstract available


  16. HASSAN IA, Araoye JB, Olawuyi DA, Effiong FB, et al
    Malaria vaccine implementation in Nigeria: Addressing the coverage challenges within the national immunization program for high impact.
    Vaccine. 2025;61:127376.
    PubMed     Abstract available


  17. FAWOLE A, Boyer B, Shahid M, Bharali I, et al
    What are the key features of an equitable global vaccine strategy for the next pandemic? A qualitative study of pandemic control experts.
    Vaccine. 2025;61:127377.
    PubMed     Abstract available


  18. QIN XX, Deng M, Wu J, Yang J, et al
    Cellular response, persistent humoral response and efficacy elicited by a CV-A16 vaccine candidate in mice.
    Vaccine. 2025;61:127276.
    PubMed     Abstract available


  19. OMAR M, Shibli H, Edelstein M
    Comparative impact of the COVID-19 pandemic on parental behaviour towards childhood vaccination in Israel and the United Kingdom: A self-controlled matched cross-sectional study.
    Vaccine. 2025;61:127385.
    PubMed     Abstract available


  20. KEUTLER A, Lainka E, Hudert C, Bufler P, et al
    Erratum to "Safety and immunogenicity of the measles-mumps-rubella vaccine in immunocompromised children with inflammatory bowel disease, or after liver transplantation: An observational study" [Vaccine 59 (2025) 127288].
    Vaccine. 2025;61:127357.
    PubMed    


  21. BERGER MN, Davies C, Mathieu E, Harmer-Ross J, et al
    Perceived safety, usability, and acceptability of microarray patches for vaccination among key populations: A mixed methods study.
    Vaccine. 2025;61:127387.
    PubMed     Abstract available


  22. LAMBACH P, Silal S, Sbarra AN, Koh M, et al
    Report from the World Health Organization's immunization and vaccines-related implementation research advisory committee (IVIR-AC) meeting, virtual gathering, 17-21 February 2025.
    Vaccine. 2025;61:127384.
    PubMed     Abstract available


  23. DONG X, Schillie SF, McNamara LA, Leidner AJ, et al
    Cost-effectiveness of pentavalent meningococcal (MenABCWY) vaccination among adolescents in the United States.
    Vaccine. 2025;61:127332.
    PubMed     Abstract available


  24. MARTINS RM, Maia MLS, Camacho LAB, Noronha TG, et al
    Phase II/III randomized immunogenicity and safety study of a Brazilian meningococcal serogroup B vaccine in children.
    Vaccine. 2025;61:127363.
    PubMed     Abstract available


  25. SIEVERS BL, Sievers EL
    It's time to change how we vaccinate for measles.
    Vaccine. 2025;61:127382.
    PubMed     Abstract available


  26. LAPEYRE R, Rezk N, McClean S, Moore AC, et al
    Systematic mapping review of preclinical and clinical studies of Staphylococcus aureus vaccines.
    Vaccine. 2025;61:127333.
    PubMed     Abstract available


  27. ALSHURMAN BA, Majowicz SE, Grindrod K, Goh J, et al
    Psychometric validation of the COVID-19 vaccine hesitancy scale for primary and booster doses among university students: A cross-sectional study.
    Vaccine. 2025;61:127368.
    PubMed     Abstract available


  28. GARFIELD S, Ali F, Murdan S
    Enhancing faith and interfaith based facilitators and reducing related barriers to enhance vaccine acceptance: a qualitative study.
    Vaccine. 2025;61:127348.
    PubMed     Abstract available


  29. ROSENMAN KD, Wang L
    Variation of COVID-19 vaccination percentage by industry and occupation in Michigan.
    Vaccine. 2025;61:127349.
    PubMed     Abstract available


  30. TSCHERNE A, Krammer F
    A review of currently licensed mucosal COVID-19 vaccines.
    Vaccine. 2025;61:127356.
    PubMed     Abstract available


  31. KIM SH, You SH, Lee JW, Kim E, et al
    Association between COVID-19 vaccination and first healthcare utilization for chronic obstructive pulmonary disease: A nationwide population-based cohort study.
    Vaccine. 2025;61:127367.
    PubMed     Abstract available


  32. DUSSAULT JM, Rivera Torres AF, Oudin Doglioni D, Gagneux-Brunon A, et al
    The effect of school-based interventions on HPV vaccine-related knowledge, attitudes, and practices among adolescents in France: Secondary results from the PrevHPV trial.
    Vaccine. 2025;61:127344.
    PubMed     Abstract available


  33. ARCOLACI A, Guidolin L, Olivieri E, Bilo MB, et al
    A real-life multicenter experience for the post-pandemic management of hypersensitivity reactions to Covid-19 vaccines.
    Vaccine. 2025;61:127337.
    PubMed     Abstract available


  34. MOSHIRIAN FARAHI SMM, Xu Y, Dort J, Caulley L, et al
    Factors associated with COVID-19 vaccine confidence among Arab, Asian, Black, Indigenous, and White individuals in Canada: Latent profile analyses.
    Vaccine. 2025;61:127358.
    PubMed     Abstract available


  35. WILLIS DE, Moore R, Selig JP, Amin NS, et al
    Corrigendum to "Pediatric HPV vaccination: Provider recommendations matter among hesitant parents" [Vaccine 42(25) (2025) 126166].
    Vaccine. 2025;61:127343.
    PubMed    


  36. MARIN-CABA E, Benavente-Fernandez A, Morales-Jimenez G, Comino-Fernandez S, et al
    Evaluation of vaccine uptake and opportunity of in-hospital vaccination against pneumococcus in vulnerable hospitalized patients.
    Vaccine. 2025;61:127364.
    PubMed     Abstract available


  37. LIU X, Li J, Zha Y, Wang Z, et al
    The efficacy and safety of SYN023 (Zamerovimab and Mazorelvimab injection), the recombinant humanized anti-rabies virus monoclonal antibody mixture, combined with rabies vaccine in a WHO category III rabies post-exposure population: A randomized, doub
    Vaccine. 2025;61:127289.
    PubMed     Abstract available


  38. MOK CC, Chan KL, Tse SM
    Long-term immunogenicity of a live attenuated herpes zoster vaccine in patients with systemic lupus erythematosus.
    Vaccine. 2025;61:127365.
    PubMed     Abstract available


  39. CHAIWONG W, Takheaw N, Laopajon W, Nisoong C, et al
    Low-dose intradermal mRNA-1273 boosting vaccine following BBiBP-CorV vaccination during the omicron pandemics.
    Vaccine. 2025;61:127330.
    PubMed     Abstract available


  40. ROUX K, Roux F, Burns S, Guy R, et al
    Effective strategies in human papillomavirus (HPV) vaccination interventions to increase uptake in rural, low socioeconomic, indigenous and migrant populations: A scoping review.
    Vaccine. 2025;61:127359.
    PubMed     Abstract available


  41. MOHAMMADI S, Sisay MM, Saraswati PW, Osman AK, et al
    COVID-19 vaccine safety studies among special populations: A systematic review and meta-analysis of 120 observational studies and randomized clinical trials.
    Vaccine. 2025;61:127342.
    PubMed     Abstract available


  42. COSTELLO LM, Kerns EK, McCulloh RJ, Roberts JR, et al
    Hesitancy and confidence in pediatric COVID-19 vaccination among diverse caregivers of unvaccinated children.
    Vaccine. 2025;61:127245.
    PubMed     Abstract available


  43. KIM C, Lee D, Oh YW, Jung SJ, et al
    Association between parental and child influenza vaccination: A national health survey analysis.
    Vaccine. 2025;61:127345.
    PubMed     Abstract available


  44. KOBAYASHI K, Masuda K, Wu JT, Lin L, et al
    Impact of digital communication message on HPV vaccine decision-making among Japanese mothers: A randomized controlled trial.
    Vaccine. 2025;61:127327.
    PubMed     Abstract available


  45. HALONEN A, Fan HSL, Masina S, Chooniedass R, et al
    Understanding COVID-19 vaccine hesitancy during parenthood in British Columbia.
    Vaccine. 2025;61:127305.
    PubMed     Abstract available


  46. HU XX, Qin ZZ, Mo ZY, Wang R, et al
    Timeliness and completeness of serial routine vaccinations among 8062 rural children in southwest China during the COVID-19 pandemic: A multi-stage stratified cluster sampling survey in 1094 villages.
    Vaccine. 2025;61:127346.
    PubMed     Abstract available


  47. ANASTASSOPOULOU C, Panagiotopoulos AP, Ferous S, Poland GA, et al
    RSV vaccines and Guillain-Barre syndrome: Insights into an emerging concern.
    Vaccine. 2025;61:127338.
    PubMed     Abstract available


  48. AKTHER A, Laurie C, Elton-Marshall T, Ly V, et al
    Healthcare workers' current practices, knowledge/awareness, barriers, and attitudes/perceptions related to pneumococcal vaccination of older adults: A mixed-methods systematic review.
    Vaccine. 2025;61:127331.
    PubMed     Abstract available


  49. JOLFAYI AG, Alipour S, Aminizadeh S, Yaghoubi SM, et al
    Dendritic cell-based vaccines, a promising prospect for ending AIDS and eradication of HIV worldwide: A narrative review on the latest updates.
    Vaccine. 2025;61:127340.
    PubMed     Abstract available


  50. WAN JIA AARON H, Yuan R, Chan SCS
    Socio-demographic and behavioral predictors of multiple-dose COVID-19 vaccine uptake among older adults in Hong Kong: A community-based cross-sectional study of the generations connect project.
    Vaccine. 2025;61:127308.
    PubMed     Abstract available


    May 2025
  51. NG YF, Lockhart K, Dawar M, Vigor D, et al
    Assessing measles immunity among healthcare workers, a systematic review of peer-reviewed literature (2013-2023). Where do we go from here?
    Vaccine. 2025;57:127214.
    PubMed     Abstract available


  52. STEPANEK L, Nakladalova M, Borikova A, Horakova D, et al
    Measles-mumps-rubella booster and post-COVID-19 immunity: A retrospective cohort study.
    Vaccine. 2025;57:127232.
    PubMed     Abstract available


  53. SIDORENKO SV, Rennert W, Zhdanov KV, Lobzin YV, et al
    Serotype dynamics of Streptococcus pneumoniae in some countries in Eastern Europe and Central Asia.
    Vaccine. 2025;57:127213.
    PubMed     Abstract available


  54. LIEN SB, Yang QW, Huang HW, Chiu KC, et al
    A novel immunogen comprising a bc loop and mutant fusion loop epitopes generates potent neutralization and protective abilities against flaviviruses without risk of disease enhancement.
    Vaccine. 2025;57:127219.
    PubMed     Abstract available


  55. BREWER NT, Rockwell EM, Tomar A, Fisher EB, et al
    Covid-19 vaccine incentives' effectiveness and differential impact on high-risk groups: A prospective cohort study.
    Vaccine. 2025;61:127302.
    PubMed     Abstract available


  56. SAYEM ASM, Musuka G, Atuhebwe PL, Dadari I, et al
    Childhood vaccination catch-up and recovery plans for mitigating immunity gap post the COVID-19 pandemic: A case study of selected African countries.
    Vaccine. 2025;61:127328.
    PubMed     Abstract available


  57. HARTON PE, Chamberlain AT, Moore A, Fletcher G, et al
    Estimating COVID-19 vaccine effectiveness among children and adolescents using data from a school-based weekly COVID-19 testing program.
    Vaccine. 2025;61:127292.
    PubMed     Abstract available


  58. COBELENS F, Pelzer PT, Churchyard GJ, Garcia-Basteiro A, et al
    Sample size efficiency of restricting participation in tuberculosis vaccine trials to interferon-gamma release assay-positive participants.
    Vaccine. 2025;61:127301.
    PubMed     Abstract available


  59. DAVE E, Culhane JF, Lundsberg LS, Partridge C, et al
    Trends in Tdap and influenza vaccination in pregnancy relative to the coronavirus disease-19 pandemic.
    Vaccine. 2025;61:127329.
    PubMed     Abstract available


  60. YADAV G, Dandu H, Malhotra HS, Jain A, et al
    COVID-19 vaccination and utility of booster dose: A community-based cross-sectional study.
    Vaccine. 2025;60:127325.
    PubMed     Abstract available


  61. HUNG CT, Wang LM, Liu DC
    National trends and disparities in herpes zoster vaccination coverage among U.S. older adults with cancer, 2008-2023.
    Vaccine. 2025;60:127326.
    PubMed     Abstract available


  62. NASREEN S, Jiang Y, Lu H, Lee A, et al
    Risk of Guillain-Barre syndrome after COVID-19 vaccination or SARS-CoV-2 infection: A multinational self-controlled case series study.
    Vaccine. 2025;60:127291.
    PubMed     Abstract available


  63. ESCOBAR-ZIEDE P, Borras-Bermejo B, Pinos-Tella L, Vivet-Escale M, et al
    Real-world effectiveness of MBA-VN vaccine against mpox, a test-negative case-control study.
    Vaccine. 2025;59:127295.
    PubMed     Abstract available


  64. ABE M, Shinmura Y, Tokieda Y, Mitsuhiro Y, et al
    A phase I, randomized, placebo-controlled, double-blind, ascending-dose and single-center study to evaluate immunogenicity and safety of a live attenuated tetravalent dengue vaccine (KD-382) in Flavivirus antibody-naive healthy adults.
    Vaccine. 2025;60:127313.
    PubMed     Abstract available


  65. ABU-RAYA B, Giles ML, Kollmann T
    Co-administration of vaccines in pregnancy: unique challenges and knowledge gaps.
    Vaccine. 2025;60:127309.
    PubMed     Abstract available


  66. SEILER P, Kaplan BS, Brice DC, Duan S, et al
    Altered germinal center responses in mice vaccinated with highly pathogenic avian influenza A(H5N1) virus.
    Vaccine. 2025;60:127311.
    PubMed     Abstract available


  67. BHATIA D, Crowcroft N, Antoni S, Danovaro-Holliday MC, et al
    Prediction of subnational-level vaccination coverage estimates using routine surveillance data and survey data.
    Vaccine. 2025;60:127277.
    PubMed     Abstract available


  68. SENPUKU K, Kunishima Y, Taniguchi K, Ito T, et al
    Development and characterization of MRC-5 and Vero cell-adapted enterovirus D68 strains for vaccine production.
    Vaccine. 2025;60:127314.
    PubMed     Abstract available


  69. LEE N, Nguyen L, Nasreen S, Austin PC, et al
    Limited durability of protection conferred by XBB.1.5 vaccines against omicron-associated severe outcomes among community-dwelling adults, Ontario, Canada.
    Vaccine. 2025;60:127300.
    PubMed     Abstract available


  70. KATSEFF AS, Toumanios C, Barahim E, McCormick AA, et al
    PcrV in an intranasal adjuvanted tobacco mosaic virus conjugate vaccine mediates protection from Pseudomonas aeruginosa via an early Th1/Th17 skewed localized and systemic immune response.
    Vaccine. 2025;60:127306.
    PubMed     Abstract available


  71. DEVKOTA B, Lal BK, Gautam A, Poudel L, et al
    Nationwide rollout of HPV vaccination in Nepal: Early key insights.
    Vaccine. 2025;60:127312.
    PubMed    


  72. KROEGER M, Fano E, Sponheim A, Schwartz KJ, et al
    Assessment of homologous and heterologous PCV2 vaccine efficacy in a PCV2d/PRRSV co-challenge model.
    Vaccine. 2025;60:127303.
    PubMed     Abstract available


  73. MALANGE V, Mohaissen T, Conway KM, Rhoads A, et al
    Influenza vaccination during early pregnancy and risk of major birth defects, US Birth Defects Study To Evaluate Pregnancy exposureS, 2014-2019.
    Vaccine. 2025;59:127297.
    PubMed     Abstract available


  74. ALSHURMAN BA, Majowicz SE, Grindrod K, Goh J, et al
    Understanding the shift in COVID-19 vaccine hesitancy and its associated factors for primary and booster doses among university students: A cross-sectional study.
    Vaccine. 2025;59:127296.
    PubMed     Abstract available


  75. LI M, Cai W, Chandrasekhar A, Hu H, et al
    Factors associated with primary care providers' recommendation of HPV vaccination for adolescent males in China: A mixed-methods study.
    Vaccine. 2025;59:127299.
    PubMed     Abstract available


  76. LAI SW, Liao KF
    Breakthrough herpes zoster risk after recombinant zoster vaccination.
    Vaccine. 2025 May 23:127294. doi: 10.1016/j.vaccine.2025.127294.
    PubMed    


  77. BAKHT P, Hussain A, Pandey S, Pathania R, et al
    Live attenuated hfq-deleted Acinetobacter baumannii vaccine provides protection against systemic infection.
    Vaccine. 2025;59:127298.
    PubMed     Abstract available


  78. MOHAMED Y, Luey E, Kata ', Tukia O, et al
    "The only vaccine that we really question is the new vaccine": A qualitative exploration of the social and behavioural drivers of human papillomavirus (HPV) vaccination in Tonga.
    Vaccine. 2025;59:127280.
    PubMed     Abstract available


  79. RAHIMI HK, Jasim AA, Rezahosseini O, Harboe ZB, et al
    Immunogenicity and adverse effects of pneumococcal vaccines co-administered with influenza or SARS-CoV-2 vaccines in adults: A systematic review and Meta-analysis.
    Vaccine. 2025;59:127293.
    PubMed     Abstract available


  80. SHAHI N, Singh B, Pande A, Chandra S, et al
    Safe and efficacious inactivated immersion vaccine against KG+ phenotype of emerging bacterial pathogen Lactococcus garvieae for early developmental stage of rainbow trout (Oncorhynchus mykiss) in India.
    Vaccine. 2025;59:127266.
    PubMed     Abstract available


  81. KIBETI DM, Hoff NA, Merritt S, Lulebo AM, et al
    Quality and usability of home-based record photos to assess vaccine coverage: A case study from the 2022 Democratic Republic of the Congo Vaccine Coverage Survey.
    Vaccine. 2025;59:127248.
    PubMed     Abstract available


  82. GANDHI K, Vijay Y, Page K, Dahari H, et al
    Challenges in coverage of future hepatitis C vaccines: Review and potential solutions.
    Vaccine. 2025;59:127256.
    PubMed     Abstract available


  83. SURI RK, Maugeais D, Maithal K
    COVID-19 pandemic: A multidimensional analysis and the strategic role played by developing countries vaccine manufacturers.
    Vaccine. 2025;59:127271.
    PubMed     Abstract available


  84. GIANNINI F, Hogan AB, Cameron E, Le H, et al
    Estimating the impact of Western Australia's first respiratory syncytial virus immunisation program for all infants: A mathematical modelling study.
    Vaccine. 2025;56:127155.
    PubMed     Abstract available


  85. MANDVIWALA AS, Munje AK, Huckriede ALW, Arankalle VA, et al
    Immunogenicity evaluation of respiratory syncytial virus prefusogenic-F based virus-like-particles consisting of G and M proteins in mice.
    Vaccine. 2025;56:127203.
    PubMed     Abstract available


  86. KISLAYA I, Caserta M, Faye SLB, Dia OK, et al
    Evaluating the effects of a multisectoral dialogue-based COVID-19 awareness-raising intervention in a limited-resource setting: A quasi-experimental study in Senegal.
    Vaccine. 2025;56:127168.
    PubMed     Abstract available


  87. ISLAM MD, Islam MM, Inoue A, Yesmin S, et al
    Neutralizing antibodies against the Japanese encephalitis virus are produced by a 12 kDa E. coli- expressed envelope protein domain III (EDIII) tagged with a solubility-controlling peptide.
    Vaccine. 2025;56:127143.
    PubMed     Abstract available


  88. XU P, Lu J, Chen L, Chen X, et al
    Development of a chicken egg yolk antibody (IgY) could effectively prevent and treat goose astrovirus infection.
    Vaccine. 2025;56:127167.
    PubMed     Abstract available


  89. HASAN Z, Masood KI, Qaiser S, Kanji A, et al
    Comparative study of humoral and cellular immunity against SARS-CoV-2 induced by different COVID-19 vaccine types: Insights into protection against wildtype, Delta and JN.1 omicron strains.
    Vaccine. 2025;59:127270.
    PubMed     Abstract available


  90. KEUTLER A, Lainka E, Hudert C, Bufler P, et al
    Safety and immunogenicity of the measles-mumps-rubella vaccine in immunocompromised children with inflammatory bowel disease, or after liver transplantation: An observational study.
    Vaccine. 2025;59:127288.
    PubMed     Abstract available


  91. TIAN X, Zhou Y, Deng P, Xu N, et al
    Effectiveness and safety of a novel intranasal influenza vaccine in Chinese children: A phase IV multi-Center, randomized, double-blind, placebo-controlled clinical trial.
    Vaccine. 2025;59:127268.
    PubMed     Abstract available


  92. QUENTIN E, Ahmed I, Duong CH, Tubert-Bitter P, et al
    Covid-19 Vaccination During Pregnancy in France: a Descriptive Study of Uptake Using the National Healthcare data System.
    Vaccine. 2025;58:127223.
    PubMed     Abstract available


  93. FITZPATRICK T, Yamoah P, Summerby-Murray D, Cowan J, et al
    Neurological adverse events following COVID-19 vaccination among Canadians referred to the special immunization clinic network.
    Vaccine. 2025;59:127254.
    PubMed     Abstract available


  94. BUSSINK-VOOREND D, Hulscher MEJL, Akkermans R, Krom A, et al
    Vaccine hesitancy among Dutch parents of newborn children and its associated characteristics, values and uptake of vaccines.
    Vaccine. 2025;59:127244.
    PubMed     Abstract available


  95. NHAM E, Song JY, Sohn JW, Choi WS, et al
    Real-world effectiveness of COVID-19 XBB.1.5 monovalent mRNA vaccine: Analysis over nine months.
    Vaccine. 2025;59:127275.
    PubMed     Abstract available


  96. SCHAFFER AL, Hulme WJ, Horne E, Parker EPK, et al
    Effect of the 2022 COVID-19 booster vaccination campaign in people aged 50 years in England: Regression discontinuity analysis in OpenSAFELY-TPP.
    Vaccine. 2025;59:127257.
    PubMed     Abstract available


  97. MYBURGH L, van Loon K, Huijbers EJM, van Beijnum JR, et al
    Guided design for the development of an evolution-proof influenza vaccine.
    Vaccine. 2025;59:127281.
    PubMed     Abstract available


  98. HATTORI F, Higashimoto Y, Miura H, Kawamura Y, et al
    Epidemiology and clinical features of breakthrough varicella in the 9 years after universal vaccination began in Japan.
    Vaccine. 2025;59:127274.
    PubMed     Abstract available


  99. FURUSE Y, Tabuchi T
    Impact of COVID-19 vaccination by implementation timing and coverage rate in relation to misinformation prevalence in Japan.
    Vaccine. 2025;59:127273.
    PubMed     Abstract available


  100. LIAW K, Konrath KM, Trachtman AR, Tursi NJ, et al
    DNA co-delivery of seasonal H1 influenza hemagglutinin nanoparticle vaccines with chemokine adjuvant CTACK induces potent immunogenicity for heterologous protection in vivo.
    Vaccine. 2025;59:127231.
    PubMed     Abstract available


  101. MALTEZOU HC, Medic S, Cassimos DC, Effraimidou E, et al
    Routine vaccination rates globally: A continuing and alarming situation.
    Vaccine. 2025;59:127269.
    PubMed    


  102. SOARES LMC, de Medonca AEO, de Souza DLB, Carvalho AV, et al
    Factors associated with HPV vaccine hesitancy: A nationally representative cross-sectional study.
    Vaccine. 2025;59:127278.
    PubMed     Abstract available


  103. LUPTON D, Whitten T, Tay AK, Beek K, et al
    Mental health and psychosocial factors predicting concerns about the COVID-19 vaccine among refugee background and Australian-born women.
    Vaccine. 2025;58:127251.
    PubMed     Abstract available


  104. NUNEZ IA, Ross TM
    Corrigendum to "Human COBRA 2 vaccine contains two major epitopes that are responsible for eliciting neutralizing antibody responses against heterologous clades of viruses" [Vaccine 38 (4) (2020) 830-839].
    Vaccine. 2025;58:127205.
    PubMed    


  105. AVERIN A, Quinn E, Atwood M, Weycker D, et al
    Cost-effectiveness of bivalent respiratory syncytial virus Prefusion F (RSVpreF) maternal vaccine among infants in the United States.
    Vaccine. 2025;58:127191.
    PubMed     Abstract available


  106. SASAKI E, Hamaguchi I, Hasegawa H, Takahashi Y, et al
    Establishment of a novel adjuvant screening system for the development of intranasal vaccine adjuvants.
    Vaccine. 2025;58:127267.
    PubMed     Abstract available


  107. NIINIKOSKI V, Barkoff AM, Mertsola J, Holubova J, et al
    Alterations in the expression of Bordetella pertussis antigens in relation to the use of acellular pertussis vaccine in Finland.
    Vaccine. 2025;58:127279.
    PubMed     Abstract available


  108. EINARSON TA, Musana E, Balonde J, Lorentzen KB, et al
    Corrigendum to "Human papillomavirus awareness, vaccination rate, and sociodemographic covariates of vaccination status in a low-income country: A cross-sectional study in the rural Busoga region of Uganda" [Vaccine 53 (2025) 127089].
    Vaccine. 2025;58:127204.
    PubMed    


  109. HUNG SH, Torres JL, Chen F, Giang E, et al
    Antigenic and EM characterization of the Chiron experimental hepatitis C virus vaccine.
    Vaccine. 2025;58:127239.
    PubMed     Abstract available


  110. BUHL E, Vedel JO, Nanque LM, Correia C, et al
    Does timing of the Bacillus Calmette-Guerin vaccine affect weight in children under the age of 5 years? An observational study in Guinea-Bissau.
    Vaccine. 2025;58:127246.
    PubMed     Abstract available


  111. SOBLE A, Malhame M, Malvolti S, Mantel C, et al
    Identification and sizing of the current use cases for seasonal influenza vaccines.
    Vaccine. 2025 May 15:127233. doi: 10.1016/j.vaccine.2025.127233.
    PubMed     Abstract available


  112. MOORE DCBC, Nehab MF, Reis AT, Junqueira-Marinho MF, et al
    Childhood vaccine hesitancy: The power of metaphors.
    Vaccine. 2025;58:127221.
    PubMed     Abstract available


  113. PATTYN J, Hanning N, Valckx S, Claessens T, et al
    Investigating the state of vaccine confidence among the general public and parents with children up to 13 years in Flanders (Belgium).
    Vaccine. 2025;58:127250.
    PubMed     Abstract available


  114. MERRITT A, Bansal S
    Prison Vaccination in a pandemic: Geographic disparities and policy insights.
    Vaccine. 2025;58:127218.
    PubMed     Abstract available


  115. ELLIS JT, Kennedy PJ
    Multi-criteria decision making and its application to in silico discovery of vaccine candidates for Toxoplasma gondii.
    Vaccine. 2025;58:127242.
    PubMed     Abstract available


  116. VARMA A, Bolotin S, De Serres G, Didierlaurent AM, et al
    What is the current evidence base for measles vaccination earlier than 9 months of age?: Report from an informal technical consultation of the World Health Organization.
    Vaccine. 2025;57:127187.
    PubMed     Abstract available


  117. KUMARI M, Su SC, Lin HT, Ko SH, et al
    Enhanced immunogenicity of an mRNA vaccine against dengue virus serotype 2 with modified key residue.
    Vaccine. 2025;57:127216.
    PubMed     Abstract available


  118. PEARCE A, Henery P, Dundas R, Katikireddi SV, et al
    Socio-economic inequalities in uptake and timing of childhood vaccination: Taking a life course approach in an administrative cohort in Scotland.
    Vaccine. 2025;57:127222.
    PubMed     Abstract available


  119. MOU J, LaSalle G, Pflugeisen C, Sherls-Jones J, et al
    Practice, beliefs and intent in influenza vaccination among Hispanic patients during the pandemic: An interventional study.
    Vaccine. 2025;58:127207.
    PubMed     Abstract available


  120. LE DOARE K, Benassi V, Cavaleri M, Enwere G, et al
    Clinical and regulatory development strategies for GBS vaccines intended for maternal immunisation in low- and middle-income countries.
    Vaccine. 2025;58:127131.
    PubMed     Abstract available


  121. SPURGERS K, Wynn M, Charles L, Hamm S, et al
    A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the emergent vesicular stomatitis virus (VSV) viral vector vaccine for Lassa fever.
    Vaccine. 2025;58:127137.
    PubMed     Abstract available


  122. WANG-LU H, Valerio Mendoza OM, Chen S, Geldsetzer P, et al
    Regional mobility and COVID-19 vaccine hesitancy: Evidence from China.
    Vaccine. 2025;58:127179.
    PubMed     Abstract available


  123. GELLERT FR, Gonzalez C, Mokdad AH
    Bridging the gap: A mixed-methods analysis of Canadian and U.S. immunization programs for enhancing racial equity in childhood vaccinations.
    Vaccine. 2025;57:127249.
    PubMed     Abstract available


  124. ANYANGO RO, Nyawanda BO, Onyando BO, Haidara FC, et al
    Factors associated with laboratory-confirmed SARS-Cov-2 infection among patients with severe respiratory illness (SRI): Findings from the COVID-19 vaccine effectiveness evaluation in Kenya and Mali, 2022-2023.
    Vaccine. 2025 May 12:127234. doi: 10.1016/j.vaccine.2025.127234.
    PubMed     Abstract available


  125. PATRICK E, Iuliano A, Bakare D, Salako J, et al
    Non-specific effects of routine vaccinations on child survival between 12-59 months of age in Jigawa, Nigeria: A secondary analysis of the INSPIRING Jigawa trial.
    Vaccine. 2025;57:127211.
    PubMed     Abstract available


  126. NAVARRETE JAY, Rodriguez D, Kanno AI, de Cerqueira Leite LC, et al
    Modulation of immune responses induced by recombinant BCG expressing LTAK63 adjuvant in an immunotherapeutic model vaccine.
    Vaccine. 2025;57:127215.
    PubMed     Abstract available


  127. NTAKIYISUMBA E, Tanveer M, Won G
    A comprehensive analysis of the current strategy for developing live attenuated vaccines against African swine fever: A systematic review and meta-analysis.
    Vaccine. 2025;57:127243.
    PubMed     Abstract available


  128. CARTER DM, Bloom CE, Kirchenbaum GA, Tsvetnitsky V, et al
    Corrigendum to "Cross-protection against H7N9 influenza strains using a live-attenuated H7N3 virus vaccine" [Vaccine (2015) 33(1) 108-16].
    Vaccine. 2025;57:127174.
    PubMed    


  129. SAXTON P, Hollingshead BM, Rich J, Saini S, et al
    Mpox vaccine eligibility, uptake and coverage among gay, bisexual and other men who have sex with men in Aotearoa New Zealand.
    Vaccine. 2025;57:127247.
    PubMed     Abstract available


  130. HU J, Cao H, Luan N, Zhang X, et al
    Herpes simplex virus 1 fusion glycoprotein B H516P prefusion mutation had no effect on vaccine immunogenicity.
    Vaccine. 2025;57:127241.
    PubMed     Abstract available


  131. ANGULO M, Ramos-Vega A, Angulo C
    Trained immunity-based Adjuvated vaccines (TIbAV) approach: beta-glucans as example.
    Vaccine. 2025;57:127240.
    PubMed     Abstract available


  132. MACLENNAN CA, Cunningham AF, Dean JE, Pope S, et al
    BactiVac, the Bacterial Vaccines Network.
    Vaccine. 2025;57:127210.
    PubMed     Abstract available


  133. XIONG Y, Wu C, Zhang Y, Guo D, et al
    Can levels of HPV vaccine knowledge mitigate HPV vaccine hesitation among guardians of children aged 9-14 years? A moderated mediation model.
    Vaccine. 2025;57:127208.
    PubMed     Abstract available


  134. MEESTERS K, Sadarangani M, Clark SA, Borrow R, et al
    Characterization of Canadian Neisseria meningitidis serogroup B isolates and factor-H binding protein expression, data from the Canadian Immunization Monitoring Program Active (IMPACT), 2013-2020.
    Vaccine. 2025;55:127030.
    PubMed     Abstract available


  135. GAGNON D, Gubany C, Ouakki M, Malo B, et al
    Factors influencing acceptance of RSV immunization for newborns among pregnant individuals: A mixed-methods study.
    Vaccine. 2025;55:127062.
    PubMed     Abstract available


  136. SOTO-NOGUERON A, Carnalla-Barajas MN, Sanchez-Gonzalez G, Solorzano-Santos F, et al
    Distribution of pneumococcal serotypes causing invasive and non-invasive diseases in children in Mexico after introduction of PCV13 (2012-2023). Results from the GIVEBPVac group.
    Vaccine. 2025;55:127031.
    PubMed     Abstract available


  137. XIE F, Du K, Li J, Zhong S, et al
    Head-to-head immunogenicity comparison of one-dose Cecolin and Gardasil in Chinese girls aged 9-14 years: A randomized and open-label clinical trial.
    Vaccine. 2025;55:127015.
    PubMed     Abstract available


  138. PUTZ EJ, Andreasen CB, Stasko JA, Hamond C, et al
    Circulating foamy macrophages and other features of bacillus Calmette-Guerin challenge in Golden Syrian hamsters.
    Vaccine. 2025;55:127037.
    PubMed     Abstract available


  139. HAO T, Ryan GE, Lydeamore MJ, Cromer D, et al
    Predicting immune protection against outcomes of infectious disease from population-level effectiveness data with application to COVID-19.
    Vaccine. 2025;55:126987.
    PubMed     Abstract available


  140. KIM GL, Pyo SW, Kim SH, Song HJ, et al
    Serological correlates of protection and long-term efficacy of a novel recombinant protective antigen-based anthrax vaccine in a rabbit model.
    Vaccine. 2025;57:127212.
    PubMed     Abstract available


  141. ADAME BJ, Corman SR, Von Feldt PA, Meneses CM, et al
    Reactance as a cause of COVID-19 vaccination hesitancy.
    Vaccine. 2025;57:127209.
    PubMed     Abstract available


  142. ROULEAU I, Issa Kana KDN, Zafack JG, Viger YB, et al
    New-onset anesthesia/paresthesia following the administration of COVID-19 vaccines in Quebec, Canada.
    Vaccine. 2025;57:127217.
    PubMed     Abstract available


  143. GEORGIADIS N, Katsimpris A, Tzanakaki G, Tsiodras S, et al
    Cross-protection of meningococcal B vaccines against gonorrhea: A systematic review and Meta-analysis.
    Vaccine. 2025;56:127180.
    PubMed     Abstract available


  144. MASHAMBA M, Msibi T, Tshabalala G, Tsotetsi L, et al
    Factors influencing influenza vaccine uptake among adults in Johannesburg, South Africa: A qualitative study.
    Vaccine. 2025;57:127133.
    PubMed     Abstract available


  145. RAHA JR, Kim KH, Le CTT, Bhatnagar N, et al
    Intranasal vaccination with multi-neuraminidase and M2e virus-like particle vaccine results in greater mucosal immunity and protection against influenza than intramuscular injection.
    Vaccine. 2025;57:127206.
    PubMed     Abstract available


  146. GUMASING MJJ
    Rebuilding Public Trust: Factors Influencing Dengue Vaccine Uptake in the Aftermath of the Dengvaxia Controversy in the Philippines: A Partial Least Structural Equation Modeling Approach.
    Vaccine. 2025;57:127220.
    PubMed     Abstract available


  147. VIETHS S, Waibler Z, Schumann GG
    Opting for the appropriate methodology for quantification of residual DNA impurities in mRNA vaccines.
    Vaccine. 2025;56:127186.
    PubMed    


  148. SZONDY I, Lorincz K, Walter A, Mohammed AA, et al
    Evaluating cross-protection: Meningococcal vaccines show effectiveness in gonorrhoea prevention - A systematic review and meta-analysis.
    Vaccine. 2025;56:127188.
    PubMed     Abstract available


  149. PADRON-REGALADO E, Escudero Gonzalez NA, Del Carmen Selvera HN
    Morbidity of viral vaccine preventable diseases in the Mexican states bordering the U.S., 2014-2023.
    Vaccine. 2025;56:127192.
    PubMed     Abstract available


  150. ASHRAF U, Lee A, Gao Q, Gonzalez JC, et al
    Impact of age and prior COVID-19 on the response to influenza a components in the 2020-2021 Fluzone vaccine.
    Vaccine. 2025;56:127171.
    PubMed     Abstract available


  151. BOUADDI O, Khalis M, Abdellatifi M, Seedat F, et al
    Behavioural and social drivers of vaccination among child and adult migrants in Morocco: A qualitative interview study.
    Vaccine. 2025;56:127166.
    PubMed     Abstract available


  152. PITTER JG, Mihajlovic J, Nagy D, van der Schans J, et al
    Underreported influenza mortality in Central and Eastern Europe hinders the extension of seasonal influenza vaccination programs in older adults.
    Vaccine. 2025;56:127184.
    PubMed     Abstract available


  153. ANNEQUIN M, Mora M, Fressard L, Cogordan C, et al
    The relationship between men who have sex with men on PrEP and care providers is essential for HPV vaccination: A mixed-methods study in France.
    Vaccine. 2025;56:127190.
    PubMed     Abstract available


  154. ALGREN MH, Timmermann A, Valentiner-Branth P, Thygesen LC, et al
    Comparing Risk Behaviour among 14,614 Human Papillomavirus Vaccinated and Unvaccinated Danish Young Women.
    Vaccine. 2025;56:127202.
    PubMed     Abstract available


  155. SEFAT KMSR, Kulkarni R, Trinh J, Leekha A, et al
    Mucosal vaccines with STING-agonist liposomal formulations inhibit RSV (respiratory syncytial virus) replication in cotton rats.
    Vaccine. 2025;56:127183.
    PubMed     Abstract available


  156. ZHANG Z, Yildirim M, Keskinocak P, Dasthagirisaheb YBS, et al
    Serotype specific pneumococcal vaccine effectiveness in children with sickle cell disease: A two-decade analysis.
    Vaccine. 2025;56:127193.
    PubMed     Abstract available


  157. WHELDRAKE K, Sisnowski J, AHoure M, Anagnostou N, et al
    Surveillance of adverse events following immunisation with meningococcal B vaccine (4CMenB), South Australia, 2018-2022.
    Vaccine. 2025;56:127158.
    PubMed     Abstract available


  158. CHAN YT, Chair SY, Gao RT, Ng MH, et al
    Effect of vaccine education intervention on vaccine uptake and vaccine knowledge among older adults: A systematic review with meta-analysis.
    Vaccine. 2025;56:127182.
    PubMed     Abstract available


  159. IBARZ-PAVON AB, Bielsky MC, Bose R, Cavaleri M, et al
    Consultation report - considerations for a regulatory pathway for bivalent Salmonella Typhi/Paratyphi A vaccines for use in endemic countries.
    Vaccine. 2025;56:127189.
    PubMed     Abstract available


  160. AKMATOVA R, Otorbaeva D, Ebama MS
    Impact of the COVID-19 pandemic on influenza knowledge, attitudes, and vaccination practices in at-risk groups in the Kyrgyz Republic: A comparative study.
    Vaccine. 2025;56:127159.
    PubMed     Abstract available


  161. OTORBAEVA D, Akmatova R, Cooley KM, Iwamoto C, et al
    Corrigendum to "Post-introduction evaluation (PIE) of the seasonal influenza vaccination program in Kyrgyzstan in 2023" Vaccine 55 (2025) 127052.
    Vaccine. 2025;56:127123.
    PubMed    


  162. BADZI CD, Modey E, Apreku A, Guure C, et al
    Factors influencing COVID-19 vaccine uptake among pregnant women in Greater Accra Region, Ghana.
    Vaccine. 2025 May 1:127073. doi: 10.1016/j.vaccine.2025.127073.
    PubMed     Abstract available


  163. KANESHITA S, Chambers CD, Johnson D, Kavanaugh A, et al
    Short-term side effects following COVID-19 vaccination in pregnancies complicated by autoimmune inflammatory rheumatic diseases: A prospective cohort study.
    Vaccine. 2025;56:127194.
    PubMed     Abstract available


    April 2025
  164. MOTTA M, Callaghan T, Ross JC, Gargano L, et al
    Promoting RSV vaccine confidence through reversal narrative (RN) messaging.
    Vaccine. 2025;56:127178.
    PubMed     Abstract available


  165. PAUL MJ, Hudda MT, Pallett S, Groppelli E, et al
    Mucosal immune responses to SARS-CoV-2 infection and COVID-19 vaccination.
    Vaccine. 2025;56:127175.
    PubMed     Abstract available


  166. WAN J, Wu M, Zhu Z, Liu X, et al
    Vaccination of a CdrA fragment conferred protection against Pseudomonas aeruginosa in wound infection via inhibition of biofilm formation.
    Vaccine. 2025;56:127185.
    PubMed     Abstract available


  167. ZHENG F, Zhu M, Ran H, He J, et al
    Assessment of recombinant Lactobacillus vector-based expressing IFITM3 protein anti-PRV infection in mice.
    Vaccine. 2025;54:127093.
    PubMed     Abstract available


  168. JAROVSKY D, Cereda RF, Figueiredo LM, Berezin EN, et al
    Epidemiology and clinical burden of invasive pneumococcal disease in older adults in the city of Sao Paulo, Brazil.
    Vaccine. 2025;54:126992.
    PubMed     Abstract available


  169. BOLOTIN S, Wright J, McLachlan E, Severini A, et al
    Investigating the measles susceptibility gap in Ontario infants.
    Vaccine. 2025;54:126908.
    PubMed     Abstract available


  170. WIBOWO DP, Chalid MT, Rasyak MR, El Khobar KE, et al
    Characteristics of hepatitis B virus surface protein and occult hepatitis B infection in infants with immunoprophylaxis failure from Indonesia.
    Vaccine. 2025;56:127130.
    PubMed     Abstract available


  171. SHANKER A, Vlaev I
    The social influence of the corrections of vaccine misinformation on social media.
    Vaccine. 2025;56:127177.
    PubMed     Abstract available


  172. OSEI I, Mendy E, van Zandvoort K, Sarwar G, et al
    Effect of the 13-valent pneumococcal conjugate vaccine on pneumococcal carriage in rural Gambia 10 years after its introduction: A population-based cross-sectional study.
    Vaccine. 2025;56:127181.
    PubMed     Abstract available


  173. BAYSAC DJ, Guay M, Chen R, Dube E, et al
    Did inequalities in COVID-19 vaccination resolve over time? Insights from the Canadian Community Health Survey.
    Vaccine. 2025;56:127153.
    PubMed     Abstract available


  174. LONG Q, Wang H, He Q, Liu W, et al
    Effectiveness of rBS/WC cholera vaccine against bacterial infectious diarrhea: A test-negative study on children aged 2-6 years in Guangzhou China.
    Vaccine. 2025;56:127139.
    PubMed     Abstract available


  175. MELN I, Van Molle W, Velez MP, Abrahamsen G, et al
    Advancing regulatory dialogue: In silico models for improved vaccine biomanufacturing - an expert meeting report.
    Vaccine. 2025;56:127170.
    PubMed     Abstract available


  176. HANSEN BT, Kristoffersen AB, Stecher M
    Vaccination readiness among adults in Norway: A cross-sectional survey using the 7C model.
    Vaccine. 2025;56:127169.
    PubMed     Abstract available


  177. SINGLETON KL, Post DJ, Augustine AD, Ison MG, et al
    Collaborative influenza vaccine innovation centers (CIVICs) program.
    Vaccine. 2025;54:127118.
    PubMed     Abstract available


  178. ESSINK BJ, Vermeulen W, Andrade C, de Rooij R, et al
    Corrigendum to 'A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults aged 50 years and older' Vaccine 51 (2025) 126791.
    Vaccine. 2025;56:127127.
    PubMed    


  179. FATIMAH MNN, Thian BYZ, Wong CL, Ong HK, et al
    Chimeric virus-like particles of nodavirus displaying M2e of human and avian influenza A viruses as a potential dual-use vaccine: Inducing a broader immune response and protecting mice against viral infections.
    Vaccine. 2025;56:127165.
    PubMed     Abstract available


  180. OHNO M, Sekiya T, Obeng-Kyeremeh R, Handabile C, et al
    Optimization of the preparation method of inactivated intact virus particle vaccine for COVID-19.
    Vaccine. 2025;56:127173.
    PubMed     Abstract available


  181. MELCHINGER H, Khemsara M, Ahmed N, Belgaumi SM, et al
    Assessment of mpox awareness, attitudes, and vaccination intent among the United States public following an outbreak of mpox clade Ib in Africa.
    Vaccine. 2025;56:127141.
    PubMed     Abstract available


  182. JACOVETTY J, Wagner AL, Ichsan I, Yufika A, et al
    Associations between parental vaccine hesitancy, religion-based vaccine hesitancy, and childhood full vaccination in a cross-sectional study in Aceh, Indonesia, 2023.
    Vaccine. 2025;56:127154.
    PubMed     Abstract available


  183. SUH TY, Park JH, Hwang SY, Park CR, et al
    Safety and efficacy of a Vero-adapted live attenuated vaccine candidate for African swine fever.
    Vaccine. 2025;56:127172.
    PubMed     Abstract available


  184. LANATA CF, Ochoa TJ, Bancalari EM, Baylor NW, et al
    Testing an experimental vaccine during a public health emergency: Lessons from a Peruvian case.
    Vaccine. 2025;56:127176.
    PubMed     Abstract available


  185. BUSTAMANTE Q, Sparkes D, Findlater L, Munro K, et al
    Understanding occupational and attitudinal factors influencing UK healthcare worker decisions for COVID-19 and influenza vaccination: A cross-sectional survey within SIREN.
    Vaccine. 2025;56:127160.
    PubMed     Abstract available


  186. AGRUPIS KA, Crisostomo MV, Daag JV, Sarol J Jr, et al
    Effectiveness of a single-dose mass dengue vaccination in Cebu, Philippines: Final results of a 5-year case-control study.
    Vaccine. 2025;56:127142.
    PubMed     Abstract available


  187. MCGRATH LJ, Khan FL, Lopez SMC, Brouillette MA, et al
    2023-2024 COVID-19 vaccine uptake among immunocompromised individuals in two US states.
    Vaccine. 2025;56:127120.
    PubMed     Abstract available


  188. HONDA-OKUBO Y, Sakala IG, Li L, Bielefeldt-Ohmann H, et al
    Advax(R)-adjuvanted inactivated influenza vaccine provides accelerated protection of mice via early induction of an influenza-specific IgM response.
    Vaccine. 2025;56:127144.
    PubMed     Abstract available


  189. ZHANG X, Shi H, Ross TM
    Multivalent H3 COBRA-based influenza vaccine elicits enhanced immune response in a pre-immune elderly ferret model.
    Vaccine. 2025;56:127156.
    PubMed     Abstract available


  190. LUKA MM, Ferguson EA, Rees E, Hoffu H, et al
    Optimising human rabies vaccine supply chains: A modelling study.
    Vaccine. 2025 Apr 21:127108. doi: 10.1016/j.vaccine.2025.127108.
    PubMed     Abstract available


  191. JURADO-MARTIN I, Tomas-Cortazar J, Rezk N, Hou Y, et al
    The novel antigen, lipopolysaccharide export protein LptH, protects mice against Pseudomonas aeruginosa acute pneumonia in monovalent and multivalent vaccines.
    Vaccine. 2025;56:127145.
    PubMed     Abstract available


  192. KAHN R, Moiane B, Lessa FC, Massora S, et al
    Corrigendum to "Nasopharyngeal carriage of Streptococcus pneumoniae among children and their household members in southern Mozambique five years after PCV10 introduction" Vaccine, Volume 47, 15 February 2025, 126,691.
    Vaccine. 2025;56:127124.
    PubMed    


  193. FINNEY J, Kuraoka M, Song S, Watanabe A, et al
    Fluorescence-barcoded cell lines stably expressing membrane-anchored influenza neuraminidases.
    Vaccine. 2025;56:127157.
    PubMed     Abstract available


  194. XIA Y, Zhu W, Shi Z, Shen Y, et al
    Herpes zoster vaccination coverage and factors associated among adults aged 40 and older in China: A population-based survey.
    Vaccine. 2025;56:127122.
    PubMed     Abstract available


  195. FERRERAS-COLINO E, de la Fuente J, Couto J, Golovchenko M, et al
    Immunostimulant effect of heat-inactivated Mycobacterium bovis in mice challenged with vector-borne pathogens.
    Vaccine. 2025;53:127076.
    PubMed     Abstract available


  196. LUN J, Zheng P, Liang X, Hu Y, et al
    Identification of a conserved cryptic epitope with cross-immunoreactivity in outer membrane protein K (OmpK) from Vibrio species.
    Vaccine. 2025;53:126964.
    PubMed     Abstract available


  197. TAKEUCHI N, Chang B, Ishiwada N, Cho Y, et al
    Nationwide population-based surveillance of invasive pneumococcal disease in children in Japan (2014-2022): Impact of 13-valent pneumococcal conjugate vaccine and COVID-19 pandemic.
    Vaccine. 2025;54:127138.
    PubMed     Abstract available


  198. DE MELO ARAUJO AC, Oliveira TM, Souza JFA, da Fonseca Victer TN, et al
    Incorporating vaccines into vaccination schedules around the world: A scoping review.
    Vaccine. 2025;54:127132.
    PubMed     Abstract available


  199. MANTLO EK, Huang YS
    Knowledge-based mitigation of the environmental risk of Orthoflavivirus live-attenuated vaccines by targeting viral encoded determinants for the mosquito attenuated phenotype.
    Vaccine. 2025;54:127114.
    PubMed     Abstract available


  200. MO AX, McGugan G, Pesce JT
    Meeting report: Expert consultation on late arresting replication competent (LARC) malaria sporozoite vaccine research & development.
    Vaccine. 2025;54:127009.
    PubMed     Abstract available


  201. ARSENAULT C, Ravishankar S, Lewis T, Armeni P, et al
    The role of health systems in shaping vaccine decisions: Insights from Italy, Mexico, the United Kingdom, and the United States.
    Vaccine. 2025;54:127134.
    PubMed     Abstract available


  202. STONER MCD, Michaels J, Stocks JB, Mancuso N, et al
    Evaluating concurrency and gaps between self-report and vaccine card data for COVID-19 vaccination.
    Vaccine. 2025;54:127136.
    PubMed     Abstract available


  203. WANG Z, Wang M, Wang F, Luo Y, et al
    Corrigendum to "Dendritic cell targeting peptide plus Salmonella FliCd flagellin fused outer membrane protein H (OmpH) demonstrated increased efficacy against infections caused by different Pasteurella multocida serogroups in mouse models" [Vaccine 42
    Vaccine. 2025;54:127126.
    PubMed    


  204. URIU K, Kaku Y, Kihara M, Sato K, et al
    Antiviral humoral immunity against SARS-CoV-2 omicron JN.1 subvariants induced by JN.1 recombinant protein vaccine.
    Vaccine. 2025;54:127129.
    PubMed    


  205. TONG F, Zhou T, Tang L, Wu X, et al
    Evaluating the impact of influenza vaccine on preventing stroke hospitalization and death in Chinese elderly hypertensive patients: A retrospective cohort study.
    Vaccine. 2025;54:127004.
    PubMed     Abstract available


  206. WEETS CM, Wilson R, Swadley H, Katz R, et al
    Strengthening health security through routine vaccination policy: A comprehensive analysis of childhood vaccination laws across 194 countries.
    Vaccine. 2025;54:127121.
    PubMed     Abstract available


  207. ENTRICAN G, Bredell H, Charlier J, Cunningham AF, et al
    Opportunities and challenges for the adoption of novel platform technologies to develop veterinary bacterial vaccines.
    Vaccine. 2025;54:127117.
    PubMed     Abstract available


  208. YE Q, Li H, Xie Z, Gao X, et al
    Corrigendum to "Antibody persistence in Chinese toddlers at 1 year and 2 years after two different 4-dose schedules of a novel 13-valent pneumococcal conjugate vaccine (PCV13-TT)" [Vaccine 49 (7) (2025) 126815].
    Vaccine. 2025;54:127125.
    PubMed    


  209. WANG F, Zheng J, Qiu F, Yang Y, et al
    Long-term effectiveness of vaccination for prevention of hepatitis B virus mother-to-child transmission in Yunnan, China.
    Vaccine. 2025;54:127128.
    PubMed     Abstract available


  210. LEYNS C, McClenaghan E, Rodriguez P, Nguipdop-Djomo P, et al
    Hybrid, vaccine-induced and natural immunity against SARS-CoV-2 in traditional food markets in Bolivia (2020-2022): A cross-sectional analysis of a serological survey.
    Vaccine. 2025;54:127104.
    PubMed     Abstract available


  211. SYROGIANNOPOULOS GA, Michoula AN, Moriondo M, Nieddu F, et al
    Childhood invasive pneumococcal disease and acute otitis media in Central Greece during 2005-2024 - A report at the doorstep of the new multivalent PCV era.
    Vaccine. 2025;52:126765.
    PubMed     Abstract available


  212. OLIVEIRA LMA, Prasad N, Lynfield R, Ip M, et al
    WHO defeating meningitis symposium, 3rd international symposium on Streptococcus agalactiae disease (ISSAD) in Rio de Janeiro, Brazil: State-of-the-art overview of S. agalactiae meningitis.
    Vaccine. 2025;52:126895.
    PubMed     Abstract available


  213. RESIK S, Lopez Cavestany R, Tejeda A, Diaz M, et al
    Tropis needle-free injector for fractional-dose IPV administration: A pilot study for integration into routine immunization services in Cuba.
    Vaccine. 2025;52:126903.
    PubMed     Abstract available


  214. DEY A, Jackson J, Wang H, Lambert SB, et al
    Australia's rotavirus immunisation program: Impact on acute gastroenteritis and intussusception hospitalisations over 13 years.
    Vaccine. 2025;52:126789.
    PubMed     Abstract available


  215. JOSHI R, Ayele HT, Johnson KD, Velentgas P, et al
    Anticipated impact of novel adult-specific pneumococcal conjugate vaccine.
    Vaccine. 2025;53:127080.
    PubMed     Abstract available


  216. JOHN TJ, Dharmapalan D, Steinglass R, Hirschhorn N, et al
    Lessons for polio eradication from the geographic variations of vaccine efficacy of oral polio.
    Vaccine. 2025;53:127115.
    PubMed    


  217. WALTENBURG MA, Kainulainen MH, Whitesell A, Nyakarahuka L, et al
    Corrigendum to "Knowledge, attitudes, and practices and long-term immune response after rVSVDeltaG-ZEBOV-GP Ebola vaccination in healthcare workers in high-risk districts in Uganda" [Vaccine 24 (22) (2024) 126031].
    Vaccine. 2025;54:127119.
    PubMed    


  218. CHAN MXJ, Wouters OJ, Chan HY, Terblanche P, et al
    Regional cooperation on pandemic preparedness and vaccine equity from an economic, regulatory and legal perspective.
    Vaccine. 2025 Apr 10:127107. doi: 10.1016/j.vaccine.2025.127107.
    PubMed     Abstract available


  219. BRUXVOORT KJ, Sy LS, Contreras R, Lewin B, et al
    Development and validation of a clinical prediction tool for non-receipt of updated COVID-19 vaccines.
    Vaccine. 2025;53:127074.
    PubMed     Abstract available


  220. DYMOCK M, Marsh JA, Murray K, Snelling TL, et al
    What is the quality of evidence informing vaccine clinical practice recommendations in Australia?
    Vaccine. 2025;53:127105.
    PubMed     Abstract available


  221. ZHANG L, Xia Y, Chu L, Sundaram ME, et al
    Differences in seasonal influenza vaccine hesitancy profiles between clinicians practicing traditional Chinese medicine and modern Western medicine: A national cross-sectional survey.
    Vaccine. 2025;53:127106.
    PubMed     Abstract available


  222. JANI B, Hokororo A, Mchomvu J, Cortese MM, et al
    Corrigendum to "Detection of rotavirus before and after monovalent rotavirus vaccine introduction and vaccine effectiveness among children in mainland tanzania" [Vaccine 36(47) (2018 Nov 12) 7149-7156].
    Vaccine. 2025;53:127103.
    PubMed    


  223. NA EJ, Chae SB, Oh B, Jeong CG, et al
    A novel approach using IFNAR1 KO mice for assessing Akabane virus pathogenicity and vaccine efficacy.
    Vaccine. 2025;53:127094.
    PubMed     Abstract available


  224. EINARSON TA, Musana E, Balonde J, Lorentzen KB, et al
    Human papillomavirus awareness, vaccination rate, and sociodemographic covariates of vaccination status in a low-income country: A cross-sectional study in the rural Busoga region of Uganda.
    Vaccine. 2025;53:127089.
    PubMed     Abstract available


  225. SHARIF E, Mobasheri T, Mohit E
    Bioengineered ClearColi-derived outer membrane vesicles displaying CT26 neoepitopes as potent vaccine adjuvants against colon carcinoma in a preventive mouse model.
    Vaccine. 2025;53:127088.
    PubMed     Abstract available


  226. LA EM, Sweeney C, Davenport E, Bunniran S, et al
    Pharmacy and healthcare provider offices as convenient adult vaccination settings in the US: Patient experiences from a survey of recently-vaccinated adults.
    Vaccine. 2025;54:127057.
    PubMed     Abstract available


  227. SASANKAN S, Gathers D, Bellerose A, Pankratz VS, et al
    Behaviors, perceptions, and impact of the COVID-19 pandemic and vaccination on oncology patients in New Mexico with substantial representation of racial minorities and rural residents.
    Vaccine. 2025;53:127091.
    PubMed     Abstract available


  228. ZASZTOWT-STERNICKA M, Jagielska A, Rzad M, Szymusik I, et al
    Immunogenicity of inactivated quadrivalent influenza vaccine in pregnant women, including the level of postvaccination antibodies in umbilical cord blood.
    Vaccine. 2025;53:127047.
    PubMed     Abstract available


  229. LLOYD PC, Acharya G, Zhao H, Shah N, et al
    Safety monitoring of health outcomes following influenza vaccination during the 2023-2024 season among U.S. Medicare beneficiaries aged 65 years and older.
    Vaccine. 2025;53:127069.
    PubMed     Abstract available


  230. YUILL S, Hall MT, Caruana M, Lui G, et al
    Erratum to "Predicted impact of HPV vaccination and primary HPV screening on precancer treatment rates and adverse pregnancy outcomes in Australia 2010-2070: Modelling in a high income, high vaccination coverage country with HPV-based cervical screeni
    Vaccine. 2025;53:127079.
    PubMed    


  231. ASSONI L, Valim V, Couto AJM, Trentini M, et al
    In-silico and experimental analysis of Klebsiella pneumoniae fimbriae subunits for vaccine development.
    Vaccine. 2025;53:127075.
    PubMed     Abstract available


  232. PRALL S, Lopes A
    "Better to die trying": Vaccine perceptions and COVID-19 experiences in rural Namibian pastoralists.
    Vaccine. 2025;55:127061.
    PubMed     Abstract available


  233. MOLLO A, Peri M, Lodi L, Gissi A, et al
    Considering recombinant herpes zoster vaccine for fragile pediatric patients: A new opportunity.
    Vaccine. 2025;53:127072.
    PubMed     Abstract available


  234. FROSTH S, Reddick D, Righetti F, Bjerketorp J, et al
    Sow vaccination with a novel recombinant protein vaccine protects piglets against Streptococcus suis infection.
    Vaccine. 2025;53:127077.
    PubMed     Abstract available


  235. DIEZ A, Arrieta-Aguirre I, Carrano G, Bregon-Villahoz M, et al
    A synthetic peptide vaccine induces protective immune responses against Candida albicans infection in immunocompromised mice.
    Vaccine. 2025;53:127102.
    PubMed     Abstract available


  236. SHEARN C, Postavaru GI, Hylton L, Morris H, et al
    COVID-19 vaccine decision-making and the role of institutions across the pandemic in UK Black African and Black Caribbean communities.
    Vaccine. 2025;53:127071.
    PubMed     Abstract available


  237. LI G, Cao S, Xu B, Hu J, et al
    Safety, immunogenicity and immune persistence of a lyophilized purified human diploid cells rabies vaccine following rabies PEP regimen Essen and Zagreb: A randomized, blinded controlled phase 3 trial in healthy participants aged 10-60 years old.
    Vaccine. 2025;53:127082.
    PubMed     Abstract available


  238. LEADER AE, Burke-Garcia A, Afanaseva D, Cutroneo E, et al
    Partnering with social media influencers to promote HPV vaccination in diverse communities.
    Vaccine. 2025;53:127085.
    PubMed     Abstract available


  239. SHALASH AO, Wang W, Xia Y, Hussein WM, et al
    Evaluation of novel single-dose vaccine candidates against gonadotropin-releasing hormone (GnRH) in mice.
    Vaccine. 2025;53:127092.
    PubMed     Abstract available


  240. BERNARD C, Drouin J, Le Vu S, Botton J, et al
    COVID-19 vaccination rates among pregnant women in France: A nationwide cohort study.
    Vaccine. 2025;53:127070.
    PubMed     Abstract available


  241. FISHER KA, Goldthwait L, Desrochers O, Zemel M, et al
    Reasons for COVID-19 vaccination late in the pandemic: A qualitative study.
    Vaccine. 2025;53:127084.
    PubMed     Abstract available


  242. FLYNN PM, Stull C, Jain VM, Evans MD, et al
    A national cross-sectional study of dentists' vaccine hesitancy and intention to provide HPV vaccines following emergency COVID-19 vaccination authorization.
    Vaccine. 2025;53:127035.
    PubMed     Abstract available


  243. CHEN PL, Richardson RA, Rovito S, Yang G, et al
    Live-attenuated pandemic H1N1 influenza vaccines expressing computationally optimized broadly reactive antigens (COBRAs) are immunogenic and protective in mice and ferrets.
    Vaccine. 2025;53:127090.
    PubMed     Abstract available


  244. PAYNE AB, Novosad S, Sung HM, Zhang Y, et al
    Effectiveness of 2023-2024 COVID-19 vaccines against COVID-19-associated hospitalizations among adults aged >/=18 years with end stage kidney disease - United States, September 2023-April 2024.
    Vaccine. 2025;55:127010.
    PubMed     Abstract available


  245. EIDEN AL, Mackie DS, Modi K, Drakeley S, et al
    Corrigendum to the article titled, "Attitudes and beliefs about vaccination among adults in the United States: A real-world, cross-sectional, web-based survey study" [Vaccine 50 (2025) 126807].
    Vaccine. 2025;53:127053.
    PubMed    


  246. FELIX P, Melo AA, Costa JP, Colaco M, et al
    Exploring TLR agonists as adjuvants for COVID-19 oral vaccines.
    Vaccine. 2025;53:127078.
    PubMed     Abstract available


  247. MCCOSKER LK, Dyer B, Sudarmana T, Seale H, et al
    COVID-19 vaccination uptake in people experiencing homelessness during the first three years of the global COVID-19 vaccination effort: A systematic review and meta-analysis.
    Vaccine. 2025;53:127050.
    PubMed     Abstract available


  248. ANTILLON M, Verjans A, El Sheikh F, Scarna T, et al
    Microarray patch vaccines for typhoid conjugate vaccines: A global cost-effectiveness analysis.
    Vaccine. 2025;53:127055.
    PubMed     Abstract available


  249. DAVIDSON N, Fisher J
    "If I know about it of course I would give my son and daughter", barriers to and enablers of accessing human papillomavirus vaccination among women from refugee and asylum-seeking backgrounds resettling in Melbourne, Australia - A qualitative study.
    Vaccine. 2025;53:127064.
    PubMed     Abstract available


  250. EIDEN AL, Drakeley S, Modi K, Mackie DS, et al
    Corrigendum to, "Attitudes and beliefs of healthcare providers toward vaccination in the United States: A cross-sectional online survey" [Vaccine (2024) Dec 2 42(26) 126437].
    Vaccine. 2025;53:127054.
    PubMed    


  251. MCKECHNIE JL, Kepl E, Louth J, Sun CJ, et al
    Nanoparticles displaying fHbp elicit an enhanced antibody response against meningococcal B isolates compared to low valency fHbp antigens.
    Vaccine. 2025;51:126885.
    PubMed     Abstract available


  252. CARNALLA M, Gaspar-Castillo C, Dimas-Gonzalez J, Aparicio-Antonio R, et al
    A population-based measles serosurvey in Mexico: Implications for re-emergence.
    Vaccine. 2025;51:126886.
    PubMed     Abstract available


  253. MONCHAUSSE T, Launay T, Rossignol L, Ait El Belghiti F, et al
    Clinical characteristics of cases during the 2024 pertussis epidemic in France, January 2024 to December 2024.
    Vaccine. 2025;51:126862.
    PubMed     Abstract available


  254. OLIVIERI G, Amodio D, Manno EC, Santilli V, et al
    Shielding the immunocompromised: COVID-19 prevention strategies for patients with primary and secondary immunodeficiencies.
    Vaccine. 2025;51:126853.
    PubMed     Abstract available


  255. JOHNSTONE SL, Shapiro D, Chiwandire N, Matoti L, et al
    Effectiveness of BNT162b2 and Ad26.COV2.S vaccines against COVID-19-related hospitalisation amongst adult members of a private health insurance plan in South Africa during the Delta and Omicron periods: A test-negative case-control study.
    Vaccine. 2025 Apr 2:127068. doi: 10.1016/j.vaccine.2025.127068.
    PubMed     Abstract available


  256. PEREZ MARC G, Coria LM, Ceballos A, Rodriguez JM, et al
    Immunogenicity and safety of monovalent and bivalent SARS-CoV-2 variant adapted RBD-based protein booster vaccines in adults previously immunized with different vaccine platforms: A phase II/III, randomized clinical trial.
    Vaccine. 2025;54:127045.
    PubMed     Abstract available


  257. HE X, Pu Y, Li Z, Huan S, et al
    The global regulatory landscape for combined vaccines: A comparative case study of registration strategies for diphtheria-tetanus-pertussis-containing vaccines.
    Vaccine. 2025;54:127017.
    PubMed     Abstract available


  258. PATRICK R, Mahale P, Ackerson BK, Hong V, et al
    Respiratory syncytial virus vaccine uptake among adults aged >/=60 years in a large, integrated healthcare system in Southern California 2023-2024.
    Vaccine. 2025;53:127033.
    PubMed     Abstract available


  259. FORAN AM, Jetten J, Muldoon OT
    Religious group membership and conspiracy beliefs influence vaccine uptake: Insights from 20 European countries.
    Vaccine. 2025;53:127086.
    PubMed     Abstract available


  260. ALVES K, Kouassi A, Plested JS, Kalkeri R, et al
    Immunogenicity and safety of a monovalent Omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine in previously unvaccinated, SARS-CoV-2 seropositive participants: Primary day-28 analysis of a phase 2/3 open-label study.
    Vaccine. 2025;55:127046.
    PubMed     Abstract available


  261. STRONG C, Joson P, Chu IY, Chuang TT, et al
    Prioritization and barriers of mpox vaccination uptake among gay, bisexual and other men who have sex with men in Taiwan: 2023 HEART survey.
    Vaccine. 2025;53:127059.
    PubMed     Abstract available


  262. VADREVU KM, Chavan A, Chawla A, Chakravarthy BS, et al
    A double-blind, randomised phase III clinical trial to evaluate safety, immunogenicity, non-inferiority & lot to lot consistency of single component oral cholera vaccine BBV131 (Hillchol(R)) in comparison to Shanchol.
    Vaccine. 2025;55:126998.
    PubMed     Abstract available


  263. OTORBAEVA D, Akmatova R, Cooley KM, Iwamoto C, et al
    Post-introduction evaluation (PIE) of the seasonal influenza vaccination program in Kyrgyzstan in 2023.
    Vaccine. 2025;55:127052.
    PubMed     Abstract available


    March 2025
  264. KARAN S, Opdensteinen P, Ma Y, De Oliveira JFA, et al
    A replicon-based COVID-19 vaccine candidate delivered by tobacco mosaic virus-like particles.
    Vaccine. 2025;53:127063.
    PubMed     Abstract available


  265. DA SILVA TMR, de Sa ACMGN, Prates EJS, Veloso GA, et al
    Trends and spatial distribution of the burden of vaccine-preventable diseases in children under five in Brazil from 2000 to 2019.
    Vaccine. 2025;55:127060.
    PubMed     Abstract available


  266. JIANG J, Lam KF, Lau EHY, Yin G, et al
    Estimation of trajectory of COVID-19 vaccines effectiveness against infection.
    Vaccine. 2025;55:127067.
    PubMed     Abstract available


  267. NEWBERN EC, Shoaibi A, Haynes K, Blacketer C, et al
    A rapid cycle analytics framework for vaccine safety surveillance within a real-world data network: Experience with enhanced surveillance of the Janssen COVID-19 vaccine.
    Vaccine. 2025;55:127044.
    PubMed     Abstract available


  268. LEE JW, Lee DY, Baek S, Jeong JY, et al
    Sensitive detection of pertussis toxin in acellular pertussis vaccines using HRH1-mediated calcium signaling.
    Vaccine. 2025;54:127056.
    PubMed     Abstract available


  269. CENAT JM, Moshirian Farahi SMM, Dalexis RD, Xu Y, et al
    Vaccine hesitancy among racially diverse parents in Canada: The important role of health literacy, conspiracy beliefs and racial discrimination.
    Vaccine. 2025;55:127049.
    PubMed     Abstract available


  270. TIRUNEH YM, Choi J, Cuccaro PM, Martinez J, et al
    Sociodemographic and health-related predictors of COVID-19 booster uptake among fully vaccinated adults.
    Vaccine. 2025;54:127048.
    PubMed     Abstract available


  271. OKOLI GN, Grossman Moon A, Soos AE, Neilson CJ, et al
    Hepatitis B vaccination initiation and vaccination series completion: An in-depth systematic evidence review, with meta-analysis of associations with individual socioeconomic and health-related factors.
    Vaccine. 2025;55:127051.
    PubMed     Abstract available


  272. STRAVORAVDI AS, Ladas AI, Frantzidis CA, Papazisis G, et al
    HAVI: A novel tool to explore vaccine hesitancy among adults in Greece.
    Vaccine. 2025;55:127042.
    PubMed     Abstract available


  273. VYSOTSKAYA V, Gassowski M, Kasper A, Gasich E, et al
    Hepatitis B serosurvey to validate the achievement of regional hepatitis B control targets in Belarus.
    Vaccine. 2025;55:127058.
    PubMed     Abstract available


  274. MOUCHERAUD C, Ochieng E, Kweka A, Wang P, et al
    Parent-daughter agreement about HPV vaccination status in Kenya and Malawi.
    Vaccine. 2025;55:127025.
    PubMed     Abstract available


  275. KANG M, Marks KM, Cox AL, Sherman KE, et al
    An efficient vaccine clinical trial: ACTG A5379 hepatitis B vaccine trial in persons with HIV.
    Vaccine. 2025;55:127028.
    PubMed     Abstract available


  276. FUNK T, Norgaard SK, Hallundbaek L, Grau J, et al
    Effect of a proactive childhood vaccination reminder system on vaccination coverage and uptake in Denmark: A register-based cohort study.
    Vaccine. 2025;54:126934.
    PubMed     Abstract available


  277. ZHANG Y, Sullivan N, Abraham M, Haley HD, et al
    Evaluation of HPV-loaded PLGA microparticles as single-dose HPV vaccine: Insights for sustained-release vaccine development.
    Vaccine. 2025;55:127024.
    PubMed     Abstract available


  278. VEDEL JO, Furtado O, Almeida LL, Martins JSD, et al
    Refresher training in administering intradermal BCG-vaccine increased BCG-scarring rates in rural Guinea-Bissau.
    Vaccine. 2025;55:127039.
    PubMed     Abstract available


  279. EMARY K, Bentsi-Enchill AD, Giersing BK, Gordon M, et al
    Landscape analysis of invasive non-typhoidal salmonella (iNTS) disease and iNTS vaccine use case and demand: Report of a WHO expert consultation.
    Vaccine. 2025;55:127008.
    PubMed     Abstract available


  280. BAKARE AA, Gobbo E, Akinsola KO, King C, et al
    "It's easier to deal with the vaccines you know than the ones you don't know": A qualitative study on healthcare workers' vaccine confidence in Nigeria.
    Vaccine. 2025;55:127020.
    PubMed    


  281. FRIVOLD C, Giersing B, Amorij JP, Mvundura M, et al
    Identification of potential vaccines for use with microarray patches in low- and middle-income countries: An assessment from the Vaccine Innovation Prioritisation Strategy Alliance.
    Vaccine. 2025;55:126996.
    PubMed     Abstract available


  282. BLACKWELL CK, Bekelman T, Bakre S, Jacobson LP, et al
    Sociodemographic differences in parental hesitancy to the COVID-19 vaccine.
    Vaccine. 2025;55:127041.
    PubMed     Abstract available


  283. GOEDERS N, Vanneste K, Roosens NHC, Bogaerts B, et al
    Molecular and WGS-based characterization of invasive Neisseria meningitidis isolates collected in Belgium (2016-2022) and MenB-FHbp vaccine coverage estimation of serogroup B.
    Vaccine. 2025;55:127026.
    PubMed     Abstract available


  284. MELOT L, Thyfault E, Hester K, Prausnitz MR, et al
    Perceptions of non-needle-based vaccination devices in the state of Georgia.
    Vaccine. 2025;55:127038.
    PubMed     Abstract available


  285. HARALAMBIEVA IH, Ratishvili T, Goergen KM, Grill DE, et al
    Effect of lymphocyte miRNA expression on influenza vaccine-induced immunity.
    Vaccine. 2025;55:127023.
    PubMed     Abstract available


  286. FRANCIS MJ
    A rapid human vaccine process development map outlining lessons learnt from ChAdOx1 nCoV-19 vaccine during the COVID-19 pandemic.
    Vaccine. 2025;55:127040.
    PubMed     Abstract available


  287. AHMAD I, Burton R, Arshad R, Younis BB, et al
    Humoral immune response to 10-valent pneumococcal conjugate vaccine (PCV10) in individuals with type 2 diabetes mellitus.
    Vaccine. 2025;55:127029.
    PubMed     Abstract available


  288. YAN K, Xu S, Fang H, Yang H, et al
    Next-generation immunotherapeutic strategy and clinical advances of vaccines against nicotine addiction.
    Vaccine. 2025;55:127036.
    PubMed     Abstract available


  289. GOLDMAN RD, Hart RJ, Bone JN, Seiler M, et al
    Adverse events among early caregivers' COVID-19 vaccination correlated inversely with intention to vaccinate their children.
    Vaccine. 2025;55:127001.
    PubMed     Abstract available


  290. SALLOUM M, Lariviere Y, Bikioli Bolombo F, Zola Matuvanga T, et al
    The exclusion of pregnant women from an Ebola vaccine trial in Boende, western DRC: Perceptions of female participants who became pregnant and community members.
    Vaccine. 2025;55:127000.
    PubMed     Abstract available


  291. VACHON A, Keeshan A, Galipeau Y, Crawley AM, et al
    Alcohol consumption does not influence SARS-CoV-2 vaccine immunogenicity: A stop the spread Ottawa cohort analysis.
    Vaccine. 2025;55:127034.
    PubMed     Abstract available


  292. KAISER S, Kaiser S, Reis J, Marschalek R, et al
    Quantification of objective concentrations of DNA impurities in mRNA vaccines.
    Vaccine. 2025;55:127022.
    PubMed     Abstract available


  293. CRAWLEY AW, Murphy K, Plumb ID, Ocansey GA, et al
    Challenges and enablers to establishing COVID-19 vaccine effectiveness studies in the World Health Organization Africa region: A mixed-methods evaluation of the African region monitoring vaccine effectiveness (AFRO-MoVE) network.
    Vaccine. 2025 Mar 20:126823. doi: 10.1016/j.vaccine.2025.126823.
    PubMed     Abstract available


  294. HAMID S, Simeone RM, Newhams MM, Halasa N, et al
    Concordance between parent-reported and documented COVID-19 vaccination status among hospitalized children and adolescents: Implications for vaccine effectiveness estimates, May 2021-October 2023.
    Vaccine. 2025;54:126891.
    PubMed     Abstract available


  295. SHINO MY, Ibarrondo FJ, Yang OO
    SARS-CoV-2 spike antibody levels in lung transplantation recipients versus the spectrum in non-immunocompromised persons.
    Vaccine. 2025;50:126851.
    PubMed     Abstract available


  296. HAGEDORN B, Frey K, Scarna T, El Sheikh F, et al
    Microarray patches likely to reduce the operational costs of immunization: A Monte Carlo simulation study.
    Vaccine. 2025;50:126840.
    PubMed     Abstract available


  297. ILIYASU Z, Danzomo AA, Jeyaseelan V, Gofama MM, et al
    Impact of novel Oral Poliovirus Type 2 vaccination campaigns: A seroprevalence survey in Nigeria, 2022.
    Vaccine. 2025;54:126978.
    PubMed    


  298. THORS V, Vias RD, Bjornsdottir K, Palsdottir EB, et al
    Influenza vaccine effectiveness in Iceland 2014-2022: A test-negative design.
    Vaccine. 2025;55:126981.
    PubMed     Abstract available


  299. RASKIN N, Hiligsmann M, Luyten J, Tubeuf S, et al
    Socio-demographic differences in citizen' preferences for distributing a scarce, lifesaving resource: A case study using COVID-19 vaccine distribution in Belgium.
    Vaccine. 2025;55:126997.
    PubMed     Abstract available


  300. NAZIAT H, Rahman MH, Das RC, Islam M, et al
    Impact of 10-valent pneumococcal conjugate vaccine on the epidemiology of otitis media with otorrhea among Bangladeshi children.
    Vaccine. 2025;55:126995.
    PubMed     Abstract available


  301. CHOI J, Feelemyer J, Choe K, Lynch K, et al
    Anti-vaccine attitudes and COVID-19 vaccine status at the end of the U.S. public health emergency.
    Vaccine. 2025;55:127003.
    PubMed     Abstract available


  302. BALDOLLI A, Fournier A, Roger H, Piednoir E, et al
    Implementation of school-based vaccination in French middle schools: Efficient or not?
    Vaccine. 2025;55:127007.
    PubMed     Abstract available


  303. MPABALWANI EM, Sakala C, Kamiji E, Simwaka J, et al
    Challenges and lessons learned during the switching of rotavirus vaccine from Rotarix to Rotavac in Zambia.
    Vaccine. 2025;55:127012.
    PubMed     Abstract available


  304. HEGMANN TE, Walter EB, Smith MJ, Campbell J, et al
    A phase I study of the safety, reactogenicity and immunogenicity of two quadrivalent seasonal influenza vaccines (Fluzone(R) or Flublok(R)) with or without one of two adjuvants (AF03 or Advax-CpG55.2) in healthy adults 18-45 years of age.
    Vaccine. 2025;54:126991.
    PubMed     Abstract available


  305. GHARPURE R, Vegvari C, Abdissa A, Alimi Y, et al
    Meeting report: CEPI workshop on Rift Valley fever epidemiology and modeling to inform human vaccine development, Nairobi, 4-5 June 2024.
    Vaccine. 2025;54:126860.
    PubMed     Abstract available


  306. MACGIBBON J, Storer D, Bavinton BR, Cornelisse VJ, et al
    Mpox vaccination coverage among Australian gay and bisexual men and non-binary people: Results of behavioural surveillance in early 2024.
    Vaccine. 2025;55:127014.
    PubMed     Abstract available


  307. YANAI T, Yoshida S, Kawakami K
    Gastroenteritis hospitalizations over 19 years before and after introduction of rotavirus vaccine in Japan: A nationwide claims database.
    Vaccine. 2025;55:127027.
    PubMed     Abstract available


  308. YUILL S, Hall MT, Caruana M, Lui G, et al
    Predicted impact of HPV vaccination and primary HPV screening on precancer treatment rates and adverse pregnancy outcomes in Australia 2010-2070: Modelling in a high income, high vaccination coverage country with HPV-based cervical screening.
    Vaccine. 2025;54:126986.
    PubMed     Abstract available


  309. ZHANG X, Zhao T, Cai X, Zhang W, et al
    Are health education effective to improve herpes zoster vaccine willingness in vulnerable elderly.
    Vaccine. 2025;54:126975.
    PubMed     Abstract available


  310. XU J, Davoudpour S, Phillips G 2nd
    Applying the health belief model (HBM) to understand COVID-19 vaccine uptake among youth and young adults: Findings from a 6-month follow-up study in the United States.
    Vaccine. 2025;54:127002.
    PubMed     Abstract available


  311. PATTHAMMAVONG C, Wodniak N, Phounphenghack K, Tengbriacheu C, et al
    Factors associated with influenza and COVID-19 vaccination among health workers in Lao PDR, 2023.
    Vaccine. 2025;54:127006.
    PubMed     Abstract available


  312. RICCI L, Fery C, Tubach F, Agrinier N, et al
    Health care institutions and their physicians are the greatest promoters of COVID-19 vaccine acceptance among health care workers.
    Vaccine. 2025;54:127005.
    PubMed     Abstract available


  313. MYBURGH L, Karsjens H, Blanas A, de Ligt A, et al
    Targeting the early life stages of SARS-CoV-2 using a multi-peptide conjugate vaccine.
    Vaccine. 2025;54:126989.
    PubMed     Abstract available


  314. LU H
    Generative AI for vaccine misbelief correction: Insights from targeting extraversion and pseudoscientific beliefs.
    Vaccine. 2025;54:127018.
    PubMed     Abstract available


  315. FIRTH C, Emary K, Stuart A, Browne R, et al
    Acceptability of the gonorrhoea human challenge model to accelerate vaccine development in UK men.
    Vaccine. 2025;54:127013.
    PubMed     Abstract available


  316. SKOCZYNSKA A, Golebiewska A, Wrobel-Pawelczyk I, Ronkiewicz P, et al
    The direct impact of mandatory PCV10 vaccination on invasive pneumococcal disease in Polish children.
    Vaccine. 2025;54:126999.
    PubMed     Abstract available


  317. TAMIR TT, Tekeba B, Techane MA, Alemu TG, et al
    Coverage of complete basic childhood vaccination and its variation by basic characteristics among children aged 12-23 months in 41 low- and middle-income countries: A Meta-analysis of demographic and health survey reports between 2015 and 2025.
    Vaccine. 2025;54:127019.
    PubMed     Abstract available


  318. VEDEL JO, Furtado O, Almeida LL, Nehal KR, et al
    Childhood vaccination coverages in rural Guinea-Bissau before and during the early COVID-19 pandemic, a cohort study.
    Vaccine. 2025;54:127011.
    PubMed     Abstract available


  319. MARTINON-TORRES F, Martinez SN, Kline MJ, Drozd J, et al
    A phase 3 study of 20-valent pneumococcal conjugate vaccine in healthy toddlers previously vaccinated in infancy with 13-valent pneumococcal conjugate vaccine.
    Vaccine. 2025;53:126931.
    PubMed     Abstract available


  320. DAVIS P, Montroy J, Warshawsky B, Abrams EM, et al
    Immunogenicity of pre-exposure rabies vaccination comparing number of doses and routes of administration: A systematic review and meta-analyses.
    Vaccine. 2025;53:126878.
    PubMed     Abstract available


  321. SIKUVI K, Nghitukwa N, Kakehongo N, Katjitae I, et al
    Effectiveness of COVID-19 vaccines against laboratory-confirmed SARS-CoV-2 infection amongst health workers, Windhoek, Namibia.
    Vaccine. 2025 Mar 11:126977. doi: 10.1016/j.vaccine.2025.126977.
    PubMed     Abstract available


  322. BOLU O, Alo OD, Iwara E, Longley AT, et al
    Feasibility of cohort event monitoring and assessment of reactogenicity and adverse events among a cohort of AstraZeneca and Moderna COVID-19 vaccine recipients in Nigeria, 2021.
    Vaccine. 2025;52:126907.
    PubMed     Abstract available


  323. DI CHIARA C, Karimi-Shahrbabak E, Peresin J, Farrar DS, et al
    A review of Canadian online resources providing information on COVID-19 vaccination for caregivers of children aged 5-11 years.
    Vaccine. 2025;54:126990.
    PubMed     Abstract available


  324. MEERAUS W, Postema A, Gray CM, Lee A, et al
    Second booster doses of adenoviral- and mRNA-based COVID-19 vaccines increase protection against COVID-19 hospitalization: Final analysis from the REFORCO-Brazil real-world effectiveness study during Omicron.
    Vaccine. 2025;53:126955.
    PubMed     Abstract available


  325. KRAMMER F
    Next-generation seasonal influenza virus vaccines need a neuraminidase component.
    Vaccine. 2025;54:126994.
    PubMed    


  326. OTIENO NA, Kalani R, Ayugi J, Nyawanda BO, et al
    Seasonal influenza vaccination in Kenya: What determines healthcare Workers' willingness to accept and recommend vaccination?
    Vaccine. 2025;54:126963.
    PubMed     Abstract available


  327. DE SOUZA RA, Barreto FR, de Jesus Lima CCO, da Natividade MS, et al
    Efficacy of BCG vaccination on incidence, severity and clinical progression of COVID-19: A BCG-REVAC population analysis.
    Vaccine. 2025;54:126911.
    PubMed     Abstract available


  328. JI C, Senthinathan A, Apajee J, Dubey V, et al
    Impact of the COVID-19 pandemic on routine immunization coverage of children and teenagers in Ontario, Canada.
    Vaccine. 2025;49:126811.
    PubMed     Abstract available


  329. FORZY T, Tesfaye L, Getnet F, Misganew A, et al
    Assessing the geographic and socioeconomic determinants of vaccine coverage in Ethiopia: A spatial and multistage analysis at the district level.
    Vaccine. 2025;53:126834.
    PubMed     Abstract available


  330. DESILVA MB, Vazquez-Benitez G, Seburg EM, Henderson MSG, et al
    Pregnant persons perceptions and uptake of prenatal RSV vaccine - Minnesota, 2023-2024.
    Vaccine. 2025;54:126958.
    PubMed     Abstract available


  331. DOWGIER G, Hobbs A, Greenwood D, Shawe-Taylor M, et al
    Accurate evaluation of live-virus microneutralisation for SARS-CoV-2 variant JN.1 in the assessment of vaccination and therapeutics.
    Vaccine. 2025;54:126960.
    PubMed     Abstract available


  332. NAVAEISEDDIGHI Z, Schmit T, Wang Z, Ahamed N, et al
    The vaccine dosing effect overcomes the reduced immunogenic potential and in vivo efficacy of 33F pneumococcal serotype.
    Vaccine. 2025;54:126983.
    PubMed     Abstract available


  333. LEE DW, Nasir A, Elbashir S, Jani H, et al
    mRNA-1273 vaccines adapted to JN.1 or KP.2 elicit cross-neutralizing responses against the JN.1 sublineages of SARS-CoV-2 in mice.
    Vaccine. 2025;54:126961.
    PubMed     Abstract available


  334. ABAASA AM, Kusemererwa S, Ankunda V, Ongaria TA, et al
    Effectiveness of COVID-19 vaccine against SARS-CoV-2 infection among symptomatic COVID-19 patients in Uganda.
    Vaccine. 2025 Mar 6:126976. doi: 10.1016/j.vaccine.2025.126976.
    PubMed     Abstract available


  335. KUSEMERERWA S, Ankunda V, Ongaria TA, Abaasa A, et al
    COVID-19 vaccination status and associated factors among patients presenting with COVID-19-like symptoms in Uganda.
    Vaccine. 2025 Mar 6:126984. doi: 10.1016/j.vaccine.2025.126984.
    PubMed     Abstract available


  336. CARTER JJ, Smith RA, Scherer EM, Skibinski DAG, et al
    Corrigendum to "Long-Term immune memory responses to human papillomavirus (HPV) vaccination following 2 versus 3 doses of HPV vaccine" [Vaccine, Volume 50, 19 March 2025, 126,817].
    Vaccine. 2025;54:126974.
    PubMed    


  337. TILLYA R, Abdallah G, Msuya H, Bajaria S, et al
    Associated factors for dropout of first versus third doses of pentavalent vaccination in Tanzania.
    Vaccine. 2025;54:126962.
    PubMed     Abstract available


  338. XIMENES R, Simmons AE, Gebretekle GB, Nam A, et al
    Cost-effectiveness analysis of 21-valent pneumococcal conjugated vaccine among adults in Canada.
    Vaccine. 2025;54:126985.
    PubMed     Abstract available


  339. MINUTTI AF, Sasse JP, Dos Santos Silva AC, Martins TA, et al
    Evaluation of a DNA vector plasmid encoding a partial rop18 gene from toxoplasma gondii in domestic cats as a vaccine candidate.
    Vaccine. 2025;54:126965.
    PubMed     Abstract available


  340. GORDON JL, Boespflug EL, Coleman A, Taylor K, et al
    Development of broadly protective coronavirus vaccines: A joint NIAID-CEPI workshop report.
    Vaccine. 2025;54:126909.
    PubMed    


  341. CARROLL M, Fox HB, Tran A, Chellappan G, et al
    SARS-CoV-2 conjugate vaccine elicits robust immune responses that can protect against evolving variants.
    Vaccine. 2025;54:126988.
    PubMed     Abstract available


  342. PROCTOR RA, Jackson AM, Fowler VG
    The lack of a biorepository during vaccine trials: A lost opportunity to understand staphylococcal immunity.
    Vaccine. 2025;53:126896.
    PubMed     Abstract available


  343. GATES CJ, Brazel EB, Kennedy EV, Brown JS, et al
    A gamma-irradiated pneumococcal vaccine elicits superior immunogenicity in comparison to heat or chemically inactivated whole-cell vaccines.
    Vaccine. 2025;54:126982.
    PubMed     Abstract available


  344. MOORE M, Anderson L, Schiffer JT, Matrajt L, et al
    Durability of COVID-19 vaccine and infection induced immunity: A systematic review and meta-regression analysis.
    Vaccine. 2025;54:126966.
    PubMed     Abstract available


  345. CHISNALL G, Letley L, Mounier-Jack S, Bedford H, et al
    Parents' experiences of accessing childhood vaccination services in England: A qualitative longitudinal cohort study.
    Vaccine. 2025;52:126921.
    PubMed     Abstract available


  346. RAMIREZ-BENCOMO F, Thistlethwaite A, Viviani V, Bartolini E, et al
    Identification of immunogenic outer membrane vesicle vaccine antigen components using a meningococcal protein microarray.
    Vaccine. 2025;53:126953.
    PubMed     Abstract available


  347. PEIXOTO DE MIRANDA EJF, Calado RT, Boulos FC, de Sousa Moreira JA, et al
    Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Results of a randomized vaccine-controlled phase I ADAPTCOV trial in Brazil.
    Vaccine. 2025;52:126680.
    PubMed     Abstract available


  348. CHU CF, Chang TH, Ho JJ
    Comparative analysis of fourteen COVID-19 vaccine injury compensation systems and claim approval rates.
    Vaccine. 2025;52:126830.
    PubMed     Abstract available


  349. HAMIDI A, Willemsen M, Robert T, Drugmand JC, et al
    Sabin inactivated polio vaccine upstream process development using fixed-bed bioreactor technology.
    Vaccine. 2025;53:126950.
    PubMed     Abstract available


  350. ZHAO T, Xu Q, Cai X, Wang M, et al
    Global spatio-temporal distribution of coronavirus disease 2019 vaccine hesitancy between 2020 and 2022: A meta-analysis.
    Vaccine. 2025;53:126933.
    PubMed     Abstract available


  351. MAFUTA EM, Lulebo AM, Kasonga JN, Mvuama NM, et al
    Designing a National Rapid Vaccine Coverage Survey in low-resource settings: Experiences from the Democratic Republic of the Congo 2018-2023.
    Vaccine. 2025;53:126956.
    PubMed     Abstract available


  352. FRANCA AP, Domingues CMAS, Domingues RAS, Barata RB, et al
    Vaccine hesitancy in the vaccination of children in Brazil.
    Vaccine. 2025;53:126905.
    PubMed     Abstract available


  353. COTTER LM, Hopkins-Sheets M, Yang S, Passmore SR, et al
    Increasing confidence for pediatric COVID-19 and influenza vaccines using messages affirming parental autonomy: A randomized online experiment.
    Vaccine. 2025;53:126947.
    PubMed     Abstract available


  354. AYAD C, Porter D, Lambert E, Libeau P, et al
    An LNP-mRNA vaccine protects fish against rhabdovirus infection.
    Vaccine. 2025;53:126957.
    PubMed     Abstract available


  355. TENGATTINI S, Bavaro T, Rinaldi F, Temporini C, et al
    Novel tuberculosis vaccines based on TB10.4 and Ag85B: State-of-art and advocacy for good practices.
    Vaccine. 2025;53:126932.
    PubMed     Abstract available


  356. ONYANDO BO, Nyawanda BO, Onguru D, Haidara FC, et al
    Factors associated with mortality among patients aged 12 years and above requiring hospitalization for severe respiratory illness (SRI): Findings from the COVID-19 vaccine effectiveness evaluation in Kenya and Mali, 2022-2023.
    Vaccine. 2025 Mar 1:126910. doi: 10.1016/j.vaccine.2025.126910.
    PubMed     Abstract available


  357. DAVIES A, Schreiber D, Carey C, Tucker SB, et al
    Community pharmacists' pneumococcal vaccine knowledge and perceived barriers to vaccination.
    Vaccine. 2025;53:126930.
    PubMed     Abstract available


  358. KEELING MJ, Hill EM, Petrou S, Tran PB, et al
    Cost-effectiveness of routine COVID-19 adult vaccination programmes in England.
    Vaccine. 2025;53:126948.
    PubMed     Abstract available


  359. NIU Y, Yan Y, Hu Y, Yang X, et al
    A novel tetravalent influenza vaccine based on one chimpanzee adenoviral vector.
    Vaccine. 2025;53:126959.
    PubMed     Abstract available


    February 2025
  360. SHAO Q
    Corrigendum to The origin of vaccine nationalism [Vaccine 51 (2025) 126897].
    Vaccine. 2025;53:126935.
    PubMed    


  361. RIGAMONTI V, Torri V, Morris SK, Ieva F, et al
    Real-world effectiveness of influenza vaccination in preventing influenza and influenza-like illness in children.
    Vaccine. 2025;53:126946.
    PubMed     Abstract available


  362. WANG B, Lassi Z, Andraweera P, Chen G, et al
    Pregnant women's choices for preventing respiratory syncytial virus (RSV).
    Vaccine. 2025;48:126790.
    PubMed     Abstract available


  363. ZHOU S, Wang J, Lv M, Lan W, et al
    Long-term antibody trajectories after PPSV23 in elderly: Results from a 4-year follow-up study.
    Vaccine. 2025;48:126737.
    PubMed     Abstract available


  364. ADU P, Popoola T, Iqbal N, Roemer A, et al
    A cross-country network analysis of disease infodemics: Looking through the lens of the COVID-19 pandemic.
    Vaccine. 2025;48:126733.
    PubMed     Abstract available


  365. AN SJ, Yang JS, Chae MH, Woo JS, et al
    Development of invasive non-typhoidal Salmonella conjugate vaccines and their evaluation in a trivalent formulation with typhoid conjugate vaccine.
    Vaccine. 2025;52:126913.
    PubMed     Abstract available


  366. GUTTIERES D, Van Riet C, Vandaele N, Decouttere C, et al
    Dynamics of global emergency vaccine stockpiles: A systems analysis and application to cholera.
    Vaccine. 2025;52:126889.
    PubMed     Abstract available


  367. KIM HJ, Lee SH, Park YS, Seo DW, et al
    Utility of edible plant-derived exosome-like nanovesicles as a novel delivery platform for vaccine antigen delivery.
    Vaccine. 2025;52:126902.
    PubMed     Abstract available


  368. SHEERAH HA, Al-Jedai AH, Al-Jerian NA, Al-Otaiby MA, et al
    COVID-19 and influenza hospitalizations and the role of COVID-19 vaccination in the post-pandemic period: A cross-sectional study from Saudi Arabia.
    Vaccine. 2025;52:126937.
    PubMed     Abstract available


  369. SINGER D, Salem A, Stempniewicz N, Ma S, et al
    Corrigendum to "The potential impact of increased recombinant zoster vaccine coverage on the burden of herpes zoster among adults aged 50-59 years" [Vaccine 41 (37) (23 August 2023) 5360-5367].
    Vaccine. 2025;52:126805.
    PubMed    


  370. MATHUR I, Ruisch A, Conlin M, Oyatoye I, et al
    COVID-19 vaccination integration, innovations and key populations: Results from a global survey.
    Vaccine. 2025;52:126863.
    PubMed     Abstract available


  371. ARABIAN S, Sadr M, Ayati MH, Ince F, et al
    The earliest report of smallpox oral vaccination by Baha' al-Dawlah Razi in the 16th century.
    Vaccine. 2025;52:126949.
    PubMed     Abstract available


  372. PEREZ-PEREZ A, Vallejo JR
    Francisco Oller y Ferrer (1758-1831). The surgeon who performed the first smallpox vaccination in a Hispanic American territory.
    Vaccine. 2025;51:126875.
    PubMed     Abstract available


  373. GRIFFIN LB, Polnaszek BE, Shin J, Clark MA, et al
    Parental status and gender are associated with differences in Tdap vaccination rates among United States adults.
    Vaccine. 2025;52:126901.
    PubMed     Abstract available


  374. BENDERA A, Nakamura K, Tran XMT, Kapologwe NA, et al
    Persistent socioeconomic disparities in childhood vaccination coverage in Tanzania: Insights from multiple rounds of demographic and health surveys.
    Vaccine. 2025;52:126904.
    PubMed     Abstract available


  375. DHINGRA MS, Peterson J, Hedrick J, Pan J, et al
    Corrigendum to "Immunogenicity, safety and inter-lot consistency of a meningococcal conjugate vaccine (MenACYW-TT) in adolescents and adults: A Phase III randomized study" [Vaccine (38) (2020) 5194-5201].
    Vaccine. 2025;52:126912.
    PubMed    


  376. DIYA O, Gayed J, Lowry FS, Ma H, et al
    A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults >/=18 years old.
    Vaccine. 2025;52:126869.
    PubMed     Abstract available


  377. LEBLANG D, Smith MD, Wesselbaum D
    Global perspectives on COVID-19 vaccination: Impacts on well-being and inequality.
    Vaccine. 2025;52:126906.
    PubMed     Abstract available


  378. ANDERSEN KM, Allen KE, Nepal RM, Mateus JS, et al
    Effectiveness of BNT162b2 XBB.1.5 vaccine in immunocompetent adults using tokenization in two U.S. states.
    Vaccine. 2025;52:126881.
    PubMed     Abstract available


  379. DUDLEY MZ, Zapf AJ, Delamater P, Proveaux TM, et al
    Attitudes of California school personnel on potential COVID-19 vaccine mandates and state law SB277 to remove nonmedical vaccine exemptions.
    Vaccine. 2025;52:126888.
    PubMed     Abstract available


  380. GARLING A, Goursat C, Seguy C, Martin P, et al
    Development of intimin-enriched outer membrane vesicles (OMVs) as a vaccine to control intestinal carriage of Enterohemorrhagic Escherichia coli.
    Vaccine. 2025;52:126899.
    PubMed     Abstract available


  381. FARAH Z, Bazant ES, Basha I, Saleh N, et al
    Determinants of seasonal influenza vaccination uptake, intention and recommendations among Lebanese physicians.
    Vaccine. 2025;52:126890.
    PubMed     Abstract available


  382. CHIBA S, Halfmann PJ, Iida S, Hirata Y, et al
    Correction to "Recombinant Spike protein vaccines coupled with adjuvants that have different modes of action induce protective immunity against SARS-CoV-2" [Vaccine 2023 Sep 22 41(41) 6025-6035. Doi: 10.1016/j.vaccine.2023.08.054].
    Vaccine. 2025;52:126880.
    PubMed     Abstract available


  383. YE Q, Xiao Z, Bai C, Yao H, et al
    Unveiling the multi-characteristic potential of hyper-productive suspension MDCK cells for advanced influenza A virus propagation.
    Vaccine. 2025;52:126900.
    PubMed     Abstract available


  384. MACKENZIE LJ, Bousie JA, Newman P, Cunningham J, et al
    What three years of COVID-19 vaccine administration reveals about the incidence of shoulder injury related to vaccine administration (SIRVA).
    Vaccine. 2025;51:126892.
    PubMed     Abstract available


  385. VAN BEEK LF, van der Gaast-de Jongh C, Platenburg PP, Hilgers L, et al
    Improving the immunogenicity of the pneumococcal conjugate vaccine using a synthetic carbohydrate fatty acid monosulphate squalane-in-water adjuvant.
    Vaccine. 2025;51:126893.
    PubMed     Abstract available


  386. ATTI A, England A, Sung J, Foulkes S, et al
    Estimating neutralising antibody responses against emerging SARS-CoV-2 variants utilising convalescent sera before the roll-out of XBB-lineage vaccines.
    Vaccine. 2025;51:126898.
    PubMed     Abstract available


  387. MEYERS E, De Rop L, Deschepper E, Duysburgh E, et al
    SARS-CoV-2 seroreversion and all-cause mortality in nursing home residents and staff post-primary course vaccination in Belgium between February and December 2021.
    Vaccine. 2025;51:126865.
    PubMed     Abstract available


  388. BERGSTROM F, Gunther F, Britton T
    A counterfactual analysis quantifying the COVID-19 vaccination impact in Sweden.
    Vaccine. 2025;52:126870.
    PubMed     Abstract available


  389. DERBISE A, Guillas C, Echenique-Rivera H, Carniel E, et al
    Contribution of the type 3 secretion system to adaptive and innate immunity induced by a live Yersinia pseudotuberculosis plague vaccine.
    Vaccine. 2025;51:126887.
    PubMed     Abstract available


  390. SHAO Q
    The origin of vaccine nationalism.
    Vaccine. 2025;51:126897.
    PubMed    


  391. HALL C, Lanning J, Romano CJ, Bukowinski AT, et al
    COVID-19 vaccine initiation in pregnancy and risk for adverse neonatal outcomes among United States military service members, January-December 2021.
    Vaccine. 2025;51:126894.
    PubMed     Abstract available


  392. ZHAO T, Liu X, Huang X, Wang L, et al
    Development and evaluation of mosaic VLPs vaccine for enhanced broad-Spectrum immunity against influenza B virus lineages in mice.
    Vaccine. 2025;51:126882.
    PubMed     Abstract available


  393. TAAFFE J, Goldin S, Lambach P, Sparrow E, et al
    Global production capacity of seasonal and pandemic influenza vaccines in 2023.
    Vaccine. 2025;51:126839.
    PubMed     Abstract available


  394. DARWAR R, Huang X, Abayeneh A, Alemayehu Beshah S, et al
    Costing approaches for vaccine-preventable disease surveillance: Lessons from Ethiopia and Nepal.
    Vaccine. 2025;50:126776.
    PubMed     Abstract available


  395. SIERRA MS, Carvajal LJ, Dull P, Herrero R, et al
    Human papillomavirus type 16 and 18 viral clearance and progression to precancer among women aged 18-25 years enrolled in the Costa Rica HPV prophylactic vaccine trial (CVT).
    Vaccine. 2025;50:126841.
    PubMed     Abstract available


  396. APPEL AM, Janbek J, Laursen TM, Gasse C, et al
    Dementia and influenza vaccination: Time trends and predictors of vaccine uptake among older adults.
    Vaccine. 2025;51:126864.
    PubMed     Abstract available


  397. MONTROY J, Yan C, Khan F, Forbes N, et al
    Post-exposure prophylaxis for the prevention of measles: A systematic review.
    Vaccine. 2025;47:126706.
    PubMed     Abstract available


  398. KAHN R, Moiane B, Lessa FC, Massora S, et al
    Nasopharyngeal carriage of Streptococcus pneumoniae among children and their household members in southern Mozambique five years after PCV10 introduction.
    Vaccine. 2025;47:126691.
    PubMed     Abstract available


  399. YILDIRIM M, Keskinocak P, Hinderstein S, Tran K, et al
    A comprehensive analysis of serotype-specific invasive capacity, clinical presentations, and mortality trends of invasive pneumococcal disease.
    Vaccine. 2025;47:126692.
    PubMed     Abstract available


  400. KEMP M, Capriola A, Schauer S
    RSV immunization uptake among infants and pregnant persons - Wisconsin, October 1, 2023-March 31, 2024.
    Vaccine. 2025;47:126674.
    PubMed     Abstract available


  401. YE Q, Li H, Xie Z, Gao X, et al
    Antibody persistence in Chinese toddlers at 1 year and 2 years after two different 4-dose schedules of a novel 13-valent pneumococcal conjugate vaccine (PCV13-TT).
    Vaccine. 2025 Feb 15:126815. doi: 10.1016/j.vaccine.2025.126815.
    PubMed     Abstract available


  402. CHANG C, Patel H, Ferrari A, Scalzo T, et al
    sa-mRNA influenza vaccine raises a higher and more durable immune response than mRNA vaccine in preclinical models.
    Vaccine. 2025;51:126883.
    PubMed     Abstract available


  403. BENN CS
    Non-specific effects of vaccines: The status and the future.
    Vaccine. 2025;51:126884.
    PubMed    


  404. THOMPSON EL, Akpan IN, Alkhatib S, Grace J, et al
    Implementation of mid-adult HPV vaccination guidelines into clinical practice.
    Vaccine. 2025;51:126867.
    PubMed     Abstract available


  405. SMITH DS, Postma M, Fisman D, Mould-Quevedo J, et al
    Cost-effectiveness models assessing COVID-19 booster vaccines across eight countries: A review of methods and data inputs.
    Vaccine. 2025;51:126879.
    PubMed     Abstract available


  406. DEANE A, White C, Morrissey Y, Jessop L, et al
    The impact of HPV vaccine disinformation and misinformation in disadvantaged educational settings in Ireland: A multi-year analysis of a school immunisation system.
    Vaccine. 2025;51:126868.
    PubMed     Abstract available


  407. BERRYMAN S, Asfor A, Benham E, Howe N, et al
    Foot-and-mouth disease vaccine quality: A universal test for intact viral capsids based on detection of VP4.
    Vaccine. 2025;51:126845.
    PubMed     Abstract available


  408. VAN DIEMEN PM, Lean FZX, Ramsay A, Mollett BC, et al
    Evaluation of a nanoparticle influenza vaccine in the pig model.
    Vaccine. 2025;49:126844.
    PubMed     Abstract available


  409. KIM SY, Song M, Kwon SL
    Impact of caregiver vaccination status on child influenza vaccination hesitancy: A time-to-vaccination analysis for 2023-2024 season in the Republic of Korea.
    Vaccine. 2025;49:126852.
    PubMed     Abstract available


  410. COTUGNO N, Sanna M, Amodio D, Morrocchi E, et al
    Pre-vaccination immune markers predict response to BNT162b2 mRNA vaccine in vulnerable groups - The CONVERS project, report from a pediatric tertiary hospital.
    Vaccine. 2025;49:126778.
    PubMed     Abstract available


  411. SHERMAN ME, Michalski J, Das S, Yang H, et al
    BECC-engineered live-attenuated Shigella vaccine candidates display reduced endotoxicity with robust immunogenicity in mice.
    Vaccine. 2025;50:126779.
    PubMed     Abstract available


  412. ADAMS L, Karachaliou Prasinou A, Trotter C
    Modelling the impact and cost effectiveness of universal varicella vaccination in England.
    Vaccine. 2025;50:126831.
    PubMed     Abstract available


  413. ESSINK BJ, Vermeulen W, Andrade C, de Rooij R, et al
    A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults aged 50 years and older.
    Vaccine. 2025;51:126791.
    PubMed     Abstract available


  414. WILLIAMS JTB, Johnson D, Weinshenker D, O'Leary ST, et al
    Co-creation of pediatric influenza digital stories via rapid community translation.
    Vaccine. 2025;51:126866.
    PubMed     Abstract available


  415. O'KENNEDY MM, Reedy SE, Abolnik C, Khan A, et al
    Protective efficacy of a bivalent equine influenza H3N8 virus-like particle vaccine in horses.
    Vaccine. 2025;50:126861.
    PubMed     Abstract available


  416. CAPAO A, Araujo MF, Tort LFL, Toledo TS, et al
    Impact in the humoral and cellular immune response to SARS-CoV-2 variants after primary vaccination with AZD1222/COVISHIELD protocol in healthy adults.
    Vaccine. 2025;50:126785.
    PubMed     Abstract available


  417. HOULE SKD, Constantinescu C, Dube E
    Navigating the 'sea of Cs' in vaccine hesitancy: Where does collaboration fit?
    Vaccine. 2025;51:126876.
    PubMed    


  418. SHARMA A, Kerkhoff AD, Haambokoma M, Shamoya B, et al
    Intention to receive new vaccines post-COVID-19 pandemic among adults and health workers in Lusaka, Zambia.
    Vaccine. 2025;50:126846.
    PubMed     Abstract available


  419. GEIGER M, Betsch C, Bohm R
    Mind the jingle: A call to consider construct validity of the 7C of vaccination readiness.
    Vaccine. 2025 Feb 8:126843. doi: 10.1016/j.vaccine.2025.126843.
    PubMed    


  420. FAUSTINI SE, Backhouse C, Duggal NA, Toellner KM, et al
    Time of day of vaccination does not influence antibody responses to pneumococcal and annual influenza vaccination in a cohort of healthy older adults.
    Vaccine. 2025;49:126770.
    PubMed     Abstract available


  421. NAFICY A, Chugh Y, Tariq M, Hawksworth H, et al
    Immune response and safety of the adjuvanted recombinant zoster vaccine in adults 50 years of age and older in India: A randomized phase 3 trial.
    Vaccine. 2025;50:126819.
    PubMed     Abstract available


  422. SCALSKY R, Dwivedi A, Stabler TC, Mbambo G, et al
    Whole-genome sieve analysis: Identification of protective malaria antigens by leveraging allele-specific vaccine efficacy.
    Vaccine. 2025;50:126783.
    PubMed     Abstract available


  423. FU Y, Xu Z, Wang Q, Zhang J, et al
    Effectiveness and coverage of COVID-19 vaccination among the infection-naive population: A community-based retrospective cohort study in China.
    Vaccine. 2025;50:126836.
    PubMed     Abstract available


  424. FRITSCHI N, Heininger U
    Pertussis vaccination campaign among health care workers and validity of recall of previous adverse events following immunization.
    Vaccine. 2025;50:126850.
    PubMed     Abstract available


  425. ABBAD A, Yueh J, Yellin T, Singh G, et al
    Co-administration of seasonal quadrivalent influenza and COVID-19 vaccines leads to enhanced immune responses to influenza virus and reduced immune responses to SARS-CoV-2 in naive mice.
    Vaccine. 2025;50:126825.
    PubMed     Abstract available


  426. KRAJCAR N, Trkulja V, Butic I, Tesovic G, et al
    Impact of the 10-valent pneumococcal conjugate vaccine (PCV10) on pneumococcal carriage in healthy children and children with acute otitis media and pneumonia: emergence of serotypes 3, 6C and 19A in Croatia.
    Vaccine. 2025;50:126848.
    PubMed     Abstract available


  427. GEBREAL A, Ashmawy R, Ahmed MJ, Khattab M, et al
    A systematic review and meta-analysis on parental uptake and willingness to vaccinate children against human papillomavirus in the Eastern Mediterranean Region.
    Vaccine. 2025 Feb 6:126832. doi: 10.1016/j.vaccine.2025.126832.
    PubMed     Abstract available


  428. NAKAYAMA T, Hamada S, Kawamura A, Sogawa Y, et al
    Non-inferiority and vaccine titer-confirmation studies of MMR vaccine (JVC-001; measles AIK-C, mumps RIT4385, and rubella Takahashi strains) in healthy 1-year-old Japanese children.
    Vaccine. 2025 Feb 6:126698. doi: 10.1016/j.vaccine.2024.126698.
    PubMed     Abstract available


  429. VAHORA MS, Leao O, da Silveira MF, Domingues MR, et al
    Impacts of vaccination, school attendance, and nutrition on SARS-CoV-2 antibody titer in a prospective birth cohort in Brazil.
    Vaccine. 2025;49:126838.
    PubMed     Abstract available


  430. MCCLYMONT E, Wong JMH, Forward L, Blitz S, et al
    Acceptance and preference between respiratory syncytial virus vaccination during pregnancy and infant monoclonal antibody among pregnant and postpartum persons in Canada.
    Vaccine. 2025;50:126818.
    PubMed     Abstract available


  431. KANG HS, Kim SY, De Gagne JC, Chae SM, et al
    Pregnant women's experiences of and attitudes toward COVID-19 vaccination: A qualitative descriptive study.
    Vaccine. 2025;50:126835.
    PubMed     Abstract available


  432. SOENS M, Ananworanich J, Hicks B, Lucas KJ, et al
    A phase 3 randomized safety and immunogenicity trial of mRNA-1010 seasonal influenza vaccine in adults.
    Vaccine. 2025;50:126847.
    PubMed     Abstract available


  433. JENNINGS MC, Nabia S, Morgan C, Nduka CC, et al
    Realist review of low- to upper-middle-income country experiences on integration of HPV vaccination with other adolescent health services.
    Vaccine. 2025;50:126833.
    PubMed     Abstract available


  434. HONDA-OKUBO Y, Sajkov D, Wauchope B, Turner JV, et al
    Immunogenicity and safety study of a single dose of SpikoGen(R) vaccine as a heterologous or homologous intramuscular booster following a primary course of mRNA, adenoviral vector or recombinant protein COVID-19 vaccine in ambulatory adults.
    Vaccine. 2025;49:126744.
    PubMed     Abstract available


  435. PORTER RM, Bednarczyk RA
    Better, worse, or holding the course? Analysis of HPV vaccination patterns in the US, 2008-2020.
    Vaccine. 2025;50:126824.
    PubMed     Abstract available


  436. DOUA J, Ndembi N, Auerbach J, Kaseya J, et al
    Advancing local manufacturing capacities for vaccines within Africa - Opportunities, priorities and challenges.
    Vaccine. 2025;50:126829.
    PubMed     Abstract available


  437. CARTER JJ, Smith RA, Scherer EM, Skibinski DAG, et al
    Term immune memory responses to human papillomavirus (HPV) vaccination following 2 versus 3 doses of HPV vaccine.
    Vaccine. 2025;50:126817.
    PubMed     Abstract available


  438. WALKER RI
    Conserved antigens for enteric vaccines.
    Vaccine. 2025;50:126828.
    PubMed     Abstract available


  439. SORENSEN JK, Jensen A, Zimakoff AC, Vittrup DM, et al
    Genetic associations with measles PRNT and IgG antibody response to MMR vaccination in 6- and 15-month-old children.
    Vaccine. 2025;50:126788.
    PubMed     Abstract available


  440. GAO MZ, Awonusi OO, Ramkumar SP, Myint JA, et al
    The Affordable Care Act and change in human papillomavirus (HPV) vaccine uptake in the United States.
    Vaccine. 2025;50:126842.
    PubMed     Abstract available


  441. KAN AKC, Mak HWF, Chiang V, Yim JSH, et al
    Leveraging COVID-19 vaccine allergy evaluations with coincident drug allergy delabelling: Effectiveness and impact on quality of life.
    Vaccine. 2025;50:126849.
    PubMed     Abstract available


  442. URSELLI F, Gomez A, Gray MD, Cameron CE, et al
    Identification of antibodies induced by immunization with the syphilis vaccine candidate Tp0751.
    Vaccine. 2025;50:126804.
    PubMed     Abstract available


  443. POWELL A, Jones A, Van Hout MC, Montgomery C, et al
    Influenza vaccine uptake in socially deprived areas: A multilevel retrospective population-based cross-sectional study using electronic health records in Liverpool, United Kingdom.
    Vaccine. 2025;50:126837.
    PubMed     Abstract available


  444. VAN ENTER BJD, de Zeeuw J, Bakar O, Bakhlakh S, et al
    Health system barriers to HPV-vaccination in adolescent females with a Moroccan or Turkish migration background in the Netherlands: A qualitative study.
    Vaccine. 2025;50:126827.
    PubMed     Abstract available


  445. GE Y, Handel A, Giabbanelli PJ, Lemacks J, et al
    Exploring bias due to below-limit-of-detection values in influenza vaccine antibody modeling: A case study and instructional guide for the CIVIC study.
    Vaccine. 2025;49:126802.
    PubMed     Abstract available


  446. PIGHI L, Salvagno GL, Lippi G
    Correlation between basal humoral immunogenicity and side effects after receiving the bivalent formulation of a mRNA-based vaccine.
    Vaccine. 2025 Feb 1:126803. doi: 10.1016/j.vaccine.2025.126803.
    PubMed    


  447. CHUNG H, Krishnasamy M, Joyce T, Dryden T, et al
    "It's a risk-benefit analysis": Qualitative perspectives on barriers and enablers to post-treatment vaccination from adults affected by a haematological malignancy in Australia.
    Vaccine. 2025;50:126826.
    PubMed     Abstract available


  448. EIDEN AL, Mackie DS, Modi K, Drakeley S, et al
    Attitudes and beliefs about vaccination among adults in the United States: A real-world, cross-sectional, web-based survey study.
    Vaccine. 2025;50:126807.
    PubMed     Abstract available


    January 2025
  449. MCGOLDRICK M, Truong TBQ, Campa C, Ali M, et al
    How to accelerate the supply of vaccines to all populations worldwide? Part III: Reflections after the pandemic.
    Vaccine. 2025;49:126782.
    PubMed     Abstract available


  450. GSCHWEND MH, Marchese AM, Poelaert D, Warren B, et al
    Efficacy, immunogenicity, and safety of the Novavax COVID-19 vaccine in immunocompromised patients: A targeted literature review.
    Vaccine. 2025;49:126777.
    PubMed     Abstract available


  451. GRAILEY K, Crespo RF, Woldmann L, Chisambi M, et al
    Implementing behavioural science-informed letter interventions to increase COVID-19 vaccination uptake in London residents. A difference-in-difference study in London, United Kingdom.
    Vaccine. 2025;49:126781.
    PubMed     Abstract available


  452. FETENSA G, Tolossa T, Besho M, Yadesa G, et al
    Willingness to take Mpox vaccine and associated factors among health professionals in Ethiopia: A cross-sectional study.
    Vaccine. 2025;49:126822.
    PubMed     Abstract available


  453. BARAL R, Amponsa-Achiano K, Barros I, Cofie P, et al
    What will introducing and delivering new maternal vaccines cost in Ghana and Mozambique? A prospective analysis.
    Vaccine. 2025;49:126769.
    PubMed     Abstract available


  454. DALE KD, Denholm JT
    Optimising the M72/AS01E tuberculosis vaccine candidate phase 3 trial based on the phase 2b trial results.
    Vaccine. 2025;49:126816.
    PubMed    


  455. ONO S, Nakajima M, Yamana H, Michihata N, et al
    Tetanus toxoid vaccination uptake by trauma patients in Japan: A retrospective cohort study using large administrative claims data.
    Vaccine. 2025;49:126812.
    PubMed     Abstract available


  456. YILMAZ IC, Ipekoglu EM, Golcuklu BS, Bildik T, et al
    A phase I/II study of CpG/alum-adjuvanted mammalian-derived quadruple antigen carrying virus-like particle COVID-19 vaccine.
    Vaccine. 2025;49:126787.
    PubMed     Abstract available


  457. MWENDA JM, Mandomando I, Worwui AK, Gacic-Dobo M, et al
    A decade of rotavirus vaccination in the World Health Organization African Region: An in-depth analysis of vaccine coverage from 2012 to 2023.
    Vaccine. 2025 Jan 30:126768. doi: 10.1016/j.vaccine.2025.126768.
    PubMed     Abstract available


  458. JIANG Y, Luo Y, Xiao X, Li X, et al
    Global, regional, and national burdens of vaccine-preventable infectious diseases with high incidence among middle-aged and older adults aged 55-89 years from 1990 to 2021: Results from the global burden of disease study 2021.
    Vaccine. 2025;49:126786.
    PubMed     Abstract available


  459. HASHIMOTO M, Tsujii K, Nakajima-Yoshida H, Akiyama N, et al
    A-910823, a squalene-based emulsion adjuvant, enhances robust and broad immune responses of quadrivalent influenza vaccine in ferrets.
    Vaccine. 2025;49:126780.
    PubMed     Abstract available


  460. VIGEZZI GP, Vecchio R, Barbati C, Bonazza G, et al
    Historical analysis of the first smallpox vaccination campaigns in early 19-century northern Italy: organisation and communication insights for contemporary epidemics' prevention and control.
    Vaccine. 2025;49:126764.
    PubMed     Abstract available


  461. WIEGAND RE, Devine O, Wallace M, Ortega-Sanchez IR, et al
    Estimating COVID-19 associated hospitalizations, ICU admissions, and in-hospital deaths averted in the United States by 2023-2024 COVID-19 vaccination: A conditional probability, causal inference, and multiplier-based approach.
    Vaccine. 2025;49:126808.
    PubMed     Abstract available


  462. KHAN A, Zhu Y, Babcock HM, Busse LW, et al
    COVID-19 and influenza vaccine Hesitancy among adults hospitalized in the United States, 2019-2022.
    Vaccine. 2025 Jan 29:126806. doi: 10.1016/j.vaccine.2025.126806.
    PubMed     Abstract available


  463. STRECKENBACH B, Baldt J, Heidler F, Frahm N, et al
    Corrigendum to "General vaccination willingness and current vaccination status in relation to clinical and psychological variables in patients with multiple sclerosis" [Vaccine 40 (23) (2022 May 20) 3236-3243].
    Vaccine. 2025;48:126741.
    PubMed    


  464. FLECK-VIDAL C, Doubell A, Gerke C, Lamichhane U, et al
    Vaccines and AMR: An analysis of the funding landscape for human bacterial vaccines in low-and middle-income countries.
    Vaccine. 2025;49:126771.
    PubMed     Abstract available


  465. ITO S, Tsuchida N, Kusunoki S, Kaneko Y, et al
    Safety comparison between Pfizer BNT162b2, Moderna mRNA-1273, and AstraZeneca AZD1222 in a Nationwide prospective cohort survey at the beginning of the severe acute respiratory syndrome coronavirus 2 vaccination in Japan.
    Vaccine. 2025;49:126754.
    PubMed     Abstract available


  466. LAO G, Feng J, Wu L, Su W, et al
    Development of a genetically modified full-length human respiratory syncytial virus preF protein vaccine.
    Vaccine. 2025;49:126799.
    PubMed     Abstract available


  467. ROPER LE, Link-Gelles R, Surie D, DeCuir J, et al
    A framework for monitoring RSV prevention product effectiveness in the United States.
    Vaccine. 2025;45:126633.
    PubMed     Abstract available


  468. EURICH DT, Weaver O, McDermott C, Soprovich A, et al
    Describing COVID-19 immunizations for First Nations people on-reserve in Alberta using real-time integration of point of care and provincial data.
    Vaccine. 2025;45:126614.
    PubMed     Abstract available


  469. CONLIN K, Jenkin D, de Whalley P, Weckx LY, et al
    Predictors of severity of SARS-CoV-2 infections in Brazil: Post hoc analyses of a randomised controlled trial.
    Vaccine. 2025;45:126582.
    PubMed     Abstract available


  470. WEI Y, Wang J, Wang L, Liu B, et al
    Comparative study on the inactivation and immunogenicity of Mycoplasma hyopneumoniae and Mycoplasma hyorhinis vaccines prepared using different inactivants.
    Vaccine. 2025 Jan 24:126766. doi: 10.1016/j.vaccine.2025.126766.
    PubMed     Abstract available


  471. KHETSURIANI N, Tursunova D, Kasimova R, Sharapov S, et al
    Prevalence of chronic hepatitis B virus infection among children in Uzbekistan: Impact of vaccination.
    Vaccine. 2025;48:126743.
    PubMed     Abstract available


  472. GLOANEC N, Guyard-Nicodeme M, Chemaly M, Dory D, et al
    Reverse vaccinology: A strategy also used for identifying potential vaccine antigens in poultry.
    Vaccine. 2025;48:126756.
    PubMed     Abstract available


  473. OKA E, Ueda Y, Yagi A, Machida M, et al
    Challenges to promoting maternal respiratory syncytial virus vaccination in Japan.
    Vaccine. 2025;48:126767.
    PubMed     Abstract available


  474. FARNSWORTH MG, Khanipov K, Botnar K, Weaver SC, et al
    Real-world evidence of yellow Fever vaccination data-driven study.
    Vaccine. 2025;48:126758.
    PubMed     Abstract available


  475. SATO R
    Closing the gap on vaccine uptake in developing countries: Is there a role for cash incentives?
    Vaccine. 2025;48:126763.
    PubMed     Abstract available


  476. BJERKHAUG AU, Ramalingham S, Mboizi R, Le Doare K, et al
    Corrigendum to "The immunogenicity and safety of Group B Streptococcal maternal vaccines: A systematic review" [Vaccine 42 (2024) 84-98].
    Vaccine. 2025;48:126732.
    PubMed    


  477. PROSSER LA, Perroud J, Chung GS, Gebremariam A, et al
    The cost-effectiveness of vaccination against COVID-19 illness during the initial year of vaccination.
    Vaccine. 2025;48:126725.
    PubMed     Abstract available


  478. NGOCHO JS, de Jongh CEVG, Sebba J, Mtei M, et al
    Emerging of non-vaccine Streptococcus pneumoniae serotypes colonizing the nasopharynx of children under the age of five years in the 13-vallent pneumococcal conjugate vaccine era in Moshi district, Tanzania. A short communication.
    Vaccine. 2025;48:126724.
    PubMed     Abstract available


  479. HINMAN AR, Banerjee E, Brewer NT, Hayes ES, et al
    Corrigendum to "Sustainability of measles, rubella, and congenital rubella syndrome (CRS) elimination in the United States, January 2022 - June 2024" [Vaccine 46C (2025) 126681].
    Vaccine. 2025;48:126739.
    PubMed    


  480. GIOVANETTI M, Cella E, Sampaio SC, Elias MC, et al
    Dengue vaccination and outbreaks: Bridging clinical diagnosis with genomic surveillance.
    Vaccine. 2025 Jan 20:126755. doi: 10.1016/j.vaccine.2025.126755.
    PubMed    


  481. CLAESSENS T, Eagan RL, Hendrickx G, Van Damme P, et al
    Navigating vaccine confidence: A mixed methods study investigating healthcare providers' perspectives across four non-EU European regions.
    Vaccine. 2025;47:126694.
    PubMed     Abstract available


  482. MARTINON-TORRES F, Wysocki J, Szenborn L, Carmona-Martinez A, et al
    Corrigendum to "A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1)" [Vaccine 41 (2023) 3387-339
    Vaccine. 2025;48:126628.
    PubMed    


  483. LIAO Z, Deng L, Luo J, Shi M, et al
    Association between adults' vaccine literacy and their intention to recommend older family members for influenza vaccine.
    Vaccine. 2025;48:126757.
    PubMed     Abstract available


  484. RAINERI D, Mazzucca CB, Moia R, Bruna R, et al
    Impairment of the T cell memory response in chronic lymphocytic leukemia patients after SARS-CoV-2 vaccination.
    Vaccine. 2025;48:126723.
    PubMed     Abstract available


  485. BANU S, Kishor PV, Krishnappa S, Ramasamy Periyasamy TS, et al
    Effect of vaccination against foot-and-mouth disease during mid-pregnancy on the neutralizing antibody response in the cow.
    Vaccine. 2025;48:126738.
    PubMed     Abstract available


  486. MADESH S, McGill J, Jaworski DC, Ferm J, et al
    Prolonged immune response to tick-borne Ehrlichia chaffeensis infection using a genetically modified live vaccine.
    Vaccine. 2025;48:126730.
    PubMed     Abstract available


  487. SILVA-FERNANDES AT, Moreira SB, Gaspar LP, Cajaraville ACDRA, et al
    Safety and immunogenicity of different 17DD yellow fever vaccines in golden-headed tamarins (Leontopithecus chrysomelas): Inhibition of viremia and RNAemia after homologous live-attenuated vaccination.
    Vaccine. 2025;48:126721.
    PubMed     Abstract available


  488. TRANTER I, Judd D, Stickley M, Vasant B, et al
    Promoting aged care COVID-19 and influenza vaccination through education of Australian residential aged care staff: A mixed methods project evaluation.
    Vaccine. 2025;48:126742.
    PubMed     Abstract available


  489. SHAH RM, Parzen-Johnson S, Sun S, Patel SJ, et al
    Childhood opportunity index and vaccine uptake in pediatric COVID-19 hospitalizations.
    Vaccine. 2025;48:126734.
    PubMed     Abstract available


  490. DOS SANTOS CVB, Coelho LE, de Noronha TG, Goedert GT, et al
    The impact of vaccination on the length of stay of hospitalized COVID-19 patients in Brazil.
    Vaccine. 2025;48:126735.
    PubMed     Abstract available


  491. POURAKBARI B, Mahmoudi S, Sajedi Moghaddam S, Jafari E, et al
    Evaluation of anti-Pertussis antibody levels in Iranian infants and children: Is it time to include booster acellular Pertussis Vaccines in the immunization schedule?
    Vaccine. 2025;48:126736.
    PubMed     Abstract available


  492. KUMAR S, Hazlett K, Bai G
    Mucosal immunity elicited by a human-Fcgamma receptor-I targeted intranasal vaccine platform enhances resistance against nasopharyngeal colonization of Streptococcus pneumoniae and induces broadly protective immunity against respiratory pathogens.
    Vaccine. 2025;48:126729.
    PubMed     Abstract available


  493. SONG H, Jin S, Yang GJ, Lim NWH, et al
    Modelling the impact and cost-effectiveness of upcoming Zika virus vaccines on congenital Zika syndrome.
    Vaccine. 2025;48:126728.
    PubMed     Abstract available


  494. SANTANA AP, Soborg B, Jacobsen SU, Zettler I, et al
    Danish parents' vaccination readiness is associated with their children's officially registered vaccination history.
    Vaccine. 2025;47:126693.
    PubMed     Abstract available


  495. ISLAM EA, Fegan JE, Zeppa JJ, Ahn SK, et al
    Adjuvant-dependent impacts on vaccine-induced humoral responses and protection in preclinical models of nasal and genital colonization by pathogenic Neisseria.
    Vaccine. 2025;48:126709.
    PubMed     Abstract available


  496. AANYU HT, Nalunkuma C, Kaudha E, Nalumansi E, et al
    Effectiveness of monovalent rotavirus vaccine against hospital-attended rotavirus gastroenteritis among children in Uganda.
    Vaccine. 2025;48:126726.
    PubMed     Abstract available


  497. DE OLIVEIRA PMN, Hartmann K, Bhamare C, Lucchesi MBB, et al
    Active vaccine safety surveillance in low- and middle-income countries: Challenges for vaccine manufacturers from emerging countries.
    Vaccine. 2025;48:126727.
    PubMed     Abstract available


  498. ZHANG Y, Li X, Yang Y, Yin Y, et al
    Impact of SARS-CoV-2 inactivated vaccine on symptoms following omicron variant breakthrough infection.
    Vaccine. 2025;48:126722.
    PubMed     Abstract available


  499. COROMINAS J, Garriga C, Prenafeta A, Moros A, et al
    Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial.
    Vaccine. 2025;47:126685.
    PubMed     Abstract available


  500. XIE W, Luo D, Soni V, Wang Z, et al
    Functional characterization of MMAR_1296 in Mycobacterium marinum and its potential as a vaccine candidate.
    Vaccine. 2025;48:126720.
    PubMed     Abstract available


  501. GONG X, Huang Z, Zheng Y, Xiao W, et al
    Rotavirus vaccine effectiveness and coverage among children younger than 5 years old in Shanghai, China: A test-negative case control study.
    Vaccine. 2025;48:126731.
    PubMed     Abstract available


  502. ROSENTHAL M, Stoecker C, Leidner AJ, Cho BH, et al
    Cost-effectiveness of 15-valent or 20-valent pneumococcal conjugate vaccine for U.S. adults aged 65 years and older and adults 19 years and older with underlying conditions.
    Vaccine. 2025;44:126567.
    PubMed     Abstract available


  503. ESCABI-WOJNA E, Alvelo-Fernandez PM, Suarez E, Colon-Lopez V, et al
    Sex differences in parental reasons for lack of intent to initiate HPV vaccination among adolescents ages 13-17 years: National Immunization Survey - Teen 2019-2021.
    Vaccine. 2025;44:126584.
    PubMed     Abstract available


  504. MARCHESE AM, Beyhaghi H, Rousculp MD, Huang V, et al
    Local and systemic reactogenicity after mRNA and protein-based COVID-19 vaccines compared to meningococcal vaccine (MenACWY) in a UK blinded, randomized phase 2 trial (COV-BOOST).
    Vaccine. 2025;44:126569.
    PubMed     Abstract available


  505. FILIMONOVIC J, Stosic M, Gazibara T, Dotlic J, et al
    The trend in national childhood immunization program coverage throughout Serbian communities in Kosovo and Metohija from 2003 to 2022: pre-COVID-19 period vs. COVID-19 pandemic.
    Vaccine. 2025;44:126576.
    PubMed     Abstract available


  506. CARNEIRO GB, Yerneni SS, Chinaia K, Araujo AP, et al
    Protection induced by Streptococcus pneumoniae extracellular vesicles against nasal colonization and invasive infection in mice and the role of PspA.
    Vaccine. 2025;44:126566.
    PubMed     Abstract available


  507. OLIVERO-DEIBE N, Frigini EN, Ramos N, Carrion F, et al
    The stability of PCV2 virus-like particles from mammalian cells and challenges for biotechnological applications.
    Vaccine. 2025;44:126549.
    PubMed     Abstract available


  508. HARTEVELD LM, van Leeuwen LM, Euser SM, Smit LJ, et al
    Respiratory syncytial virus (RSV) prevention: Perception and willingness of expectant parents in the Netherlands.
    Vaccine. 2025;44:126541.
    PubMed     Abstract available


  509. LI Y, Chen L, Xiao J, Feng K, et al
    Immunoprotective efficacy of Escherichia coli-derived outer membrane vesicles displaying PlpE protein of Pasteurella multocida.
    Vaccine. 2025;44:126532.
    PubMed     Abstract available


  510. DE LIMA EDS, Antunes MOB, de Souza JS, Jones MH, et al
    Effectiveness of BNT162b2 and CoronaVac against COVID-19-related severe outcomes among children and adolescents: A Brazilian nationwide cohort study.
    Vaccine. 2025;44:126550.
    PubMed     Abstract available


  511. SILVA HM
    Return of poliomyelitis: A real risk in a country afflicted by scientific denialism.
    Vaccine. 2025;44:126449.
    PubMed     Abstract available


  512. DAVIES C, Baker B, Berger MN, Knox SL, et al
    Vaccine microarray patch self-administration: A preliminary study in adults 50 years of age and over.
    Vaccine. 2025 Jan 12:126699. doi: 10.1016/j.vaccine.2024.126699.
    PubMed     Abstract available


  513. VITTRUP DM, Charabi S, Jensen A, Stensballe LG, et al
    A systematic review and meta-analysis of adverse events following measles-containing vaccines in infants less than 12 months of age.
    Vaccine. 2025;47:126687.
    PubMed     Abstract available


  514. RITCHIE AJ, Meeyai A, Trotter C, Douglas AD, et al
    Routine childhood rabies pre-exposure prophylaxis can be cost effective in low- and middle-income countries.
    Vaccine. 2025;47:126703.
    PubMed     Abstract available


  515. OSEI I, Schmidt-Chanasit J, Licciardi PV, Secka O, et al
    Immunogenicity of yellow fever vaccine co-administered with 13-valent pneumococcal conjugate vaccine in rural Gambia: A cluster-randomised trial.
    Vaccine. 2025;47:126712.
    PubMed     Abstract available


  516. FREY SE, Brady R, Jackson L, Goepfert P, et al
    Safety and immunogenicity of ascending doses of influenza A(H7N9) inactivated vaccine with or without MF59(R).
    Vaccine. 2025;47:126702.
    PubMed     Abstract available


  517. HONDA-OKUBO Y, Vaghasiya U, Petrovsky N
    Immunogenicity in mice and non-human primates of an Advax-CpG55.2-adjuvanted recombinant hemagglutinin seasonal quadrivalent influenza vaccine.
    Vaccine. 2025;47:126707.
    PubMed     Abstract available


  518. GENDLER Y, Ofri L, Videl H
    Understanding factors contributing to vaccination underutilization among Jewish ultra-orthodox communities in Israel: A cross-sectional study.
    Vaccine. 2025;47:126711.
    PubMed     Abstract available


  519. SHIELDS T, King KD, Cripps S, Edwards SA, et al
    Perspectives on vaccination among unvaccinated members of a Canadian indigenous population.
    Vaccine. 2025;47:126665.
    PubMed     Abstract available


  520. CHIU CY, Sampathkumar P, Brumble LM, Vikram HR, et al
    Optimizing hepatitis B virus seroprotection in thoracic organ transplantation: The role of HepB-CpG (Heplisav-B) vaccination schedule.
    Vaccine. 2025;47:126705.
    PubMed     Abstract available


  521. NAVARRO-TORNE A, Anderson A, Panwar K, Ghys E, et al
    Corrigendum to How has post-implementation surveillance of high-coverage vaccination with HPV16/18-AS04 vaccine in England added to evidence about its cross-protective effects? Vaccine. 2024 Oct 24;42(24):126215. doi: 10.1016/j.vaccine.2024.126215. Ep
    Vaccine. 2025;47:126701.
    PubMed    


  522. CASPERSEN IH, Skodvin SN, Blix K, Robertson AH, et al
    Post-COVID symptoms after SARS-CoV-2 omicron infection and the effect of booster vaccination: A population-based cohort study.
    Vaccine. 2025;47:126664.
    PubMed     Abstract available


  523. CAO Y, da Silva Araujo M, Lorang CG, Dos Santos NAC, et al
    Distinct immunogenicity outcomes of DNA vaccines encoding malaria transmission-blocking vaccine target antigens Pfs230D1M and Pvs230D1.
    Vaccine. 2025;47:126696.
    PubMed     Abstract available


  524. LE N, McMann TJ, Wenzel C, Li Z, et al
    COVID-19 pediatric vaccine Hesitancy: Themes and interactions with verified twitter accounts.
    Vaccine. 2025;47:126688.
    PubMed     Abstract available


  525. SEO H, Kim BJ, Oh J, Jung S, et al
    Protection against tuberculosis by vaccination of secreted chorismate mutase (Rv1885c) combined with a hepatitis B virus (HBV)-derived peptide, Poly6, and alum adjuvants.
    Vaccine. 2025;47:126710.
    PubMed     Abstract available


  526. SU Q, Qiu F, Gao Z, Zhao Y, et al
    Long-term efficacy and anamnestic response of hepatitis B vaccine derived from Chinese hamster ovary cell after 18-20 years.
    Vaccine. 2025;47:126655.
    PubMed     Abstract available


  527. ZHANG S, Liu G, Wang C, Guo A, et al
    Enhanced immunogenicity of a BoHV-1 gG-/tk- vaccine.
    Vaccine. 2025;47:126704.
    PubMed     Abstract available


  528. LI W, Li YA, Wang S, Shi H, et al
    A universal live vaccine platform against multiple serotypes Streptococcus suis based on polyvalent antigen protein.
    Vaccine. 2025;47:126700.
    PubMed     Abstract available


  529. DE LA FUENTE J, Gortazar C, Contreras M, Kabi F, et al
    Anti-tick vaccine in Uganda - from bench to field.
    Vaccine. 2025 Jan 6:126695. doi: 10.1016/j.vaccine.2024.126695.
    PubMed    


  530. EL SAHLY HM, Anderson EJ, Jackson LA, Neuzil KM, et al
    Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza a(H7N9) vaccine regimens.
    Vaccine. 2025;47:126689.
    PubMed     Abstract available


  531. NAKANO T, Tanaka T
    Looking back at the 27th Academic Conference of the Japanese Society for Vaccinology.
    Vaccine. 2025;47:126697.
    PubMed    


  532. DUAN Y, Suo L, Li X, Bai C, et al
    Association between underlying conditions, multimorbidity, and COVID-19 vaccination status of adults aged >/=80 years old in Beijing, China.
    Vaccine. 2025;47:126677.
    PubMed     Abstract available


  533. ALVARADO-FACUNDO E, Herrup R, Wang W, Colombo RE, et al
    Comparison of neuraminidase inhibiting antibody responses elicited by egg- and cell-derived influenza vaccines.
    Vaccine. 2025;46:126669.
    PubMed     Abstract available


  534. ANSELEM O, Charlier C, Viaud M, Lelong N, et al
    Barriers to influenza vaccination during pregnancy in France: A national population-based study.
    Vaccine. 2025;47:126671.
    PubMed     Abstract available


  535. KAUL R, Leidner AJ, Chesson HW
    Trends in costs of routinely recommended vaccines in the United States, 2001-2023.
    Vaccine. 2025;47:126667.
    PubMed     Abstract available


  536. POLAND GA, de la Fuente J
    Quantum vaccinology: A new science and epistemological abstraction framework for developing new vaccines and understanding the generation of the immune response.
    Vaccine. 2025;46:126641.
    PubMed    


  537. GALETTI SC, Gadoth A, Halbrook M, Tobin NH, et al
    Historic smallpox vaccination and Mpox cross-reactive immunity: Evidence from healthcare workers with childhood and adulthood exposures.
    Vaccine. 2025;46:126661.
    PubMed     Abstract available


  538. GIERSING B, Mo AX, Hwang A, Baqar S, et al
    Meeting summary: Global vaccine and immunization research forum, 2023.
    Vaccine. 2025;46:126686.
    PubMed     Abstract available


  539. POSTON TB, Girardi J, Kim M, Zwarycz P, et al
    Intranasal immunization with CPAF combined with ADU-S100 induces an effector CD4 T cell response and reduces bacterial burden following intravaginal infection with Chlamydia muridarum.
    Vaccine. 2025;43.
    PubMed     Abstract available


  540. LANG BALIJA M, Jagusic M, Forcic D, Ivancic-Jelecki J, et al
    Mumps virus neurovirulence assessment-impact of viral doses, animal sex and age on results dispersion.
    Vaccine. 2025;43.
    PubMed     Abstract available


  541. CHAUDHARY M, Cutland CL, Bonet M, Gentile A, et al
    Burden of Lassa fever disease in pregnant women and children and options for prevention.
    Vaccine. 2025;43.
    PubMed     Abstract available


  542. DERMENCHYAN A, Choi KR, Bokhoor PR, Cho DJ, et al
    Receipt of respiratory vaccines among patients with heart failure in a multicenter health system registry.
    Vaccine. 2025;46:126682.
    PubMed     Abstract available


  543. FLORES-VALDEZ MA
    Intravenous vaccination with BCG against tuberculosis: Strengths and questions deserving further research.
    Vaccine. 2025 Jan 1:126666. doi: 10.1016/j.vaccine.2024.126666.
    PubMed    


    December 2024
  544. GURRY CE, Mwenda JM, Nardone A, Cohuet S, et al
    Establishing the African region monitoring vaccine effectiveness (AFRO-MoVE) network for respiratory pathogens.
    Vaccine. 2024 Dec 31:126616. doi: 10.1016/j.vaccine.2024.126616.
    PubMed     Abstract available


  545. FERNANDEZ A, Askenazy F, Thummler S
    Letter to the editor: SARS-CoV-2 vaccination in children and adolescents with neurodevelopmental or psychiatric disorders.
    Vaccine. 2024 Dec 30:126679. doi: 10.1016/j.vaccine.2024.126679.
    PubMed    


  546. HUSSEIN I, Valiverronen E, Nohynek H, Lamsa R, et al
    What makes an expert in childhood vaccinations? Perceptions of parents in Finland.
    Vaccine. 2024;46:126645.
    PubMed     Abstract available


  547. PILAPITIYA D, Lee WS, Vu MN, Kelly A, et al
    Mucosal vaccination against SARS-CoV-2 using recombinant influenza viruses delivering self-assembling nanoparticles.
    Vaccine. 2024;46:126668.
    PubMed     Abstract available


  548. CHOI YJ, Jung J, Kang M, Choi MJ, et al
    Corrigendum to The risk of pregnancy-related adverse outcomes after COVID-19 vaccination: propensity score-matched analysis with influenza vaccination.
    Vaccine. 2024;46:126676.
    PubMed    


  549. ERBS G, Jakobsen JT, Schmidt ST, Christensen D, et al
    Retinoic acid-adjuvanted vaccine induces antigen-specific secretory IgA in the gut of newborn piglets.
    Vaccine. 2024;46:126672.
    PubMed     Abstract available


  550. TANG E, Ray I, Arnold BF, Acharya NR, et al
    Recombinant zoster vaccine and the risk of dementia.
    Vaccine. 2024;46:126673.
    PubMed     Abstract available


  551. NAZARENO AL, Wood JG, Muscatello DJ, Homaira N, et al
    Estimating the cost-effectiveness of maternal respiratory syncytial virus (RSV) vaccination in Australia: A dynamic and economic modelling analysis.
    Vaccine. 2024;46:126651.
    PubMed     Abstract available


  552. MALTEZOU HC, Poland GA, de Lejarazu RO
    Influenza vaccination for children in Europe: The health of every child matters.
    Vaccine. 2024 Dec 27:126675. doi: 10.1016/j.vaccine.2024.126675.
    PubMed    


  553. SAHA R, Lo M, De P, Deb AK, et al
    Epidemiology of viral gastroenteritis in children and genetic diversity of rotavirus strains in Kolkata, West Bengal after introduction of rotavirus vaccine.
    Vaccine. 2024;45:126637.
    PubMed     Abstract available


  554. ZHANG J, Zhang L, Li J, Ma J, et al
    Moderate effectiveness of influenza vaccine in outpatient settings: A test-negative study in Beijing, China, 2023/24 season.
    Vaccine. 2024;46:126662.
    PubMed     Abstract available


  555. MA Y, Dong C, Kim JK, Zhu W, et al
    Impact of influenza immune imprinting on immune responses to subsequent vaccinations in mice.
    Vaccine. 2024;46:126670.
    PubMed     Abstract available


  556. CHO JY, Lee H, Wannaadisai W, Vietri J, et al
    Systematic literature review of cost-effectiveness analyses of adult 15- and 20-valent pneumococcal vaccines.
    Vaccine. 2024;46:126656.
    PubMed     Abstract available


  557. AI L, Gao Z, Lv H, Zhang J, et al
    Immunogenicity and safety of live attenuated influenza vaccine in children aged 3-17 years in China.
    Vaccine. 2024;46:126653.
    PubMed     Abstract available


  558. BEERENS D
    Navigating the future of vaccination strategies: Insights from the 17(th) annual vaccine congress.
    Vaccine. 2024;46:126634.
    PubMed    


  559. ZHANG Y, Zhao K, Liu Y, Xu J, et al
    An oral probiotic vaccine loaded by Lactobacillus casei effectively increases defense against GCRV infection in grass carp.
    Vaccine. 2024;45:126660.
    PubMed     Abstract available


  560. GRIMES DR
    Tortured confessions? Potentially erroneous statistical inferences may underpin misleading claims of harms in reanalyses of COVID-19 and HPV vaccines.
    Vaccine. 2024 Dec 25:126657. doi: 10.1016/j.vaccine.2024.126657.
    PubMed     Abstract available


  561. SAVULESCU C, Prats-Uribe A, Brolin K, Uuskula A, et al
    Relative effectiveness of the second booster COVID-19 vaccines against laboratory confirmed SARS-CoV-2 infection in healthcare workers: VEBIS HCW VE cohort study (1 October 2022-2 May 2023).
    Vaccine. 2024;45:126615.
    PubMed     Abstract available


  562. KILANY WH, Zain El-Abideen MA, Hisham I, Van Gaver D, et al
    Laboratory safety and immunogenicity evaluation of live attenuated avian infectious bronchitis GI-23 virus vaccine.
    Vaccine. 2024;45:126659.
    PubMed     Abstract available


  563. PEREZ-SAUCEDO D, Castro-Perea NV, Ruiz-Cruz A, Bustos-Jaimes I, et al
    Design and evaluation of a multi-epitope HIV-1 vaccine based on human parvovirus virus-like particles.
    Vaccine. 2024;45:126663.
    PubMed     Abstract available


  564. SHELDENKAR A, Ling TP, Schulz PJ, Chen MI, et al
    Trust in government vaccine recommendations during the Covid-19 pandemic in Singapore: A longitudinal survey study.
    Vaccine. 2024;45:126643.
    PubMed     Abstract available


  565. BARAL R, Fleming JA, Barros I, Cofie P, et al
    What will it take? Perspectives from five low- and middle-income countries on opportunities and challenges of introducing new maternal vaccines.
    Vaccine. 2024;45:126654.
    PubMed     Abstract available


  566. CAMPANELLA S, Volpe T, Safar Y, Lunsky Y, et al
    "They need to speak a language everyone can understand": Accessibility of COVID-19 vaccine information for Canadian adults with intellectual and developmental disabilities.
    Vaccine. 2024;45:126618.
    PubMed     Abstract available


  567. WERTHNER Q, Faehrmann L, Och K, Bragazzi NL, et al
    Client satisfaction, safety, and insights from a three-season survey on influenza vaccinations delivered at community pharmacies in Germany.
    Vaccine. 2024;45:126650.
    PubMed     Abstract available


  568. GOMEZ JA, Pannunzio ME, Karwala P, Nocita F, et al
    Impact on meningococcal disease of different vaccination strategies with 4CMenB and MenACWY-CRM197 in infants and adolescents in Argentina.
    Vaccine. 2024;45:126589.
    PubMed     Abstract available


  569. TANAKA H, Takahashi Y, Matsumoto S, Matsuyama M, et al
    Shorter incubation period in symptomatic measles patients who had no history of measles vaccination.
    Vaccine. 2024;45:126652.
    PubMed     Abstract available


  570. LIEBERMANN E, Kornides M, Matsunaga M, Lim E, et al
    Corrigendum to "Use of social media and its influence on HPV vaccine hesitancy: US National Online Survey of mothers of adolescents, 2023".
    Vaccine. 2024;45:126640.
    PubMed    


  571. SERPA GONCALVES M, de Oliveira MM, Andrade RS, de Oliveira LF, et al
    Systematic review on the effectiveness of Brucella abortus S19 and RB51 vaccine strains in field studies.
    Vaccine. 2024;45:126649.
    PubMed     Abstract available


  572. FRAIHA ALS, da Silva Santos BSA, Aguilar NR, Gallinari GC, et al
    Immunization and challenge trials in a murine model using different inactivated recombinant vaccines against H1N1 swine influenza virus circulating in Brazil.
    Vaccine. 2024;45:126638.
    PubMed     Abstract available


  573. WANG J, Tonnies T, Brinks R
    Seasonal influenza vaccination coverage and the social determinants of influenza vaccination among people over 50 with diabetes in Europe: Analyzing population-based SHARE data for the 2019-2020 and 2021-2022 influenza seasons.
    Vaccine. 2024;45:126646.
    PubMed     Abstract available


  574. KASSAM P, El-Zein M, Tota JE, Tellier PP, et al
    HPV vaccination and anal HPV infection in gay, bisexual, and other men who have sex with men.
    Vaccine. 2024;45:126644.
    PubMed     Abstract available


  575. DE OLIVEIRA LA, de Morais IRB, Marchioro SB, de Almeida GB, et al
    Corrigendum to Assessment of the Bnt162b2 covid-19 vaccine immune response in Brazilian indigenous adolescents. Vaccine Volume 43, Part 1, 1 January 2025, 126494.
    Vaccine. 2024;45:126630.
    PubMed    


  576. YANG J, Yao YL, Lv XY, Geng LH, et al
    The Safety and Efficacy of inactivated COVID-19 vaccination in couples undergoing assisted reproductive technology: A prospective cohort study.
    Vaccine. 2024;45:126635.
    PubMed     Abstract available


  577. NUZHATH T, Yang Y, Couture MC, Gu NY, et al
    Structural equation modeling to evaluate the adult vaccine hesitancy scale for vaccines recommended during pregnancy.
    Vaccine. 2024;45:126568.
    PubMed     Abstract available


  578. BIAN S, Cai Q, Wang S, Xie Y, et al
    Evaluation of the toxoplasma Urm1 gene deletion mutant (PruDeltaUrm1) as a promising vaccine candidate against toxoplasmosis in mice.
    Vaccine. 2024;45:126632.
    PubMed     Abstract available


  579. SINGER R, Hubotter I, Holzner F, Genedl C, et al
    School vaccination programmes to increase HPV vaccination coverage - Experiences from Bremen, Germany.
    Vaccine. 2024;45:126636.
    PubMed     Abstract available


  580. SUN JW, Dodge LE, Kim EJ, Zhou L, et al
    Risk of adverse events after Omicron XBB-adapted BNT162b2 COVID-19 vaccination in the United States.
    Vaccine. 2024;45:126629.
    PubMed     Abstract available


  581. PERRIER Q, Noble J, Bonadona A, Augier C, et al
    Timing of rejection events preceded by Covid-19 mRNA vaccination in recipients of solid organ transplants.
    Vaccine. 2024;45:126617.
    PubMed     Abstract available


  582. MOGHTADERI A, Callaghan T, Luo Q, Motta M, et al
    Evidence on trends in uptake of childhood vaccines and association with COVID-19 vaccination rates.
    Vaccine. 2024;45:126631.
    PubMed     Abstract available


  583. WILLIAMS JTB, Ritger C, Holliman BD, Huebschmann AG, et al
    Staff and caregivers' perceptions of digital storytelling to increase influenza vaccine confidence in an urban safety-net healthcare system.
    Vaccine. 2024;45:126572.
    PubMed     Abstract available


  584. LIMA JLC, da Silva AB, Cabral AS, de Miranda FM, et al
    Changes in population genetic structure of serotype 19A Streptococcus pneumoniae after universal childhood use of the 10-valent pneumococcal conjugate vaccine in Brazil.
    Vaccine. 2024;45:126588.
    PubMed     Abstract available


  585. BAINBRIDGE S, Mappi T, Cleaveland S, Chubwa C, et al
    Field vaccination of locally-owned cattle against malignant catarrhal fever under environmentally challenging conditions in Tanzania.
    Vaccine. 2024;45:126587.
    PubMed     Abstract available


  586. KARACHALIOU M, Espinosa A, Farre X, Blay N, et al
    Mental illness and antibody responses after COVID-19 vaccination in a prospective population-based study in Catalonia.
    Vaccine. 2024;45:126591.
    PubMed     Abstract available


  587. SLAMANIG S, Lemus N, Lai TY, Singh G, et al
    A single immunization with intranasal Newcastle disease virus (NDV)-based XBB.1.5 variant vaccine reduces disease and transmission in animals against matched-variant challenge.
    Vaccine. 2024;45:126586.
    PubMed     Abstract available


  588. ENDER E, Joshi A, Snyder M, Kumar S, et al
    Seroconversion following PPSV23 vaccination in children with type 1 diabetes mellitus.
    Vaccine. 2024;45:126592.
    PubMed     Abstract available


  589. MASSEY PM, Murray RM, Kostizak K, Lo WJ, et al
    Exploring the ethics of using fictional stories for health education on social media to share information and emotions about the HPV vaccine: A cross-sectional study with interdisciplinary health experts.
    Vaccine. 2024 Dec 10:126575. doi: 10.1016/j.vaccine.2024.126575.
    PubMed     Abstract available


  590. HOMSI MR, Davey-Rothwell MA, Alonge O, Caniza MA, et al
    Knowledge, attitudes, and practices of healthcare providers regarding vaccinating children with cancer in Latin America and the Caribbean.
    Vaccine. 2024;45:126578.
    PubMed     Abstract available


  591. MASEMOLA NM, Burnett RJ, Makamba-Mutevedzi PC, Schonfeldt M, et al
    Vaccine stock-outs: A preventable health facility obstacle contributing to missed vaccinations in South African children.
    Vaccine. 2024;45:126583.
    PubMed     Abstract available


  592. ESKENAZI B, Rauch S, Elsiwi B, Bornman R, et al
    Undernutrition and antibody response to measles, tetanus and Haemophilus Influenzae type b (Hib) vaccination in pre-school south African children: The VHEMBE birth cohort study.
    Vaccine. 2024 Dec 7:126564. doi: 10.1016/j.vaccine.2024.126564.
    PubMed     Abstract available


  593. BODY A, Lal L, Srihari S, MacIntyre CR, et al
    Comprehensive humoral and cellular immune responses to COVID-19 vaccination in adults with cancer.
    Vaccine. 2024 Dec 7:126547. doi: 10.1016/j.vaccine.2024.126547.
    PubMed     Abstract available


  594. CUNNINGHAM-ERVES J, Sanderson M, Jin SW, Davis J, et al
    Predictors of HPV vaccination coverage among adolescents in Tennessee during the COVID-19 pandemic: A cross-sectional study.
    Vaccine. 2024 Dec 7:126581. doi: 10.1016/j.vaccine.2024.126581.
    PubMed     Abstract available


  595. XIA M, Huang P, Vago FS, Jiang W, et al
    Pseudovirus nanoparticles targeting the receptor binding HA1 domains of influenza viruses elicited high HA1-specific antibody responses and protected mice against mortality caused by influenza virus challenges.
    Vaccine. 2024 Dec 7:126585. doi: 10.1016/j.vaccine.2024.126585.
    PubMed     Abstract available


  596. SANKAR C, Meyer JC, Schonfeldt M, Gunter H, et al
    Vaccine safety surveillance in South Africa through COVID-19: A journey to systems strengthening.
    Vaccine. 2024 Dec 6:126535. doi: 10.1016/j.vaccine.2024.126535.
    PubMed     Abstract available


  597. KAPLAN BS, Souza CK, Kimble JB, Brand MW, et al
    A neuraminidase-based inactivated influenza virus vaccine significantly reduced virus replication and pathology following homologous challenge in swine.
    Vaccine. 2024 Dec 6:126574. doi: 10.1016/j.vaccine.2024.126574.
    PubMed     Abstract available


  598. LIEBERMANN E, Kornides M, Matsunaga M, Lim E, et al
    Use of social media and its influence on HPV vaccine hesitancy: US National Online Survey of mothers of adolescents, 2023.
    Vaccine. 2024 Dec 5:126571. doi: 10.1016/j.vaccine.2024.126571.
    PubMed     Abstract available


  599. HODGSON D, Sanchez-Ovando S, Carolan L, Liu Y, et al
    Quantifying the impact of pre-vaccination titre and vaccination history on influenza vaccine immunogenicity.
    Vaccine. 2024 Dec 4:126579. doi: 10.1016/j.vaccine.2024.126579.
    PubMed     Abstract available


  600. HSIAO A, Lewis N, Hansen J, Timbol J, et al
    Effectiveness of 13-valent pneumococcal conjugate vaccine against vaccine-type invasive pneumococcal disease in older adults.
    Vaccine. 2024;44:126543.
    PubMed     Abstract available


  601. MATTHEWS RL, Khan N, Beckman B, Sharma S, et al
    Immune profile diversity is achieved with synthetic TLR4 agonists combined with the RG1-VLP vaccine in mice.
    Vaccine. 2024 Dec 3:126577. doi: 10.1016/j.vaccine.2024.126577.
    PubMed     Abstract available


  602. MOUSTAFA DA, Lou E, Schafer-Kestenman ME, Mateu-Borras M, et al
    Pseudomonas aeruginosa elongation factor-Tu (EF-Tu) is an immunogenic protective protein antigen.
    Vaccine. 2024;42:126476.
    PubMed     Abstract available


  603. TANG A, Zhu M, Zhu J, Zhang D, et al
    The recombinant feline herpesvirus 1 expressing feline Calicivirus VP1 protein is safe and effective in cats.
    Vaccine. 2024;42:126468.
    PubMed     Abstract available


  604. TONG K, Hernandez EM, Basore K, Fremont DH, et al
    Chikungunya virus E2 B domain nanoparticle immunogen elicits homotypic neutralizing antibody in mice.
    Vaccine. 2024;42:126405.
    PubMed     Abstract available


  605. WU R, Chen Z, Yang X, Chen Y, et al
    Investigating the characteristics of mumps outbreaks in Fujian Province, China.
    Vaccine. 2024;42:126415.
    PubMed     Abstract available


  606. FOTAKIS EA, Picasso E, Sacco C, Petrone D, et al
    Impact of the 2023/24 autumn-winter COVID-19 seasonal booster campaign in preventing severe COVID-19 cases in Italy (October 2023-March 2024).
    Vaccine. 2024;42:126375.
    PubMed     Abstract available


  607. PRY JM, McCullough K, Lai KW, Lim E, et al
    Defining long COVID using a population-based SARS-CoV-2 survey in California.
    Vaccine. 2024;42:126358.
    PubMed     Abstract available


  608. CHUN J, Yoon D, Nowakowska A, Lee HD, et al
    Delivery of SARS-CoV-2 spike and membrane genes in a single Baculoviral vector enhance the immune breadth against SARS-CoV-2 variants of concern.
    Vaccine. 2024;42:126355.
    PubMed     Abstract available


  609. CANETTI M, Barda N, Lustig Y, Weiss-Ottolenghi Y, et al
    Risk factors and correlates of protection against XBB SARS-CoV-2 infection among health care workers.
    Vaccine. 2024;42:126308.
    PubMed     Abstract available


    November 2024
  610. PICHE-RENAUD PP, Drover SSM, Austin PC, Morris SK, et al
    COVID-19 vaccine effectiveness against severe omicron-related outcomes in children aged 5 to 11 years in Ontario: A Canadian immunization research network (CIRN) study.
    Vaccine. 2024 Nov 30:126539. doi: 10.1016/j.vaccine.2024.126539.
    PubMed     Abstract available


  611. GONG S, Beukema M, De Vries-Idema J, Huckriede A, et al
    Assessing human B cell responses to influenza virus vaccines and adjuvants in a PBMC-derived in vitro culture system.
    Vaccine. 2024;44:126563.
    PubMed     Abstract available


  612. ANABE D, Terasjarvi JT, Barkoff AM, Knuutila A, et al
    Association of baseline cytokines with antibody concentrations after diphtheria-tetanus-acellular pertussis booster vaccination in Finnish children.
    Vaccine. 2024 Nov 30:126573. doi: 10.1016/j.vaccine.2024.126573.
    PubMed     Abstract available


  613. GRIGAS J, Spancerniene U, Simanavicius M, Pautienius A, et al
    Adaptive immune response to a wild boar-derived recombinant hepatitis e virus capsid protein challenge in pigs.
    Vaccine. 2024 Nov 30:126561. doi: 10.1016/j.vaccine.2024.126561.
    PubMed     Abstract available


  614. COSMA C, Radi A, Cattano R, Zanobini P, et al
    Exploring Chatbot contributions to enhancing vaccine literacy and uptake: A scoping review of the literature.
    Vaccine. 2024;44:126559.
    PubMed     Abstract available


  615. NYIKA P, Yankey D, Elam-Evans LD, Meyer S, et al
    Human papillomavirus vaccination coverage among adolescent boys and girls in the United States: A birth year cohort analysis of the National Immunization Survey-Teen, 2016-2022.
    Vaccine. 2024;44:126560.
    PubMed     Abstract available


  616. FLORES D, Luna EM
    The effectiveness of vaccines against COVID-19 in Mexico: A time series approach.
    Vaccine. 2024;44:126565.
    PubMed     Abstract available


  617. BHAT N, Vodicka E, Clifford A, Ananth KB, et al
    The evidence base for rotavirus vaccination in India: Current status, future needs.
    Vaccine. 2024;44:126551.
    PubMed     Abstract available


  618. THIEM VD, Anh DD, Ha VH, Van Thom N, et al
    Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: A randomised, comparator-controlled, phase 2 trial.
    Vaccine. 2024;44:126542.
    PubMed     Abstract available


  619. WANG Q, Yang L, Li L, Xiu S, et al
    Investigating parental perceptions of respiratory syncytial virus (RSV) and attitudes to RSV vaccine in Jiangsu, China: Insights from a cross-section study.
    Vaccine. 2024;44:126570.
    PubMed     Abstract available


  620. EDELSTEIN M, Shibli H, Bornstein J
    Differences in knowledge, attitudes and intentions towards HPV vaccination among young adults from diverse socio-cultural groups in Israel: A cross-sectional study.
    Vaccine. 2024;44:126548.
    PubMed     Abstract available


  621. BORYS D, Smulders R, Haranaka M, Nakano T, et al
    Safety, reactogenicity, and immunogenicity of a novel 24-valent pneumococcal vaccine candidate in healthy, pneumococcal vaccine-naive Japanese adults: A phase 1 randomized dose-escalation trial.
    Vaccine. 2024;44:126545.
    PubMed     Abstract available


  622. LINK EK, Tscherne A, Sutter G, Smith ER, et al
    A Brighton collaboration standardized template with key considerations for a benefit/risk assessment for a viral vector vaccine based on a non-replicating modified vaccinia virus Ankara viral vector.
    Vaccine. 2024;43.
    PubMed     Abstract available


  623. PITTS PJ, Poland GA
    Addressing vaccine misinformation: The critical need for complete product information disclosure.
    Vaccine. 2024;44:126558.
    PubMed    


  624. KASAIJA PD, Kabi F, Semakula J, Kyakuwa I, et al
    One-year follow-up evaluation of approved Subolesin anti-tick vaccine in Uganda.
    Vaccine. 2024;44:126562.
    PubMed     Abstract available


  625. GEMANDER N, Kemlin D, Depickere S, Kelkar NS, et al
    COVID-19 vaccine responses are influenced by distinct risk factors in naive and SARS-CoV-2 experienced hemodialysis recipients.
    Vaccine. 2024;44:126544.
    PubMed     Abstract available


  626. BLUKACZ A, Obach A, Vasquez P, Campana C, et al
    Determinants of COVID-19 and non-COVID-19 vaccine confidence in low- and middle-income countries: A systematic review of qualitative evidence and thematic synthesis.
    Vaccine. 2024;44:126546.
    PubMed     Abstract available


  627. AMODIO D, Angelidou A, Cotugno N, Sherman AC, et al
    Biomarkers of vaccine safety and efficacy in vulnerable populations: Lessons from the fourth international precision vaccines conference.
    Vaccine. 2024;43.
    PubMed     Abstract available


  628. CHOI YJ, Jung J, Kang M, Choi MJ, et al
    The risk of pregnancy-related adverse outcomes after COVID-19 vaccination: Propensity score-matched analysis with influenza vaccination.
    Vaccine. 2024;44:126506.
    PubMed     Abstract available


  629. DEAN NE, Halloran ME, Zarnitsyna VI
    Poor vaccine responders mask the true trend in vaccine effectiveness against progression to severe disease.
    Vaccine. 2024;43.
    PubMed     Abstract available


  630. CASTILLO-ZUNINO F, Hester KA, Keskinocak P, Nazzal D, et al
    Associations between family planning, healthcare access, and female education and vaccination among under-immunized children.
    Vaccine. 2024;44:126540.
    PubMed     Abstract available


  631. GLESER D, Cohen M, Kenigswald G, Kedmi M, et al
    Optimizing protocols for the 919 strain-based bovine ephemeral fever virus vaccine (Ultravac(R), Zoetis): Evaluation of dose-dependent effectiveness and long-term immunity.
    Vaccine. 2024;43.
    PubMed     Abstract available


  632. REED NS, Brewer CC, Akintunde G, Blackie FF, et al
    Report of a SPEAC webinar 22 september 2023: Sensorineural hearing loss, lassa virus disease and vaccines.
    Vaccine. 2024;43.
    PubMed     Abstract available


  633. TSAI Y, Leung J, Anderson TC, Zhou F, et al
    Herpes zoster vaccination among Medicare beneficiaries with and without prescription drug coverage.
    Vaccine. 2024;43.
    PubMed     Abstract available


  634. LEE M, Qin C, Lee Y, Deng J, et al
    COVID-19 vaccine acceptance and 5C psychological antecedents amid the omicron surge in South Korea and China.
    Vaccine. 2024;43.
    PubMed     Abstract available


  635. WANTUCH PL, Knoot CJ, Marino EC, Harding CM, et al
    Klebsiella pneumoniae bioconjugate vaccine functional durability in mice.
    Vaccine. 2024;43.
    PubMed     Abstract available


  636. DE OLIVEIRA LA, de Morais IRB, Marchioro SB, de Almeida GB, et al
    Assessment of the BNT162B2 COVID-19 vaccine immune response in Brazilian indigenous adolescents.
    Vaccine. 2024;43.
    PubMed     Abstract available


  637. COULTER FJ, Messer WB
    Breakthroughs and insights: A comprehensive review of yellow fever vaccine breakthrough infection across 8 decades.
    Vaccine. 2024;43.
    PubMed     Abstract available


  638. SUFFEL AM, Carreira H, Walker J, Grint D, et al
    The association of maternal mental health with vaccination coverage and timeliness in early childhood - A historical cohort study in England using electronic health records.
    Vaccine. 2024;43.
    PubMed     Abstract available


  639. HUNG CT, Wang LM, Hung YC
    Trends and characteristics of herpes zoster vaccination among older adults with asthma in the United States, 2008-2023: Findings from self-reported national surveys.
    Vaccine. 2024;43.
    PubMed     Abstract available


  640. MEELDIJK A, Vandeberg L, Akkermans R, Hautvast J, et al
    How text message reminders increase COVID-19 booster vaccine uptake: Two randomized controlled trials.
    Vaccine. 2024;43.
    PubMed     Abstract available


  641. MAO J, Kang HJ, Eom GD, Yoon KW, et al
    Vaccine efficacy induced by 2020-2021 seasonal influenza-derived H3N1 virus-like particles co-expressing M2e5x or N2.
    Vaccine. 2024;43.
    PubMed     Abstract available


  642. MARSZALEK M, Hawking MKD, Gutierrez A, Firman N, et al
    Improving the timeliness and equity of preschool childhood vaccinations: Mixed methods evaluation of a quality improvement programme in primary care.
    Vaccine. 2024;43.
    PubMed     Abstract available


  643. VASQUEZ WF, Trudeau JM
    Americans' willingness to give to global immunization programs: Political heterogeneity in preferences for program management and response to priming communications.
    Vaccine. 2024;42:126126.
    PubMed     Abstract available


  644. KIRK B, Bush C, Toyip A, Mues KE, et al
    Real-world comparative effectiveness of a third dose of mRNA-1273 versus BNT162b2 among adults aged >/= 65 years in the United States.
    Vaccine. 2024;42:126113.
    PubMed     Abstract available


  645. BONNIN FA, Talarico LB, Ferolla FM, Acosta PL, et al
    Antibody levels against respiratory syncytial virus fusion protein conformations and lack of association with life-threatening infection in previously healthy infants.
    Vaccine. 2024;42:126119.
    PubMed     Abstract available


  646. TOMATIS C, Ferrer MF, Aquila S, Thomas PD, et al
    Baculovirus surface display of a chimeric E-NS1 protein of YFV protects against YFV infection.
    Vaccine. 2024;42:126045.
    PubMed     Abstract available


  647. LEE YS, Cheong MS, Lee J, Bang EK, et al
    Immunogenicity and protection of a triple repeat domain III mRNA vaccine against Zika virus.
    Vaccine. 2024;43.
    PubMed     Abstract available


  648. PARK JY, Senevirathne A, Lee JH
    Development of a candidate vaccine against severe fever with thrombocytopenia syndrome virus using Gn/Gc glycoprotein via multiple expression vectors delivered by attenuated Salmonella confers effective protection in hDC-SIGN transduced mice.
    Vaccine. 2024;43.
    PubMed     Abstract available


  649. FURUICHI M, Ohnishi T, Yaginuma M, Yamada Y, et al
    Live-attenuated vaccine failure after liver transplantation: A 20-year cohort study.
    Vaccine. 2024;43.
    PubMed     Abstract available


  650. KIM SS, Garcia Quesada M, Prasad PV, Nelson KN, et al
    Challenges of using the test-negative design to measure vaccine effectiveness of multi-pathogen combination vaccines targeting one syndrome.
    Vaccine. 2024 Nov 12:126520. doi: 10.1016/j.vaccine.2024.126520.
    PubMed    


  651. BERTHOUD TK, Ahmed T, Nadia W, Petrov I, et al
    A three antigen hepatitis B vaccine induces T cells to Pres1 and Pres2 which correlate with anti HBs antibody titers: An investigation into the immunological mechanisms contributing to high anti-HBs titers.
    Vaccine. 2024;43.
    PubMed     Abstract available


  652. LAMBACH P, Silal S, Sbarra AN, Koh M, et al
    Report from the World Health Organization's immunization and vaccines-related implementation research advisory committee (IVIR-AC) meeting, virtual gathering, 10-13 September 2024.
    Vaccine. 2024;43.
    PubMed     Abstract available


  653. LOCKMAN A, Callaghan T, Blackburn CC, Colwell B, et al
    Vaccine spillover effects in Africa: A cross-national study of vaccine spillover and confidence in Kenya, Nigeria, and South Africa.
    Vaccine. 2024;43.
    PubMed     Abstract available


  654. JASTORFF A, Gymnopoulou E, Salas J, Merrall E, et al
    Safety and immunogenicity of the Ad26/protein preF RSV vaccine in adults aged 18 to 59 years with and without at-risk comorbidities for severe respiratory syncytial virus disease: A phase 3, randomized, controlled, immunobridging trial.
    Vaccine. 2024;43.
    PubMed     Abstract available


  655. WIJDICKS EFM
    Fatal ascending paralysis after typhoid vaccine: Guillain and Barre's description of the very first case.
    Vaccine. 2024;42:126443.
    PubMed     Abstract available


  656. CHOE S, Park GN, Kim KS, Shin J, et al
    Immunogenicity of a classical swine fever bait vaccine (Flc-LOM- BE(rns)) in hybrid-wild boars.
    Vaccine. 2024;43.
    PubMed     Abstract available


  657. REGAN AK, Couture MC, Callaghan T, Agnew B, et al
    Modification and validation of a vaccine hesitancy scale for adolescent COVID-19 vaccination.
    Vaccine. 2024;43.
    PubMed     Abstract available


  658. LOPEZ-MACIAS C, Torres M, Armenta-Copca B, Wacher NH, et al
    Phase II study on the safety and immunogenicity of single-dose intramuscular or intranasal administration of the AVX/COVID-12 "Patria" recombinant Newcastle disease virus vaccine as a heterologous booster against COVID-19 in Mexico.
    Vaccine. 2024;43.
    PubMed     Abstract available


  659. PERALTA ALVAREZ MP, Downward K, White A, Harris SA, et al
    Intravenous BCG vaccination in non-human primates induces superior serum antibody titers with enhanced avidity and opsonizing capacity compared to the intradermal route.
    Vaccine. 2024;42:126444.
    PubMed     Abstract available


  660. GWAK E, Choe SA, Bolormaa E, Choe YJ, et al
    Relative effectiveness of homologous NVX-CoV2373 and BNT162b2 COVID-19 vaccinations in South Korea.
    Vaccine. 2024;43.
    PubMed     Abstract available


  661. GOKTUNA PT, Cokcaliskan C
    Concurrent use of the foot-and-mouth disease and other vaccines in livestock.
    Vaccine. 2024;43.
    PubMed     Abstract available


  662. DE LUCA C, Hess M
    Vaccination strategies to protect chickens from fowl adenovirus (FAdV)-induced diseases: A comprehensive review.
    Vaccine. 2024;43.
    PubMed     Abstract available


  663. DILANGE L, El Belghiti FA, Demiguel V, Anselem O, et al
    Pertussis vaccination coverage in women at two months postpartum and associated factors in France, National Perinatal Survey 2021.
    Vaccine. 2024;43.
    PubMed     Abstract available


  664. PETERSON J, Drazan D, Moughan B, Maguire JD, et al
    Randomized trial showing persistence of hSBA titers elicited by a pentavalent meningococcal MenABCWY vaccine for up to 4 years following a primary series and safety and immunogenicity of a booster dose.
    Vaccine. 2024;43.
    PubMed     Abstract available


  665. MATTES F, Dratva J, Schmelzer S, Wagner A, et al
    The association between service experience in vaccination centers and expectation confirmation as a driver of future vaccination intentions: Results from a survey among users of a Swiss mass COVID-19 vaccination center.
    Vaccine. 2024;43.
    PubMed     Abstract available


  666. AGUIRRE-CAMACHO A, Hidalgo B, Rash JA
    Exposure to objective/sensationalist information moderates associations between psychological factors and COVID-19 anti-vaccination attitudes: An experimental study.
    Vaccine. 2024;43.
    PubMed     Abstract available


  667. ANGULO M, Angulo C
    Trained immunity-based vaccines: A vision from the one health initiative.
    Vaccine. 2024;43.
    PubMed     Abstract available


  668. WILLIAMS E, Echeverri Tribin F, Carreno JM, Krammer F, et al
    Proteomic signatures of vaccine-induced and breakthrough infection-induced host responses to SARS-CoV-2.
    Vaccine. 2024;43.
    PubMed     Abstract available


  669. LEWIS NM, Harker EJ, Leis A, Zhu Y, et al
    Assessment and mitigation of bias in influenza and COVID-19 vaccine effectiveness analyses - IVY Network, September 1, 2022-March 30, 2023.
    Vaccine. 2024;43.
    PubMed     Abstract available


  670. DENG Y, Hayes KN, Zhao Y, Chachlani P, et al
    Variation in the time to complete the primary COVID-19 vaccine series by race, ethnicity, and geography among older US adults.
    Vaccine. 2024;43.
    PubMed     Abstract available


  671. STEFFENS MS, Bolsewicz KT, King C, Bullivant B, et al
    Australian parents' experiences with adolescent age-based vaccinations during the COVID-19 pandemic.
    Vaccine. 2024;43.
    PubMed     Abstract available


  672. LE MARCHAND C, Singson JRC, Clark A, Shah D, et al
    Multisystem inflammatory syndrome in children (MIS-C) cases by vaccination status in California.
    Vaccine. 2024;43.
    PubMed     Abstract available


  673. KERFUA SD, Haydon DT, Wilsden G, Ludi A, et al
    Corrigendum to "Evaluation of commercial quadrivalent foot-and-mouth disease vaccines against east African virus strains reveals limited immunogenicity and duration of protection" [Vaccine 42 (1-12) (2024) 126325].
    Vaccine. 2024;43.
    PubMed    


  674. DELARUELLE K, Lermytte E, Bockstal M, Vuolanto P, et al
    Unraveling COVID-19 vaccine hesitancy in Europeans 50 and older through a lens of preventive practices.
    Vaccine. 2024;43.
    PubMed     Abstract available


  675. KIM SA, Maeda M, Murata F, Fukuda H, et al
    Effect of COVID-19 vaccination on the risk of developing post-COVID conditions: The VENUS study.
    Vaccine. 2024;43.
    PubMed     Abstract available


  676. THOBARI JA, Watts E, Carvalho N, Haposan JH, et al
    Cost effectiveness analysis of rotavirus vaccination in Indonesia.
    Vaccine. 2024;43.
    PubMed     Abstract available


  677. CHARLAND K, Quach C, Papenburg J, Pierce L, et al
    Parental decisions regarding the vaccination of children and adolescents against SARS-CoV-2 from 2020 to 2023: A descriptive longitudinal study of parents and children in Montreal, Canada.
    Vaccine. 2024;43.
    PubMed     Abstract available


  678. WARIRI O, Utazi CE, Okomo U, Dotse-Gborgbortsi W, et al
    Multi-level determinants of timely routine childhood vaccinations in The Gambia: Findings from a nationwide analysis.
    Vaccine. 2024;43.
    PubMed     Abstract available


    October 2024
  679. ZACHARIA MM, Ziema SA, Abanga WA, Kyeremeh RA, et al
    RTS, S malaria vaccination among children aged 24-59 months in the Sunyani Municipality, Ghana; 2023.
    Vaccine. 2024;42:126490.
    PubMed     Abstract available


  680. KASAMATSU A, Yahata Y, Fukushima W, Sakamoto H, et al
    Estimating influenza vaccine effectiveness among older adults using an integrated administrative database and the implications of potential bias: A population-based cohort study in Japan.
    Vaccine. 2024;42:126488.
    PubMed     Abstract available


  681. HOFSTETTER AM, Klein EJ, Strelitz B, Selvarangan R, et al
    On-time childhood vaccination before and during the COVID-19 pandemic in seven communities: Findings from the New Vaccine Surveillance Network.
    Vaccine. 2024;42:126455.
    PubMed     Abstract available


  682. MOSCHESE V, Graziani S, Spadea A, D'Amore M, et al
    Vaccinations in children of non-European origin: The Vax4globe survey.
    Vaccine. 2024;42:126466.
    PubMed     Abstract available


  683. SANCHEZ-MARTINEZ ZV, Alpuche-Lazcano SP, Stuible M, Akache B, et al
    SARS-CoV-2 spike-based virus-like particles incorporate influenza H1/N1 antigens and induce dual immunity in mice.
    Vaccine. 2024;42:126463.
    PubMed     Abstract available


  684. MACINTYRE CR, Akhtar Z, Moa A
    Corrigendum to "Influenza B/Yamagata - extinct, eradicated or hiding? [Vaccine 42/26 (2024) 126450]".
    Vaccine. 2024 Oct 29:126486. doi: 10.1016/j.vaccine.2024.126486.
    PubMed    


  685. WHITE TM, Lazarus JV, Rabin KH, Ratzan SC, et al
    Emerging global patterns of COVID-19 vaccine information fatigue in 23 countries in 2023.
    Vaccine. 2024;42:126475.
    PubMed     Abstract available


  686. LEIS AM, Wagner A, Flannery B, Chung JR, et al
    Evaluation of test-negative design estimates of influenza vaccine effectiveness in the context of multiple, co-circulating, vaccine preventable respiratory viruses.
    Vaccine. 2024;42:126493.
    PubMed     Abstract available


  687. EBERHARDT J, Al-Qerem W, Ling J
    Comparing COVID-19 booster vaccine acceptance in the United Kingdom, Germany, Austria, and Jordan: The role of protection motivation theory, conspiracy beliefs, social media use and religiosity.
    Vaccine. 2024;42:126474.
    PubMed     Abstract available


  688. GAM PH, Dung NM, Aziz JMA, Makram AM, et al
    Vaccine for hand, foot, and mouth disease (HFMD): A call to action.
    Vaccine. 2024 Oct 27:126491. doi: 10.1016/j.vaccine.2024.126491.
    PubMed    


  689. MAURE C, Khazhidinov K, Kang H, Auzenbergs M, et al
    Chikungunya vaccine development, challenges, and pathway toward public health impact.
    Vaccine. 2024;42:126483.
    PubMed     Abstract available


  690. MCGREGOR R, Paterson A, Lavender B, Hooker C, et al
    The SARS-CoV-2 neutralising antibody profile of New Zealand adults in 2023: Impact of vaccination and infection.
    Vaccine. 2024;42:126482.
    PubMed     Abstract available


  691. VIELOT NA, Ballard CAP, St Jean DT, Page S, et al
    Documenting human papillomavirus vaccine refusal among adolescents in electronic health records: A mixed methods study.
    Vaccine. 2024;42:126467.
    PubMed     Abstract available


  692. LENTAKIS E, Seale H, Lazarus R, Mounier-Jack S, et al
    Exploring the delivery of adult vaccination outside of primary care settings: A mixed methods scoping review.
    Vaccine. 2024;42:126458.
    PubMed     Abstract available


  693. HO TC, Chuang SC, Hung KC, Chang CC, et al
    Exploring risk factors for Raynaud's phenomenon post COVID-19 vaccination.
    Vaccine. 2024;42:126470.
    PubMed     Abstract available


  694. LENTAKIS E, Seale H, Lazarus R, Mounier-Jack S, et al
    Exploring the attitudes and practices of adult service users and providers towards vaccination in non-primary care settings: A mixed methods scoping review.
    Vaccine. 2024;42:126472.
    PubMed     Abstract available


  695. MOHD HISHAM AA, Mat Yassim AS, Suppian R, Azlan M, et al
    Comparable and sustained levels of S1-RBD-IgG and S1-RBD-IgA in BNT162b2 homologous and CoronaVac-BNT162b2 heterologous booster vaccination: A 22-month prospective study in Malaysia.
    Vaccine. 2024;42:126471.
    PubMed     Abstract available


  696. JORDAN E, Jenkins V, Silbernagl G, Chavez MPV, et al
    A multivalent RSV vaccine based on the modified vaccinia Ankara vector shows moderate protection against disease caused by RSV in older adults in a phase 3 clinical study.
    Vaccine. 2024;42:126427.
    PubMed     Abstract available


  697. VALENCIA-HERNANDEZ AM, Zhao G, Miranda-Hernandez S, Segura-Cerda CA, et al
    A second-generation recombinant BCG strain combines protection against murine tuberculosis with an enhanced safety profile in immunocompromised hosts.
    Vaccine. 2024;42:126291.
    PubMed     Abstract available


  698. ROWE M, Collier AY, Barouch DH
    Insights from an observational translational research program during the COVID-19 pandemic: Four years of experience.
    Vaccine. 2024;42:126306.
    PubMed     Abstract available


  699. PHAM-HUY A, Bowes J, Russell K, Amira A, et al
    Short- and long-term outcomes of cardiac adverse events following COVID-19 immunization managed in a Canadian pediatric center.
    Vaccine. 2024;42:126090.
    PubMed     Abstract available


  700. KILIC G, Debisarun PA, Alaswad A, Baltissen MP, et al
    Seasonal variation in BCG-induced trained immunity.
    Vaccine. 2024;42:126109.
    PubMed     Abstract available


  701. SHANMUGASUNDARAM D, Viswanathan R, Winter AK, Agarwal A, et al
    Rubella immunity among pregnant women and the burden of congenital rubella syndrome (CRS) in India, 2022.
    Vaccine. 2024;42:126077.
    PubMed     Abstract available


  702. SINTAYEHU K, Shaum A, Bonger ZT, Dagnachew Zeleke E, et al
    Applicability of selected Brighton Collaboration case definitions in low-resource settings: A prospective hospital-based active surveillance in Addis Ababa, Ethiopia.
    Vaccine. 2024;42:126079.
    PubMed     Abstract available


  703. GOLDIN S, Moen A, Moss WJ, Nuzzo J, et al
    The 2020 immunization programme landscape: Piloting an assessment metric to evaluate the maturity of national immunization programmes across the life course.
    Vaccine. 2024;42 Suppl 4:125541.
    PubMed     Abstract available


  704. NG AJJ, Teo DCH, Dorajoo SR, Yap AJY, et al
    Acute autoimmune hepatitis following COVID-19 mRNA vaccination: A population-based study using electronic health records in Singapore.
    Vaccine. 2024;42:126462.
    PubMed     Abstract available


  705. ESSALIM S, Tachet C, Demingo S, Bruel S, et al
    Vaccination during febrile illness, what do we know? A systematic-narrative hybrid review of the literature and international recommendations.
    Vaccine. 2024;42:126473.
    PubMed     Abstract available


  706. DARKO DM, Seaneke SK, Karikari-Boateng E, Nkansah E, et al
    Safety of mRNA COVID-19 vaccines among persons 15- years and above in Ghana: A cohort event monitoring study.
    Vaccine. 2024;42:126460.
    PubMed     Abstract available


  707. AB RAHMAN N, King TL, Peariasamy KM, Sivasampu S, et al
    Risk of major adverse cerebro-cardiovascular events following BNT162b2, CoronaVac, and ChAdOx1 vaccination and SARS-CoV-2 infection: A self-controlled case-series study.
    Vaccine. 2024;42:126465.
    PubMed     Abstract available


  708. SHARFF KA, Tandy TK, Lewis PF, Johnson ES, et al
    Incidence of ischemic stroke after COVID-19 bivalent booster vaccination in an integrated health system.
    Vaccine. 2024;42:126440.
    PubMed     Abstract available


  709. BREWER SE, Cataldi JR, Perreira C, Nederveld A, et al
    "But then that's another barrier": A qualitative study of parent and provider perspectives on rural versus urban disparities in adolescent vaccination.
    Vaccine. 2024;42:126456.
    PubMed     Abstract available


  710. WICKLINE MM, Carpenter PA, Harris JR, Iribarren SJ, et al
    Vaccine hesitancy and routine revaccination among adult HCT survivors in the United States: A convergent mixed methods analysis.
    Vaccine. 2024;42:126374.
    PubMed     Abstract available


  711. PAPAILIOU S, Soldatou A, Marmarinos A, Avgeris M, et al
    Seroprevalence of diphtheria, tetanus and pertussis antibodies and Tdap vaccination in pregnant women in Greece - A cross- sectional study.
    Vaccine. 2024;42:126435.
    PubMed     Abstract available


  712. HARRACHE A, Saker K, Mokdad B, Generenaz L, et al
    Anti-RBD IgG dynamics following infection or vaccination.
    Vaccine. 2024;42:126464.
    PubMed     Abstract available


  713. SMOK-KALWAT J, Gozdz S, Macek P, Wasinski P, et al
    FTIR monitoring of the 13-valent pneumococcal conjugate vaccine for lung cancer patients: Changes in amides vibrations correlated with biochemical assays.
    Vaccine. 2024;42:126459.
    PubMed     Abstract available


  714. AREFAINE M, Johannessen A, Teklehaymanot T, Mihret A, et al
    A prospective, multicenter study of hepatitis B birth-dose vaccine with or without hepatitis B immunoglobulin in preventing mother-to-child transmission of hepatitis B virus in Ethiopia.
    Vaccine. 2024;42:126461.
    PubMed     Abstract available


  715. MA SH, Chen TL, Ou WF, Chao WC, et al
    The risk of postherpetic neuralgia in COVID-19 vaccination-associated herpes zoster: A retrospective cohort study using TriNetX.
    Vaccine. 2024;42:126451.
    PubMed     Abstract available


  716. EVIATAR T, Ziv A, Oved A, Miller-Barmak A, et al
    Longitudinal safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in children aged 4-11 years with juvenile-onset autoimmune inflammatory rheumatic diseases: A prospective multicenter study.
    Vaccine. 2024;42:126426.
    PubMed     Abstract available


  717. ESHRAGHISAMANI R, Facciuolo A, De Buck J
    Oral paratuberculosis vaccine efficacy and mucosal immunity in cattle.
    Vaccine. 2024;42:126447.
    PubMed     Abstract available


  718. NAZARENO AL, Newall AT, Muscatello DJ, Hogan AB, et al
    Modelling the epidemiological impact of maternal respiratory syncytial virus (RSV) vaccination in Australia.
    Vaccine. 2024;42:126418.
    PubMed     Abstract available


  719. BERENDSEN MLT, Bles P, de Bree LCJ, Jensen KJ, et al
    Bacillus Calmette-Guerin vaccination induces a trained innate immunity phenotype in adults over 50 years of age: A randomized trial in Guinea-Bissau.
    Vaccine. 2024;42:126439.
    PubMed     Abstract available


  720. DUBE E, Gagnon D, Pelletier C, Comeau JL, et al
    Enhancing HPV vaccine uptake in girls and boys - A qualitative analysis of Canadian school-based vaccination programs.
    Vaccine. 2024;42:126425.
    PubMed     Abstract available


  721. TRAVILL DI, Machalek DA, Rees H, Mbulawa Z, et al
    High prevalence of human papillomavirus (HPV) in unvaccinated adolescent girls in South Africa, particularly those living with HIV.
    Vaccine. 2024;42:126442.
    PubMed     Abstract available


  722. TYAGI A, Bajaj SS, Nayeu EN, Stanford FC, et al
    No person left behind: Understanding vaccine hesitancy in low- and middle-income countries.
    Vaccine. 2024 Oct 16:126446. doi: 10.1016/j.vaccine.2024.126446.
    PubMed    


  723. SANO K, Kurosawa T, Horikawa K, Kimura Y, et al
    Cellular and humoral immunity and IgG subclass distribution after omicron XBB.1.5 monovalent vaccination in Japan.
    Vaccine. 2024;42:126452.
    PubMed     Abstract available


  724. NUZHATH T, Colwell B, Callaghan T, Hotez P, et al
    Pediatric COVID-19 vaccine hesitancy among pregnant and post-partum women: A mixed-method study.
    Vaccine. 2024;42:126420.
    PubMed     Abstract available


  725. LI J, Li X, Liu F, Jiang S, et al
    Development and characterization of HCMV recombinant subunit vaccines based on T-cell epitopes.
    Vaccine. 2024;42:126454.
    PubMed     Abstract available


  726. EIDEN AL, Drakeley S, Modi K, Mackie D, et al
    Attitudes and beliefs of healthcare providers toward vaccination in the United States: A cross-sectional online survey.
    Vaccine. 2024;42:126437.
    PubMed     Abstract available


  727. PHADKE VK, Gromer DJ, Rebolledo PA, Graciaa DS, et al
    Safety and immunogenicity of a ChAd155-vectored rabies vaccine compared with inactivated, purified chick embryo cell rabies vaccine in healthy adults.
    Vaccine. 2024;42:126441.
    PubMed     Abstract available


  728. COCKERILL R, Horney JA, Penta SC, Silver A, et al
    Factors associated with COVID-19 vaccination or intent to be vaccinated across three U.S. states.
    Vaccine. 2024;42:126457.
    PubMed     Abstract available


  729. TOP KA, Shulha HP, Muller MP, Valiquette L, et al
    Participant-reported neurological events following immunization in the Canadian National Vaccine Safety Network-COVID-19 vaccine (CANVAS-COVID) study.
    Vaccine. 2024;42:126445.
    PubMed     Abstract available


  730. HSIEH HC, Chen CC, Liu WC, Wu SC, et al
    Intranasal booster with SARS-CoV-2 RBD protein fused to E. coli enterotoxin a subunit after primary mRNA vaccination in mice.
    Vaccine. 2024;42:126448.
    PubMed     Abstract available


  731. TASKIN T, Roncancio AM, Cano MA, Valente M, et al
    Cancer fatalism is associated with HPV vaccine uptake among Hispanic emerging adult women in the US.
    Vaccine. 2024;42:126417.
    PubMed     Abstract available


  732. MASON LMK, Betancur E, Riera-Montes M, Lienert F, et al
    MVA-BN vaccine effectiveness: A systematic review of real-world evidence in outbreak settings.
    Vaccine. 2024;42:126409.
    PubMed     Abstract available


  733. SEDAGHAT M, Karami B, Najafi F, Shadmani FK, et al
    Gender differences in adverse effects following the second dose of AstraZeneca COVID-19 vaccine: a cross-sectional study among healthcare workers.
    Vaccine. 2024;42:126424.
    PubMed     Abstract available


  734. LITAO L, Feng C, Hongyu Z, Wenbin C, et al
    Field production efficiency investigation of broilers immunized with a turkey herpesvirus vector vaccine expressing hemagglutinin from H9N2 subtype avian influenza virus.
    Vaccine. 2024;42:126436.
    PubMed     Abstract available


  735. SCHULTZE A, Martin I, Messina D, Bots S, et al
    Corrigendum to "A comparison of four self-controlled study designs in an analysis of COVID-19 vaccines and myocarditis using five European databases" [Vaccine 42 (12) (2024) 3039-3048].
    Vaccine. 2024 Oct 12:126438. doi: 10.1016/j.vaccine.2024.126438.
    PubMed    


  736. BAMOUH Z, Semmate N, Mouahid M, Kerbal I, et al
    Safety and efficacy of 9R live attenuated vaccine against fowl typhoid in partridge's species.
    Vaccine. 2024;42:126413.
    PubMed     Abstract available


  737. MOUCHERAUD C, Ochieng E, Ogutu V, Chang LC, et al
    Intervention-amenable factors associated with lack of HPV vaccination in Kenya: Results from a large national phone survey.
    Vaccine. 2024;42:126410.
    PubMed     Abstract available


  738. WANG J, Gan Y, Yuan T, Huang Y, et al
    Protection against Mycoplasma hyorhinis infection in commercial pigs via immunization with inactivated vaccines prepared with homologous or heterologous strains.
    Vaccine. 2024;42:126421.
    PubMed     Abstract available


  739. GERA S, Hoq M, Danchin M, Tuckerman J, et al
    Association between parental vaccine hesitancy and geographical coverage for childhood vaccination: A cross-sectional study.
    Vaccine. 2024;42:126422.
    PubMed     Abstract available


  740. DOYON-PLOURDE P, Farley R, Krishnan R, Tunis M, et al
    Direct quantitative comparison of benefits and risks of COVID-19 vaccines used in National Immunization Technical Advisory Groups Guidance during the first two years of the pandemic.
    Vaccine. 2024;42:126406.
    PubMed     Abstract available


  741. MYLONA E, Pereira-Dias J, Keane JA, Karkey A, et al
    Phenotypic variation in the lipopolysaccharide O-antigen of Salmonella Paratyphi A and implications for vaccine development.
    Vaccine. 2024;42:126404.
    PubMed     Abstract available


  742. TAAFFE J, Ostrowsky JT, Mott J, Goldin S, et al
    Advancing influenza vaccines: A review of next-generation candidates and their potential for global health impact.
    Vaccine. 2024;42:126408.
    PubMed     Abstract available


  743. MWAMBA G, Gibson EM, Toko C, Tunda C, et al
    Effective integration of COVID-19 vaccination with routine immunization: A case study from Kinshasa, DRC.
    Vaccine. 2024 Oct 4:126392. doi: 10.1016/j.vaccine.2024.126392.
    PubMed     Abstract available


  744. PASCOE KM, Bishop S, Ci X, Ramirez M, et al
    Factors that shape COVID-19 pediatric vaccine decision-making in rural agricultural communities: A qualitative study.
    Vaccine. 2024;42:126389.
    PubMed     Abstract available


  745. HOJO-SOUZA NS, de Castro JT, Rivelli GG, Azevedo PO, et al
    SpiN-Tec: A T cell-based recombinant vaccine that is safe, immunogenic, and shows high efficacy in experimental models challenged with SARS-CoV-2 variants of concern.
    Vaccine. 2024;42:126394.
    PubMed     Abstract available


  746. TAHA, Eskandari S, Slesarenko VA, Haselhorst T, et al
    Refinement and optimisation of Neisseria gonorrhoeae NHBA and MetQ vaccine candidates.
    Vaccine. 2024;42:126416.
    PubMed     Abstract available


  747. ALANSARI KDH, Buhl C, Thabit AK, Badr AF, et al
    Validation of the Arabic translation of the vaccination attitudes examination (VAX) scale.
    Vaccine. 2024;42:126411.
    PubMed     Abstract available


  748. PERCIO J, Kobayashi CD, Silva RMA, Marinho AKBB, et al
    Safety signal detected: Anaphylaxis after attenuated dengue vaccine (TAK-003) - Brazil, march 1, 2023-march 11, 2024.
    Vaccine. 2024;42:126407.
    PubMed     Abstract available


  749. EARP M, Meng L, Black CL, Carter RJ, et al
    Using regression tree analysis to examine demographic and geographic characteristics of COVID-19 vaccination trends over time, United States, May 2021-April 2022, National Immunization Survey Adult COVID Module.
    Vaccine. 2024;42:126372.
    PubMed     Abstract available


  750. REN J, Gao Q, Zhou X, Chen L, et al
    Identification of gene and protein signatures associated with long-term effects of COVID-19 on the immune system after patient recovery by analyzing single-cell multi-omics data using a machine learning approach.
    Vaccine. 2024;42:126253.
    PubMed     Abstract available


  751. BARBOSA TN, Ferreira MRA, Scholl NR, Pegoraro HG, et al
    Iridaea cordata lipid extract associated with the rCP01850 protein of C. pseudotuberculosis elicited a Th1 immune response in immunized sheep.
    Vaccine. 2024;42:126220.
    PubMed     Abstract available


  752. SPENCER CLINTON JL, Hoornweg TE, Tan J, Peng R, et al
    The EEHV1A gH/gL complex elicits humoral and cell-mediated immune responses in mice.
    Vaccine. 2024;42:126227.
    PubMed     Abstract available


  753. RAMIREZ MA, Loaiza RA, Martinez-Balboa Y, Bruneau N, et al
    Co-administration of recombinant BCG and SARS-CoV-2 proteins leads to robust antiviral immunity.
    Vaccine. 2024;42:126203.
    PubMed     Abstract available


  754. IQBAL I, Shahid S, Kanwar S, Kabir F, et al
    Pneumococcal carriage and changes in serotype distribution post- PCV13 introduction in children in Matiari, Pakistan.
    Vaccine. 2024;42:126238.
    PubMed     Abstract available


  755. GUINAZU G, Dvorkin J, Mahmud S, Baral R, et al
    Evaluation of the potential impact and cost-effectiveness of respiratory syncytial virus (RSV) prevention strategies for infants in Argentina.
    Vaccine. 2024;42:126234.
    PubMed     Abstract available


  756. BROWN L, Bingham J, Pulliam J, Mthombothi Z, et al
    Estimation of the poliovirus type 2 immunity gap in South Africa.
    Vaccine. 2024;42:126062.
    PubMed     Abstract available


  757. HOWARD LUDLAM A, Paynter J, Goodyear-Smith F, Petousis-Harris H, et al
    Pertussis epidemiology in adults: Retrospective analysis of pertussis incidence and association with comorbidities among adult populations in Aotearoa New Zealand, using national administrative datasets.
    Vaccine. 2024;42:126048.
    PubMed     Abstract available


  758. LANGER S, Holzapfel S, August L, Badura A, et al
    Parental knowledge and attitudes to infant immunization in the context of RSV: All about confidence?
    Vaccine. 2024;42:126050.
    PubMed     Abstract available


  759. RUSSELL FA, Trim L, Bryan E, Fisher MA, et al
    Stability and antigenicity of Chlamydia muridarum major outer membrane protein antigen at body temperature.
    Vaccine. 2024;42:126047.
    PubMed     Abstract available


  760. NAHAR UJ, Wang J, Shalash AO, Lu L, et al
    Self-assembled monovalent lipidated mannose ligand as a standalone nanoadjuvant.
    Vaccine. 2024;42:126060.
    PubMed     Abstract available


  761. WEGMAN AD, Kalimuddin S, Marques ETA, Adams LE, et al
    Proceedings of the dengue endgame summit: Imagining a world with dengue control.
    Vaccine. 2024;42:126071.
    PubMed     Abstract available


  762. COLOMBATTI OLIVIERI MA, Cuerda MX, Moyano RD, Gravisaco MJ, et al
    Superior protection against paratuberculosis by a heterologous prime-boost immunization in a murine model.
    Vaccine. 2024;42:126055.
    PubMed     Abstract available


  763. GARLAND SM, Bhatla N, Woo YL
    IPVS STATEMENT on HPV vaccination: No longer supply constraints: Towards achieving WHO vaccine targets.
    Vaccine. 2024;42:126400.
    PubMed     Abstract available


  764. GUINAZU G, Dvorkin J, Mahmud S, Baral R, et al
    Corrigendum to "Evaluation of the potential impact and cost-effectiveness of respiratory syncytial virus (RSV) prevention strategies for infants in Argentina" [Vaccine. Volume 42, Issue 23, 3 October 2024, 126234].
    Vaccine. 2024 Oct 2:126402. doi: 10.1016/j.vaccine.2024.126402.
    PubMed    


  765. MIRANDA FM, da Silva LD, Fortuna LBDP, Silva AB, et al
    Long-term predominance in childhood colonization of the multidrug-resistant lineage 6C/ST386 of Streptococcus pneumoniae after universal immunization with the 10-valent pneumococcal conjugate vaccine in Brazil.
    Vaccine. 2024;42:126414.
    PubMed     Abstract available


  766. CHOI YJ, Song JY, Wie SH, Choi WS, et al
    Real-world effectiveness of influenza vaccine over a decade during the 2011-2021 seasons-Implications of vaccine mismatch.
    Vaccine. 2024;42:126381.
    PubMed     Abstract available


  767. PATRICK-SMITH M, Emary K, Hodgson SH, Thomas TM, et al
    Roles and responsibilities of participants, researchers, and the media in the communication of vaccine trials: Experience from the United Kingdom's first COVID-19 vaccine trial.
    Vaccine. 2024;42:126391.
    PubMed     Abstract available


  768. KANG S, Chung E, Hong C, Aziz AB, et al
    Raising the case of hepatitis E: Report from the 2nd international HEV symposium.
    Vaccine. 2024;42:126398.
    PubMed     Abstract available


    September 2024
  769. TEUFEL LU, Taks EJM, van Gemert J, Neacsu M, et al
    Interleukin 38 reduces antigen-presentation capacity and antibody production after vaccination.
    Vaccine. 2024;42:126396.
    PubMed     Abstract available


  770. FLETCHER MA, Vojicic J, Daigle D, Taysi B, et al
    National recommendations for adult pneumococcal vaccination in countries of the WHO regions of Americas, Africa, Eastern Mediterranean, South East Asia, and Western Pacific.
    Vaccine. 2024;42:126390.
    PubMed     Abstract available


  771. MOTTA M, Motta G, Stecula D
    Conceptual debates in the study of canine & feline vaccine hesitancy: A response to Haeder 2023.
    Vaccine. 2024 Sep 28:126397. doi: 10.1016/j.vaccine.2024.126397.
    PubMed    


  772. SPASENOSKA D, Bloem P, Akaba H, Kahn AL, et al
    Using human papillomavirus (HPV) vaccine in controlled temperature chain (CTC): A solution looking for a problem? Or a solution to problems that are not systematically documented?
    Vaccine. 2024 Sep 28:126399. doi: 10.1016/j.vaccine.2024.126399.
    PubMed    


  773. LYU X, Liu X, Hong H
    Validation of the Chinese version of the vaccine conspiracy beliefs scale during COVID-19 pandemic and its correlates.
    Vaccine. 2024;42:126395.
    PubMed     Abstract available


  774. SOTOODEH A, Hedberg P, Granath F, Alfven T, et al
    Sociodemographic determinants of COVID-19 vaccination in adolescents in Stockholm, Sweden.
    Vaccine. 2024;42:126388.
    PubMed     Abstract available


  775. SRITIPSUKHO P, Sinlapamongkolkul P, Satdhabudha A, Chaiyakulsil C, et al
    Corrigendum to "Immunogenicity during 6 months after SARS-CoV-2 infection is significantly different depending on previous COVID-19 vaccine regimens and a booster dose received" [Vaccine 42 (22) (2024) 126025].
    Vaccine. 2024 Sep 27:126403. doi: 10.1016/j.vaccine.2024.126403.
    PubMed    


  776. ARCIDIACO S, Schreiber P, Poincelot L, Loukeri S, et al
    Vaccines efficacy against infection with circulating feline calicivirus after one single injection: Comparison of Leucofeligen FeLV/RCP and Purevax RCPFeLV vaccines.
    Vaccine. 2024;42:126393.
    PubMed     Abstract available


  777. BARBIERI E, Cocchio S, Furlan P, Scamarcia A, et al
    A population database analysis to estimate the varicella vaccine effectiveness in children < 14 years in a high vaccination coverage area from 2004 to 2022.
    Vaccine. 2024;42:126387.
    PubMed     Abstract available


  778. DECEUNINCK G, Brousseau N, Lefebvre B, Quach C, et al
    Effectiveness of the ten- and thirteen-valent pneumococcal conjugate vaccines to prevent serotype 19A invasive pneumococcal disease in Quebec, Canada. A Canadian immunization research network (CIRN) study.
    Vaccine. 2024;42:126379.
    PubMed     Abstract available


  779. ENGLAND A, Sung J, Deulofeu M, Soler LF, et al
    Variant-specific neutralising antibodies levels induced by the PHH-1 V SARS-CoV-2 vaccine (Bimervax(R)) by HIPRA.
    Vaccine. 2024;42:126386.
    PubMed     Abstract available


  780. DANZELLE C, Cunha P, Noleto PG, Gilbert FB, et al
    Saccharomyces cerevisiae as a platform for vaccination against bovine mastitis.
    Vaccine. 2024;42:126385.
    PubMed     Abstract available


  781. TAN M, Zhang R, Shen T, Li A, et al
    Systematic evaluation of the induction of efficient neutralizing antibodies by recombinant multicomponent subunit vaccines against monkeypox virus.
    Vaccine. 2024;42:126384.
    PubMed     Abstract available


  782. WEITZMAN ER
    Social complexity of a fentanyl vaccine to prevent opioid overdose conference proceedings: Radcliffe institute for advanced study conference proceedings.
    Vaccine. 2024 Sep 23:126324. doi: 10.1016/j.vaccine.2024.126324.
    PubMed     Abstract available


  783. LAZARUS R, Harris R, Thirard R, Baos S, et al
    Comparison of assays used to detect antibody response in COVID-19 vaccine trials: Results from of a UK multi-Centre randomised controlled trial to determine the immunogenicity responses of COVID-19 vaccines administered concomitantly with seasonal inf
    Vaccine. 2024;42:126369.
    PubMed     Abstract available


  784. AL-DAHIR S, Hassan TAL, Moss W, Khalil A, et al
    The impact of coronavirus pandemic shutdowns on immunization completion in Hadeetha, Anbar, Iraq: A case-study of vaccine completion in a recovering healthcare system.
    Vaccine. 2024 Sep 21:126383. doi: 10.1016/j.vaccine.2024.126383.
    PubMed     Abstract available


  785. BERNADIN O, Cochin M, Driouich JS, Laprie C, et al
    Preclinical evaluation in hamster model of the mRNA COVID-19 vaccine candidate AfriVac 2121 (Wuhan) produced under the WHO/MPP mRNA Technology Transfer Programme.
    Vaccine. 2024;42:126378.
    PubMed     Abstract available


  786. LUI L, Requia WJ, Dos Santos F, Albert CE, et al
    Determining factors associated with vaccination coverage in the first year of life in Brazil (2013-2022).
    Vaccine. 2024;42:126382.
    PubMed     Abstract available


  787. LAEMMLE-RUFF I, Fryk JJ, Shenton P, Clothier HJ, et al
    Detailed review of mortality reported following COVID-19 vaccination in Victoria, Australia: 2021-2023.
    Vaccine. 2024;42:126368.
    PubMed     Abstract available


  788. SHARMA H, Parekh S, Pujari P, Shewale S, et al
    A randomized, active-controlled, multi-centric, phase-II clinical study to assess safety and immunogenicity of a fully liquid DTwP-HepB-IPV-Hib hexavalent vaccine (HEXASIIL(R)) in Indian toddlers.
    Vaccine. 2024;42:126380.
    PubMed     Abstract available


  789. WEE LE, Malek MIBA, Tan J, Chiew C, et al
    Risk of death and cardiovascular events following COVID-19 vaccination or positive SARS-CoV-2 test amongst adult Singaporeans during omicron transmission.
    Vaccine. 2024;42:126356.
    PubMed     Abstract available


  790. GOLDIN S, Brooks D, Jorgensen P, Wijesinghe P, et al
    Seasonal influenza vaccination: A global review of national policies in 194 WHO member states in 2022.
    Vaccine. 2024;42:126274.
    PubMed     Abstract available


  791. IMRAN M, Mills C, McDermott KW, Dean A, et al
    Relative effectiveness of adjuvanted versus non-adjuvanted influenza vaccines in older adults with risk factors for influenza complications during the 2019-2020 U.S. influenza season.
    Vaccine. 2024;42:126316.
    PubMed     Abstract available


  792. CHOI KY, El-Hamdi N, McGregor A
    T cell inducing vaccine against cytomegalovirus immediate early 1 (IE1) protein provides high level cross strain protection against congenital CMV.
    Vaccine. 2024;42:126357.
    PubMed     Abstract available


  793. CANDEIAS C, Almeida ST, Paulo AC, Simoes AS, et al
    Streptococcus pneumoniae carriage, serotypes, genotypes, and antimicrobial resistance trends among children in Portugal, after introduction of PCV13 in National Immunization Program: A cross-sectional study.
    Vaccine. 2024;42:126219.
    PubMed     Abstract available


  794. ROELS S, Bruckner M, Sadoff J, Cardenas V, et al
    Pre- and post-Ad26.COV2.S booster dose antibody levels predict COVID-19 disease risk.
    Vaccine. 2024;42:126159.
    PubMed     Abstract available


  795. SHEN AK, Gutu V, Druc A, Ebama M, et al
    An evaluation of the National Influenza Vaccination Program in the Republic of Moldova, 2023-2024.
    Vaccine. 2024;42:126322.
    PubMed     Abstract available


  796. WITTESAELE C, Toska E, Cluver L, Weiss HA, et al
    Vaccine coverage and timeliness among children of adolescent mothers: A community-based study in the eastern cape, South Africa.
    Vaccine. 2024;42:126318.
    PubMed     Abstract available


  797. MEANEY-DELMAN D, Carroll S, Polen K, Jatlaoui TC, et al
    Planning for the future of maternal immunization: Building on lessons learned from the COVID-19 pandemic.
    Vaccine. 2024;42 Suppl 3.
    PubMed     Abstract available


  798. JONES-JACK N, El Kalach R, Yassanye D, Link-Gelles R, et al
    Advancing public health informatics during the COVID-19 pandemic: Lessons learned from a public-private partnership with pharmacies.
    Vaccine. 2024;42 Suppl 3:125667.
    PubMed     Abstract available


  799. MAHAPATRA B, Singh A, Banerjee A, Sirohi S, et al
    A squalene oil emulsified MPL-A and anti-CD200/CD300a antibodies adjuvanted whole-killed Leishmania vaccine provides durable immunity against L. donovani parasites.
    Vaccine. 2024;42:126373.
    PubMed     Abstract available


  800. WADA YA, Mazlan M, Noordin MM, Mohd-Lila MA, et al
    Rabies epidemiology in Malaysia (2015-2023): A cross-sectional insights and strategies for control.
    Vaccine. 2024;42:126371.
    PubMed     Abstract available


  801. KRAUSE KD, D'Avanzo PA, Karr AG, Rhem C, et al
    Vaccination uptake in LGBTQ adults in two US states: Findings from the QVax study.
    Vaccine. 2024;42:126320.
    PubMed     Abstract available


  802. HEINS MJ, Spreeuwenberg P, Caini S, Hooiveld M, et al
    Measuring the impact of influenza vaccination in the Netherlands using retrospective observational primary care, hospitalisation and mortality data.
    Vaccine. 2024;42:126244.
    PubMed     Abstract available


  803. LAMBACH P, Silal S, Sbarra AN, Crowcroft NS, et al
    Report from the World Health Organization's immunization and vaccines-related implementation research advisory committee (IVIR-AC) ad hoc meeting, 28 June - 1 July 2024.
    Vaccine. 2024;42:126307.
    PubMed     Abstract available


  804. SHIU EYC, Cheng SMS, Martin-Sanchez M, Au NYM, et al
    Durability for 12 months of antibody response to a booster dose of monovalent BNT162b2 in adults who had initially received 2 doses of inactivated vaccine.
    Vaccine. 2024;42:126317.
    PubMed     Abstract available


  805. ARTETA-ACOSTA C, Villena R, Hormazabal JC, Fernandez J, et al
    Whole-genome sequencing of Neisseria meningitidis collected in Chile from pediatric patients during 2016-2019 and coverage vaccine prediction.
    Vaccine. 2024;42:126311.
    PubMed     Abstract available


  806. VAN HEESBEEN R, Bastian AR, Omoruyi E, Rosen J, et al
    Immunogenicity and safety of different dose levels of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 years and older: A randomized, double-blind, placebo-controlled, phase 2a study.
    Vaccine. 2024;42:126273.
    PubMed     Abstract available


  807. KERFUA SD, Haydon DT, Wilsden G, Ludi A, et al
    Evaluation of commercial quadrivalent foot-and-mouth disease vaccines against east African virus strains reveals limited immunogenicity and duration of protection.
    Vaccine. 2024;42:126325.
    PubMed     Abstract available


  808. CHANG JY, Chang M, Huang S, Bosco J, et al
    COVID-19 vaccine uptake in a predominantly minoritized cohort hospitalized during the early pandemic in New York City.
    Vaccine. 2024;42:126260.
    PubMed     Abstract available


  809. PHAM M, Pichichero M
    Modeling conjugate vaccine and natural induced antibody correlates of protection for pneumococcal colonization and acute otitis media infection in young children.
    Vaccine. 2024;42:126295.
    PubMed     Abstract available


  810. BAFFOUR AWUAH G, Tanaka LF, Eberl M, Donnachie E, et al
    Analysis of health claims data on vaccination coverage in older adults in Bavaria, Germany: Influenza, pneumococcus and herpes zoster.
    Vaccine. 2024;42:126354.
    PubMed     Abstract available


  811. RABOBA JL, Rahajamanana VL, Rakotojoelimaria HE, Masembe YV, et al
    Monovalent rotavirus vaccine effectiveness and long-term impact among children <5 years old in Antananarivo, Madagascar, 2010-2022.
    Vaccine. 2024;42:126321.
    PubMed     Abstract available


  812. ABARA WE, Modaressi S, Fireman B, Klein NP, et al
    Effectiveness of a serogroup B meningococcal vaccine against gonorrhea: A retrospective study.
    Vaccine. 2024;42:126312.
    PubMed     Abstract available


  813. KING LM, Lewnard JA
    Health-economic burden attributable to novel serotypes in candidate 24- and 31-valent pneumococcal conjugate vaccines.
    Vaccine. 2024;42:126310.
    PubMed     Abstract available


  814. GAUDOUEN H, Tattevin P, Thibault V, Menard G, et al
    Determinants of influenza and COVID vaccine uptake in healthcare workers: A cross-sectional survey during the post-pandemic era in a network of academic hospitals in France.
    Vaccine. 2024;42:126272.
    PubMed     Abstract available


  815. REGAN AK, Sullivan SG, Arah OA
    Maternal influenza vaccination and associated risk of fetal loss: A claims-based prospective cohort study.
    Vaccine. 2024;42:126256.
    PubMed     Abstract available


  816. WANG C, Damiano RJ, Ruebush LE, Engelen MPKJ, et al
    A randomized, triple-blinded, placebo-controlled clinical trial evaluating immune responses of Typhim Vi and PPSV23 vaccines in healthy adults: The PREP study.
    Vaccine. 2024;42:126292.
    PubMed     Abstract available


  817. PETRI E, Biswal S, Lloyd E, Tricou V, et al
    Early onset of protection of the TAK-003 dengue vaccine: Data from the DEN-301 clinical trial.
    Vaccine. 2024;42:126309.
    PubMed     Abstract available


  818. BLASCO A, Royuela A, Garcia-Gomez S, Gomez-Lozano N, et al
    Association of SARS-CoV-2 immunoserology and vaccination status with myocardial infarction severity and outcome.
    Vaccine. 2024;42:126305.
    PubMed     Abstract available


  819. RAMIREZ OR, Farraye FA, Hayney MS, Caldera F, et al
    Inadvertent live vaccine administration in adult patients with inflammatory bowel disease on immunosuppressive therapy.
    Vaccine. 2024;42:126319.
    PubMed     Abstract available


  820. WOO EJ, Miller ER, Stroud E
    Syncope after live attenuated influenza vaccine: Reports to the Vaccine Adverse Event Reporting System (2003-2024).
    Vaccine. 2024;42:126290.
    PubMed     Abstract available


  821. GROOM HC, Biel FM, Crane B, Sun E, et al
    Disparities in COVID-19 vaccination receipt by race, ethnicity, and social determinants of health among a large patient population in a network of community-based healthcare centers.
    Vaccine. 2024;42:126288.
    PubMed     Abstract available


  822. HOXIE I, Vasilev K, Clark JJ, Bushfield K, et al
    A recombinant N2 neuraminidase-based CpG 1018(R) adjuvanted vaccine provides protection against challenge with heterologous influenza viruses in mice and hamsters.
    Vaccine. 2024;42:126269.
    PubMed     Abstract available


  823. HUTTON DW, Prosser LA, Rose AM, Mercon K, et al
    Cost-effectiveness of vaccinating adults aged 60 years and older against respiratory syncytial virus.
    Vaccine. 2024;42:126294.
    PubMed     Abstract available


  824. SCHLEY K, Whichello C, Hauber B, Krucien N, et al
    Preferences of US adolescents and parents for vaccination against invasive meningococcal disease.
    Vaccine. 2024;42:126264.
    PubMed     Abstract available


  825. POH XY, Torres-Ruesta A, Yoong T, Wong N, et al
    Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trial.
    Vaccine. 2024;42:126275.
    PubMed     Abstract available


  826. CUI Y, Cibichakravarthy B, Tang X, Alameh MG, et al
    Salp14 epitope-based mRNA vaccination induces early recognition of a tick bite.
    Vaccine. 2024;42:126304.
    PubMed     Abstract available


  827. KIM C, Dunphy C, Duggar C, Pike J, et al
    Jurisdiction-level costs of the initial phase of the COVID-19 vaccination program in the United States, December 20, 2020-May 31, 2021.
    Vaccine. 2024;42:126287.
    PubMed     Abstract available


  828. BONNER C, Taba M, Fajardo MA, Batcup C, et al
    Using health literacy principles to improve understanding of evolving evidence in health emergencies: Optimisation and evaluation of a COVID-19 vaccination risk-benefit calculator.
    Vaccine. 2024;42:126296.
    PubMed     Abstract available


  829. KARUNAKARAN KP, Yu H, Jiang X, Chan QWT, et al
    Immunoproteomic discovery of Mycobacterium bovis antigens, including the surface lipoprotein Mpt83 as a T cell antigen useful for vaccine development.
    Vaccine. 2024;42:126266.
    PubMed     Abstract available


  830. LIU S, van Dijk LLA, den Hartog Y, Hoek R, et al
    mRNA-based COVID-19 vaccination of lung transplant recipients with prior SARS-CoV-2 infection induces durable SARS-CoV-2-specific antibodies and T cells.
    Vaccine. 2024;42:126250.
    PubMed     Abstract available


  831. BOTTON J, Bertrand M, Jabagi MJ, Duranteau L, et al
    Risk of heavy menstrual bleeding following COVID-19 vaccination: A nationwide case-control study.
    Vaccine. 2024;42:126252.
    PubMed     Abstract available


  832. HOU X, Li N, Zhang H, Liu W, et al
    Hepatitis B virus infection and vaccination among people who use drugs in Xi'an, China.
    Vaccine. 2024;42:126259.
    PubMed     Abstract available


  833. RICHMOND P, Nolan T, McGirr A, Napier-Flood F, et al
    Phase 1 trial of an investigational Tdap booster vaccine with CpG 1018 adjuvant compared with Boostrix in healthy adults and adolescents.
    Vaccine. 2024;42:126251.
    PubMed     Abstract available


  834. COLEMAN BL, Gutmanis I, Bondy SJ, Harrison R, et al
    Canadian health care providers' and education workers' hesitance to receive original and bivalent COVID-19 vaccines.
    Vaccine. 2024;42:126271.
    PubMed     Abstract available


    August 2024
  835. LI G, Ren T, Zhang H, Ti J, et al
    Persistence of immunity in children aged 2 months and 7 months - 5 years old after primary immunization with 13-valent pneumococcal conjugate vaccine.
    Vaccine. 2024;42:126209.
    PubMed     Abstract available


  836. VIETRI J, Maculaitis MC, Cappelleri JC, Yu H, et al
    Preferences for a Clostridioides difficile vaccine among adults in the United States.
    Vaccine. 2024;42:126261.
    PubMed     Abstract available


  837. KELLY M, Janardhanan J, Wagh C, Verma S, et al
    Development of a Shigella conjugate vaccine targeting Shigella flexneri 6 that is immunogenic and provides protection against virulent challenge.
    Vaccine. 2024;42:126263.
    PubMed     Abstract available


  838. MACKAY H, Gretton JD, Chyderiotis S, Elliott S, et al
    Confidence and barriers: Analysis of factors associated with timely routine childhood vaccination in Canada during the COVID-19 pandemic.
    Vaccine. 2024;42:126236.
    PubMed     Abstract available


  839. AIZAWA Y, Sato I, Abe Y, Sasagawa F, et al
    Impact of the emergence of severe acute respiratory syndrome coronavirus 2 omicron variants on routine childhood immunization in Japan.
    Vaccine. 2024;42:126137.
    PubMed     Abstract available


  840. MAI W, Shen J, Ma F, Zhu J, et al
    Specific humoral immune response and XBB variants re-infection risk of hemodialysis patients after Omicron BA.5 infection in China.
    Vaccine. 2024;42:126108.
    PubMed     Abstract available


  841. EYAWO O, Ugoji UC, Pan S, Oyibo P, et al
    Predictors of the willingness to accept a free COVID-19 vaccine among households in Nigeria.
    Vaccine. 2024;42:126225.
    PubMed     Abstract available


  842. CHI X, Han F, Jiang Y, Cao L, et al
    Characterization of a triple-type chimeric vaccine against human papillomavirus types 18, 45, and 59.
    Vaccine. 2024;42:126245.
    PubMed     Abstract available


  843. BRESEE JS, Lafond KE
    The partnership for international vaccine initiatives: The importance and opportunity to develop influenza vaccination programs in low- and middle-income countries.
    Vaccine. 2024 Aug 29:126255. doi: 10.1016/j.vaccine.2024.126255.
    PubMed    


  844. NAVARRO-TORNE A, Anderson A, Panwar K, Ghys E, et al
    How has post-implementation surveillance of high-coverage vaccination with HPV16/18-AS04 vaccine in England added to evidence about its cross-protective effects?
    Vaccine. 2024;42:126215.
    PubMed     Abstract available


  845. FOURIE KR, Jeffery A, Chand D, Choudhary P, et al
    Vaccination with a Lawsonia intracellularis subunit water in oil emulsion vaccine mitigated some disease parameters but failed to affect shedding.
    Vaccine. 2024;42:126254.
    PubMed     Abstract available


  846. HARADA Y, Takahashi H, Fujimoto T, Horikoshi F, et al
    Evaluation of a qualified MDCK cell line for virus isolation to develop cell-based influenza vaccine viruses with appropriate antigenicity.
    Vaccine. 2024;42:126242.
    PubMed     Abstract available


  847. DONG R, Luo Z, Shao J, Xue H, et al
    Understanding hepatitis E vaccination intention among women of childbearing-age: A theory-based cross-sectional study.
    Vaccine. 2024;42:126258.
    PubMed     Abstract available


  848. LLABRE MM, Timpano KR, Broos HC, Leite RO, et al
    Lessons from a longitudinal community-based investigation of adherence to guidelines and intent to vaccinate during the COVID-19 pandemic.
    Vaccine. 2024;42:126265.
    PubMed     Abstract available


  849. PETRI FAM, Malcher CS, Mechler-Dreibi ML, Panneitz AK, et al
    Shedding reduction and immunity modulation in piglets with an inactivated Mycoplasma hyopneumoniae vaccine encapsulated in nanostructured SBA-15 silica.
    Vaccine. 2024;42:126268.
    PubMed     Abstract available


  850. PATHER S, Charpentier N, van den Ouweland F, Rizzi R, et al
    A Brighton Collaboration standardized template with key considerations for a benefit-risk assessment for the Comirnaty COVID-19 mRNA vaccine.
    Vaccine. 2024;42:126165.
    PubMed     Abstract available


  851. KANU FA, Freeland C, Nwokoro UU, Mohammed Y, et al
    Evaluation of interventions to improve timely hepatitis B birth dose vaccination among infants and maternal tetanus vaccination among pregnant women in Nigeria.
    Vaccine. 2024;42:126222.
    PubMed     Abstract available


  852. FERREIRA-SILVA SN, Soares MEM, Vasconcelos R, Barbieri C, et al
    COVID-19 vaccine hesitancy: Meaning relations between responses in an epidemiological study and twitter messages.
    Vaccine. 2024;42:126247.
    PubMed     Abstract available


  853. HUANG X, Yang S, Zhao J, Yang J, et al
    Generation and evaluation of Salmonella entericaserovar Choleraesuis mutant strains as a potential live-attenuated vaccine.
    Vaccine. 2024;42:126262.
    PubMed     Abstract available


  854. GUZMAN RUIZ L, Zollner AM, Hoxie I, Kuchler J, et al
    Enhancing NA immunogenicity through novel VLP designs.
    Vaccine. 2024;42:126270.
    PubMed     Abstract available


  855. ADAMS K, Diallo D, Tadount F, Mouajou V, et al
    Evaluation of the decision-making process underlying the initial off-label use of vaccines: A scoping review.
    Vaccine. 2024;42:126246.
    PubMed     Abstract available


  856. SINGH D, Damasevicius R, Kumar V, Bagnoli F, et al
    Editorial: ML-driven vaccine against COVID-19: Developmental challenges and foresight.
    Vaccine. 2024;42:126267.
    PubMed    


  857. EVANS I, Jury S, Morrison A, Best E, et al
    Onward transmission of measles virus among vaccinated cases in a large community outbreak in Auckland, New Zealand, 2019.
    Vaccine. 2024;42:126257.
    PubMed     Abstract available


  858. VIELOT NA, Kelly NK, Ludema C, Rosenberg M, et al
    Patterns and predictors of COVID-19 vaccination among young adults at 44 US sites: Secondary analysis of a randomized, controlled, open-label trial, March - December 2021.
    Vaccine. 2024;42:126237.
    PubMed     Abstract available


  859. UNAGAMI K, Yoshikawa M, Egawa H, Ohfuji S, et al
    Delayed peak antibody titers after the second dose of SARS-CoV-2 vaccine in solid organ transplant recipients: Prospective cohort study.
    Vaccine. 2024;42:126221.
    PubMed     Abstract available


  860. SHINJOH M, Yaginuma M, Yamaguchi Y, Tamura K, et al
    Effectiveness of inactivated influenza vaccine in children during the 2023/24 season: The first season after relaxation of intensive COVID-19 measures.
    Vaccine. 2024;42:126241.
    PubMed     Abstract available


  861. ADAMS L, Prasinou AK, Hadley L, Ramsay M, et al
    Estimating the potential number of cases prevented by infant/ toddler immunisation with a MenACWY vaccine.
    Vaccine. 2024;42:126240.
    PubMed     Abstract available


  862. OGAR CK, Gilbert HN, Bloem LT, Leopold C, et al
    Patient-reported outcomes of adverse events after COVID-19 vaccination in Nigeria: A mixed methods study.
    Vaccine. 2024;42:126196.
    PubMed     Abstract available


  863. SKIRROW H, Lewis C, Haque H, Choudary-Salter L, et al
    'Why did nobody ask us?': A mixed-methods co-produced study in the United Kingdom exploring why some children are unvaccinated or vaccinated late.
    Vaccine. 2024;42:126172.
    PubMed     Abstract available


  864. POURAKBARI B, Ashraf Talesh S, Mahmoudi S, Sotoudeh M, et al
    Measles immunity status in Iranian infants and children and outbreak concerns: Time for reconsidering the vaccination schedule?
    Vaccine. 2024;42:126243.
    PubMed     Abstract available


  865. CHEN Z, Gou Q, Yuan Y, Zhang X, et al
    Vaccination with a trivalent Klebsiella pneumoniae vaccine confers protection in a murine model of pneumonia.
    Vaccine. 2024;42:126217.
    PubMed     Abstract available


  866. ESPOSITO GL, Fassio F, Girardi D, Picasso E, et al
    "REAl LIfe" observational study on the effectiveness of Evusheld prophylaxis against SARS-CoV-2 omicron variants in vaccine non-responder immunocompromised patients (REALISE).
    Vaccine. 2024;42:126208.
    PubMed     Abstract available


  867. SANFTENBERG L, Bader F, Rottenkolber M, Sebastiao M, et al
    Associations of mental health with vaccination readiness in informal caregivers and the vaccination status of their care recipients during the Covid-19 pandemic - A cross sectional analysis.
    Vaccine. 2024;42:126218.
    PubMed     Abstract available


  868. CASEY RM, Najjengo MS, Lubega I, Sekiziyivu AB, et al
    Adverse events following immunization (AEFI) with fractional one-fifth and one-half doses of yellow fever vaccine compared to full dose in children 9-23 months old in Uganda, 2019-2020 - Preliminary report.
    Vaccine. 2024;42:126197.
    PubMed     Abstract available


  869. WANDERA EA, Kurokawa N, Mutua MM, Muriithi B, et al
    Long-term impact of rotavirus vaccination on all-cause and rotavirus-specific gastroenteritis and strain distribution in Central Kenya: An 11-year interrupted time-series analysis.
    Vaccine. 2024;42:126210.
    PubMed     Abstract available


  870. HERNANDEZ-BERNAL F, Noa-Romero E, Quintana-Guerra J, Chavez-Chong CO, et al
    Efficacy and safety of Abdala COVID-19 subunit vaccine in children and adolescents: An open-label, single-arm, phase 2 trial (MENIQUE).
    Vaccine. 2024;42:126223.
    PubMed     Abstract available


  871. SNIDER CJ, Zaman K, Estivariz CF, Aziz AB, et al
    Assessing the mucosal intestinal and systemic humoral immunity of sequential schedules of inactivated poliovirus vaccine and bivalent oral poliovirus vaccine for essential immunization in Bangladesh: An open-label, randomized controlled trial.
    Vaccine. 2024;42:126216.
    PubMed     Abstract available


  872. HADLEY L, Soeters HM, Cooper LV, Fernandez K, et al
    Modelling control strategies for pneumococcal meningitis outbreaks in the African meningitis belt.
    Vaccine. 2024;42:125983.
    PubMed     Abstract available


  873. IHENETU G, Aylin P, Novov V, Skirrow H, et al
    Uptake of COVID-19 vaccines and association with hospitalisation due to COVID-19 in pregnancy: Retrospective cohort study.
    Vaccine. 2024 Aug 13:126214. doi: 10.1016/j.vaccine.2024.126214.
    PubMed     Abstract available


  874. FINN MB, Penfound TA, Salehi S, Ogega CO, et al
    Immunogenicity of a 30-valent M protein mRNA group A Streptococcus vaccine.
    Vaccine. 2024;42:126205.
    PubMed     Abstract available


  875. VALDES I, Suzarte E, Lazo L, Cobas K, et al
    Addition of nucleotide adjuvants enhances the immunogenicity of a recombinant subunit vaccine against the Zika virus in BALB/c mice.
    Vaccine. 2024 Aug 12:126213. doi: 10.1016/j.vaccine.2024.126213.
    PubMed     Abstract available


  876. GLEASON A, Kumar CK, Klein E, Laxminarayan R, et al
    Effect of rotavirus vaccination on the burden of rotavirus disease and associated antibiotic use in India: A dynamic agent-based simulation analysis.
    Vaccine. 2024;42:126211.
    PubMed     Abstract available


  877. CAMERON RL, Palmer TJ, Cuschieri K, Kavanagh K, et al
    Assessing real world vaccine effectiveness: A review of Scotland's approach to monitoring human papillomavirus (HPV) vaccine impact on HPV infection and cervical disease.
    Vaccine. 2024;42:126177.
    PubMed     Abstract available


  878. NASIR S, Anwer F, Ishaq Z, Saeed MT, et al
    VacSol-ML(ESKAPE)(:) Machine learning empowering vaccine antigen prediction for ESKAPE pathogens.
    Vaccine. 2024;42:126204.
    PubMed     Abstract available


  879. JOB MJ, Kim D, Acosta F, Valera S, et al
    Attitudes of pregnant women in the Dominican Republic towards a future maternal Group B Streptococcus vaccine.
    Vaccine. 2024;42:126169.
    PubMed     Abstract available


  880. WALDEN J, Stanek JR, Young J, Griffith MM, et al
    Influenza vaccine uptake among youth with sickle cell disease who are seen in clinic before and after the COVID-19 pandemic.
    Vaccine. 2024;42:126212.
    PubMed     Abstract available


  881. GRAF DD, Westphal L, Hallgreen CE
    The life cycle of vaccines evaluated by the European Medicines Agency.
    Vaccine. 2024;42:126186.
    PubMed     Abstract available


  882. BAJPAI D, Bose S, Saxena N, Kulkarni B, et al
    Antibody response to non-mRNA SARS-CoV-2 vaccine in kidney transplant recipients.
    Vaccine. 2024 Aug 8:126206. doi: 10.1016/j.vaccine.2024.126206.
    PubMed     Abstract available


  883. BLOODWORTH S, Singleton D, Perkins E, Radford A, et al
    Temporal trends and factors associated with vaccination uptake in dogs and cats from 2016 to 2022 in the United Kingdom.
    Vaccine. 2024;42:126185.
    PubMed     Abstract available


  884. O'MAHONY E, Sherman SM, Marlow R, Bedford H, et al
    UK paediatricians' attitudes towards the chicken pox vaccine: The SPOTTY study.
    Vaccine. 2024;42:126199.
    PubMed     Abstract available


  885. GOMEZ-ACEBO I, Barquin-Ruiz A, Llorente S, Alonso-Molero J, et al
    The impact of the COVID-19 pandemic on childhood vaccination rates and the role of sociodemographic factors: A cohort study.
    Vaccine. 2024;42:126207.
    PubMed     Abstract available


  886. D'SOUZA S, Ghatole B, Raghuram H, Sukhija S, et al
    Understanding structural inequities in Covid-19 vaccine access and uptake among disability, transgender and gender-diverse communities in India.
    Vaccine. 2024 Aug 7:126174. doi: 10.1016/j.vaccine.2024.126174.
    PubMed     Abstract available


  887. GAO Y, Yang X, Li X, Chen H, et al
    Lot-to-lot consistency, immunogenicity and safety of a quadrivalent split virion inactivated influenza vaccine in healthy population aged 9-59 years: A randomized, double-blind, controlled, phase IV clinical trial.
    Vaccine. 2024;42:126182.
    PubMed     Abstract available


  888. BUTLER AM, Newland JG, Sahrmann JM, O'Neil CA, et al
    Characterizing timeliness of recommended vaccinations among privately-insured children in the United States, 2009-2019.
    Vaccine. 2024;42:126179.
    PubMed     Abstract available


  889. GEORGE G, Strauss M, Lansdell E, Nota P, et al
    Factors associated with COVID-19 vaccine uptake among south African health care workers.
    Vaccine. 2024;42:126181.
    PubMed     Abstract available


  890. BOKEL J, Martins-Goncalves R, Grinsztejn E, Mendes-de-Almeida DP, et al
    Anti-PF4 positivity and platelet activation after Ad26.COV2.S vaccination in Brazil.
    Vaccine. 2024 Aug 5:126175. doi: 10.1016/j.vaccine.2024.126175.
    PubMed     Abstract available


  891. BRONSTEIN MV, Kummerfeld E, MacDonald A 3rd, Vinogradov S, et al
    Identifying psychological predictors of SARS-CoV-2 vaccination: A machine learning study.
    Vaccine. 2024;42:126198.
    PubMed     Abstract available


  892. AUGELLO M, Wagenhauser I, Krone M, Dauby N, et al
    Should SARS-CoV-2 serological testing be used in the decision to deliver a COVID-19 vaccine booster? A pro-con assessment.
    Vaccine. 2024 Aug 2:126184. doi: 10.1016/j.vaccine.2024.126184.
    PubMed     Abstract available


  893. MCCARRON M, Marcenac P, Yau TS, Lafond KE, et al
    Healthcare personnel acceptance and recommendations for influenza vaccine in twelve low- and middle-income countries: A pooled analysis from 2018 to 2020.
    Vaccine. 2024 Aug 2:125670. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  894. WOOLFORK MN, Haire K, Farinu O, Ruffin J, et al
    A health equity science approach to assessing drivers of COVID-19 vaccination coverage disparities over the course of the COVID-19 pandemic, United States, December 2020-December 2022.
    Vaccine. 2024 Aug 1:126158. doi: 10.1016/j.vaccine.2024.126158.
    PubMed     Abstract available


  895. JIANG M, Zhang H, Yao X, Wang Y, et al
    Immunization-related stress and stress-related responses of mucosal versus intramuscular COVID-19 vaccination among adults in China.
    Vaccine. 2024 Aug 1:126150. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


    July 2024
  896. ABIL OZ, Liu S, Yeh YW, Wu Y, et al
    A mucosal vaccine formulation against tuberculosis by exploiting the adjuvant activity of S100A4-A damage-associated molecular pattern molecule.
    Vaccine. 2024 Jul 31:126151. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  897. PHIRIYASART F, Aimyong N, Jirapongsuwan A, Roseh N, et al
    Corrigendum to "COVID-19 vaccine hesitancy among older adult Thai Muslim people: A case-control study" [Vaccine 2023;41(41):6048-6054].
    Vaccine. 2024 Jul 31:126180. doi: 10.1016/j.vaccine.2024.126180.
    PubMed    


  898. SANGWE CN, Budzi MN, Shifu IN, Ghangha JG, et al
    The use of community-oriented primary care (COPC) model to generate vaccine demand: The case of a remote fishing community in Cameroon.
    Vaccine. 2024 Jul 31:126173. doi: 10.1016/j.vaccine.2024.126173.
    PubMed     Abstract available


  899. DE WEERDT L, Herzog SA, Van Damme P, Maertens K, et al
    Timing of pertussis vaccination during pregnancy: Evidence and implementation - A systematic review.
    Vaccine. 2024;42:126152.
    PubMed     Abstract available


  900. GUO S, Li Z, Zheng M, Wu F, et al
    Safety and 6-month immune persistence of inactivated poliovirus vaccine (Sabin strains) simultaneously administrated with other vaccines for primary and booster immunization in Jiangxi Province, China.
    Vaccine. 2024;42:126183.
    PubMed     Abstract available


  901. MATSUMOTO N, Sasaki A, Kadowaki T, Mitsuhashi T, et al
    Kinetics of SARS-CoV-2 antibody titers after booster vaccinations during an Omicron surge in Japan.
    Vaccine. 2024;42:126156.
    PubMed     Abstract available


  902. BESBASSI H, Elias G, Meysman P, Jansens H, et al
    Modeling antigen-specific T cell dynamics following Hepatitis B Vaccination indicates differences between conventional and regulatory T cell dynamics.
    Vaccine. 2024;42:126148.
    PubMed     Abstract available


  903. ASUPOTO O, Li X, Hemberg JL, Emerson A, et al
    COVID-19 and influenza vaccine uptake in women with criminal-legal system involvement.
    Vaccine. 2024 Jul 30:126176. doi: 10.1016/j.vaccine.2024.126176.
    PubMed     Abstract available


  904. ELYASS J, Desalegn A, Trinh NTH, Orangzeb S, et al
    Individual and familial factors associated with mRNA COVID-19 vaccine uptake in pregnancy: A large-scale registry-based linkage study.
    Vaccine. 2024 Jul 29:126171. doi: 10.1016/j.vaccine.2024.126171.
    PubMed     Abstract available


  905. GE Y, Lu Y, Allen JD, Einav T, et al
    Pre-existing immunity to influenza aids ferrets in developing stronger and broader H3 vaccine-induced antibody responses.
    Vaccine. 2024 Jul 29:126149. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  906. TAHSIN A, Bhattacharjee P, Al Saba A, Yasmin T, et al
    Genetic and epigenetic analyses of IFN-gamma gene proximal promoter region underlying positive correlation between persistently high anti-SARS-CoV-2 IgG and IFN-gamma among COVID-19 vaccinated Bangladeshi adults.
    Vaccine. 2024 Jul 29:126157. doi: 10.1016/j.vaccine.2024.126157.
    PubMed     Abstract available


  907. GEBRETEKLE GB, Yeung MW, Ximenes R, Cernat A, et al
    Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants.
    Vaccine. 2024 Jul 29:126164. doi: 10.1016/j.vaccine.2024.126164.
    PubMed     Abstract available


  908. WILLIS DE, Moore R, Selig JP, Shafeek Amin N, et al
    Pediatric HPV vaccination: Provider recommendations matter among hesitant parents.
    Vaccine. 2024 Jul 29:126166. doi: 10.1016/j.vaccine.2024.126166.
    PubMed     Abstract available


  909. MOTAGHI S, Pullenayegum E, Morgan RL, Loeb M, et al
    The role of influenza Hemagglutination-Inhibition antibody as a vaccine mediator in children.
    Vaccine. 2024 Jul 28:126122. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  910. SULEMAN A, Vicente P
    COVID-19 vaccination reluctance across Europe: Lessons for the future.
    Vaccine. 2024 Jul 27:126168. doi: 10.1016/j.vaccine.2024.126168.
    PubMed     Abstract available


  911. REN J, Huang Z, Tian J, Li Z, et al
    Evaluation of pre-school pertussis booster vaccination in Shanghai, China: A cost-effectiveness analysis.
    Vaccine. 2024 Jul 27:126162. doi: 10.1016/j.vaccine.2024.126162.
    PubMed     Abstract available


  912. WILLIS DE, Moore R, Purvis RS, McElfish PA, et al
    Hesitant but vaccinated: Lessons learned from hesitant adopters.
    Vaccine. 2024 Jul 27:126135. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  913. JENA D, Ghosh A, Jha A, Prasad P, et al
    Impact of vaccination on SARS-CoV-2 evolution and immune escape variants.
    Vaccine. 2024 Jul 26:126153. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  914. ATAULLAHJAN A, Piche-Renaud PP, Shahrbabak EK, Fadaleh SA, et al
    Weighing the risks and benefits: Parental perspectives on COVID-19 vaccines for 5- to 11-year-old children.
    Vaccine. 2024 Jul 26:126154. doi: 10.1016/j.vaccine.2024.126154.
    PubMed     Abstract available


  915. WILLIAMS LR, Emary KRW, Phillips DJ, Hay J, et al
    Implementation and adherence to regular asymptomatic testing in a COVID-19 vaccine trial.
    Vaccine. 2024 Jul 26:126167. doi: 10.1016/j.vaccine.2024.126167.
    PubMed     Abstract available


  916. BILGIN GM, Munira SL, Lokuge K, Glass K, et al
    Mathematical modelling of the 100-day target for vaccine availability after the detection of a novel pathogen: A case study in Indonesia.
    Vaccine. 2024 Jul 26:126163. doi: 10.1016/j.vaccine.2024.126163.
    PubMed     Abstract available


  917. KHANAFER N, Oudot S, Maligeay M, Planckaert C, et al
    A quick access to information on influenza burden and prevention in Lyon university hospital: A prospective QR code-based information campaign in 2022-2023.
    Vaccine. 2024 Jul 26:126160. doi: 10.1016/j.vaccine.2024.126160.
    PubMed     Abstract available


  918. JIMENEZ-SEPULVEDA N, Gras-Valenti P, Chico-Sanchez P, Castro-Garcia JM, et al
    Effectiveness of mRNA booster doses in preventing infections and hospitalizations due to SARS-CoV-2 and its dominant variant over time in Valencian healthcare workers, Spain.
    Vaccine. 2024;42:4011-4021.
    PubMed     Abstract available


  919. JOHNSTON C, Scheele S, Bachmann L, Boily MC, et al
    Vaccine value profile for herpes simplex virus.
    Vaccine. 2024;42.
    PubMed     Abstract available


  920. MARTIN LB, Tack B, Marchello CS, Sikorski MJ, et al
    Vaccine value profile for invasive non-typhoidal Salmonella disease.
    Vaccine. 2024;42.
    PubMed     Abstract available


  921. LAWAL S, St-Jean M, Hu Y, Bakos B, et al
    Assessing sociodemographic disparities in HPV vaccine uptake among grade 6 and 9 students in the Vancouver Coastal Health region.
    Vaccine. 2024 Jul 25:126147. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  922. SILVER ER, Fink L, Baylis KR, Faust RA, et al
    Challenging the 'acceptable option': Public health's advocacy for continued care in the case of pediatric vaccine refusal.
    Vaccine. 2024 Jul 23:126144. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  923. YAMEY G, McDade KK, Anderson RM, Bartsch SM, et al
    Vaccine value profile for schistosomiasis.
    Vaccine. 2024 Jul 23:126020. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  924. WAGENHAUSER I, Almanzar G, Forg FB, Stein A, et al
    Heterologous and homologous COVID-19 mRNA vaccination schemes for induction of basic immunity show similar immunogenicity regarding long-term spike-specific cellular immunity in healthcare workers.
    Vaccine. 2024 Jul 20:126132. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  925. ZOU GQ, Li K, Yan C, Li YQ, et al
    Aluminum hydroxide and immunostimulatory glycolipid adjuvant combination for enhanced COVID-19 subunit vaccine immunogenicity.
    Vaccine. 2024 Jul 20:126145. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  926. CAO Y, Hayashi CTH, Araujo MDS, Tripathi AK, et al
    Evaluation of combination vaccines targeting transmission of Plasmodium falciparum and P. vivax.
    Vaccine. 2024 Jul 19:126140. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  927. SANADA T, Honda T, Kohara M
    Modeling of anti-spike IgG and neutralizing antibody waning after anti-SARS-CoV-2 mRNA vaccination.
    Vaccine. 2024 Jul 19:126146. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  928. CHAU M, Kaufman J, Holland P, Danchin M, et al
    Co-designing an intervention to improve the childhood catch-up vaccination process for migrant parents in Australia.
    Vaccine. 2024 Jul 18:S0264-410X(24)00745-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  929. BAUER BU, Herms TL, Jahnke R, Ossowski N, et al
    Control of Coxiella burnetii shedding in a dairy goat herd by annual offspring vaccination.
    Vaccine. 2024 Jul 18:S0264-410X(24)00787-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  930. WASSIL J, Sisti M, Fairman J, Rankin B, et al
    A phase 2, randomized, blinded, dose-finding, controlled clinical trial to evaluate the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults 65 years and older.
    Vaccine. 2024 Jul 17:S0264-410X(24)00786-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  931. ANDERSON S, Kuter BJ, Brien K, Bauerle Bass S, et al
    Perceptions of vaccine requirements among students at four Pennsylvania universities.
    Vaccine. 2024 Jul 17:S0264-410X(24)00801-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  932. JIN CHOI S, Lee W, Cheol Kim S, Jo HY, et al
    Longitudinal multiomic profiling and corticosteroid modulation of the immediate innate immune response to an adenovirus-vector vaccine.
    Vaccine. 2024 Jul 17:S0264-410X(24)00774-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  933. SANTIBANEZ TA, Black CL, Zhou T, Srivastav A, et al
    Parental hesitancy about COVID-19, influenza, HPV, and other childhood vaccines.
    Vaccine. 2024 Jul 16:S0264-410X(24)00802-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  934. HU TH, Tou CY, Lee YH, Chang HH, et al
    Knowledge gap of human monkeypox among high-risk individuals receiving preexposure vaccination in Taiwan.
    Vaccine. 2024 Jul 16:S0264-410X(24)00753-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  935. JIN F, Zhu L, Wang Y, Qin G, et al
    Corrigendum to "Randomized, blind, controlled phase III clinical trial: Assessing the immunogenicity and safety of freeze-dried human rabies vaccine (vero cell) with a 4-dose regimen (2-1-1) in a 10-60 year-old demographic" [Vaccine (2024) 26059].
    Vaccine. 2024 Jul 16:S0264-410X(24)00791-6. doi: 10.1016/j.vaccine.2024.
    PubMed    


  936. LIU G, Pang Y, Lv M, Lu M, et al
    Effectiveness of influenza vaccination on hospitalization outcomes among older patients with diabetes.
    Vaccine. 2024 Jul 16:S0264-410X(24)00806-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  937. STEENACKERS K, Hanning N, Bruckers L, Desombere I, et al
    Humoral immune response against SARS-CoV-2 after adapted COVID-19 vaccine schedules in healthy adults: The IMCOVAS randomized clinical trial.
    Vaccine. 2024 Jul 16:S0264-410X(24)00773-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  938. LUNA-MUSCHI A, Carmo Borges I, Dos Santos Barboza A, de Faria E, et al
    Duration of vaccine protection against breakthrough infections during five COVID-19 waves among healthcare workers primarily vaccinated with CoronaVac.
    Vaccine. 2024 Jul 16:S0264-410X(24)00752-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  939. TAKAHASHI Y, Tanaka H, Taniguchi C, Ogata T, et al
    Efficiency of indirect protection of COVID-19 vaccination and interactions between indirect and direct protection on household transmission.
    Vaccine. 2024 Jul 16:S0264-410X(24)00749-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  940. HATFIELD K, Wiegand R, Reddy S, Patel A, et al
    Effectiveness of COVID-19 bivalent vaccination against SARS-CoV-2 infection among residents of US nursing homes, November 2022 - March 2023.
    Vaccine. 2024 Jul 16:S0264-410X(24)00754-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  941. ALTAWALBEH SM, Wateska AR, Patricia Nowalk M, Lin CJ, et al
    Corrigendum to "Cost-effectiveness of an in-development adult-formulated 21-valent pneumococcal conjugate vaccine in US adults aged 50 years or older" [Vaccine 42 (2024) 3024-3032].
    Vaccine. 2024 Jul 15:S0264-410X(24)00789-8. doi: 10.1016/j.vaccine.2024.
    PubMed    


  942. STEFANIZZI P, Di Lorenzo A, Capodiferro L, Moscara L, et al
    Increasing vaccination coverage among healthcare workers: Active call and mandatory laws. Data from a large general hospital in Southern Italy.
    Vaccine. 2024 Jul 15:S0264-410X(24)00739-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  943. FISMAN DN, Simmons AE, Tuite AR
    Case-cohort design as an efficient approach to evaluating COVID-19 vaccine effectiveness, waning, heterologous immune effect and optimal dosing interval.
    Vaccine. 2024 Jul 13:S0264-410X(24)00797-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  944. JAJOU R, Lieber T, van Puijenbroek EP, Mulder E, et al
    GP consultations for menstrual disorders after COVID-19 vaccination - A self-controlled cohort study based on routine healthcare data from the Netherlands.
    Vaccine. 2024 Jul 13:S0264-410X(24)00793-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  945. DULL PM, Achilles SL, Ahmed R, Barnabas RV, et al
    Meeting report: Considerations for trial design and endpoints in licensing therapeutic HPV16/18 vaccines to prevent cervical cancer.
    Vaccine. 2024 Jul 13:S0264-410X(24)00741-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  946. VERANI JR, Omondi D, Odoyo A, Odiembo H, et al
    Long-term impact of 10-valent pneumococcal conjugate vaccine in Kenya: Nasopharyngeal carriage among children in a rural and an urban site six years after introduction.
    Vaccine. 2024 Jul 13:S0264-410X(24)00782-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  947. MIAO Q, Nguyen W, Zhu J, Liu G, et al
    A getah virus-like-particle vaccine provides complete protection from viremia and arthritis in wild-type mice.
    Vaccine. 2024 Jul 13:S0264-410X(24)00799-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  948. LE BAGOUSSE-BERNARD A, Dussart C, Pin P, Tazarourte K, et al
    Mass COVID-19 vaccination center: Optimizing the vaccination pathway during a 12 month timeframe.
    Vaccine. 2024 Jul 12:S0264-410X(24)00742-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  949. HUANG WT, Law B, Tran H, Schonborn L, et al
    Validation of the newly proposed Brighton Collaboration case definition for vaccine-induced immune thrombocytopenia and thrombosis.
    Vaccine. 2024 Jul 12:S0264-410X(24)00794-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  950. DANELIAN G, Burton L, Bayley T, Sanchez-Marroquin A, et al
    The impact and cost-effectiveness of pneumococcal immunisation strategies for the elderly in England.
    Vaccine. 2024;42:3838-3850.
    PubMed     Abstract available


  951. AGARWAL S, Harsukhbhai Chandpa H, Naskar S, Lal Meena C, et al
    Dominant B cell-T cell epitopes instigated robust immune response in-silico against Scrub Typhus.
    Vaccine. 2024;42:3899-3915.
    PubMed     Abstract available


  952. BUCHHORN DE FREITAS S, Clair Pinto Seixas Neto A, Aparecido Panagio L, Pereira Soares M, et al
    Hypothetical adhesin CAM87009.1 formulated in alum or biogenic silver nanoparticles protects mice from lethal infection by multidrug-resistant Acinetobacter baumannii.
    Vaccine. 2024;42:3802-3810.
    PubMed     Abstract available


  953. LI J, Gong L, Li J, Gong Z, et al
    Low neutralization of SARS-CoV-2 Omicron BA.5.2.48 and XBB.1 sub-variants in response to breakthrough infection by booster.
    Vaccine. 2024;42:3751-3755.
    PubMed     Abstract available


  954. SARTORI AL, Buffarini R, Machado da Silva A, Amaral de Andrade Leao O, et al
    Child COVID-19 vaccine uptake among participants of the 2015 Pelotas (Brazil) Birth Cohort Study.
    Vaccine. 2024 Jul 11:S0264-410X(24)00746-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  955. LAMBACH P, Silal S, Sbarra AN, Koh M, et al
    Corrigendum to "Report from the World Health Organization's immunization and vaccines-related implementation research advisory committee (IVIR-AC) meeting, virtual gathering, 26 February-1 March 2024" [Vaccine 42(15) (2024) 3379-3383].
    Vaccine. 2024 Jul 11:S0264-410X(24)00743-6. doi: 10.1016/j.vaccine.2024.
    PubMed    


  956. HOEVE CE, Huiberts AJ, de Gier B, Andeweg SP, et al
    COVID-19 vaccination-induced antibody responses and waning by age and comorbidity status in a large population-based prospective cohort study.
    Vaccine. 2024 Jul 11:S0264-410X(24)00783-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  957. MILLER E, Michel A, Singh P, Limaye R, et al
    Countering vaccine misinformation: Designing a learning resource for healthcare workers in eight countries.
    Vaccine. 2024 Jul 11:S0264-410X(24)00732-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  958. GARCIA S, Shin M, Gill M, He Z, et al
    Identifying the intersection of parental HPV and COVID-19 vaccine hesitancy to inform health messaging interventions in community-based settings.
    Vaccine. 2024 Jul 11:S0264-410X(24)00792-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  959. BOLIO A, Waheed DE, Mugo N, Garland SM, et al
    Overview of CHIC symposia series: Summary of Africa and South Asia symposia.
    Vaccine. 2024;42 Suppl 2:S9-S15.
    PubMed     Abstract available


  960. NDIAYE C, Kyesi F, Masupha T, Ranyali M, et al
    Integrating HPV vaccine service delivery with adolescent health programmes - Experiences and perspectives from selected countries in Africa.
    Vaccine. 2024;42 Suppl 2:S45-S48.
    PubMed     Abstract available


  961. SIDIBE A, Kouassi KS, Ekra D, Bloem P, et al
    Accelerating and broadening multisectoral partnerships for introducing and rebuilding HPV vaccination programmes.
    Vaccine. 2024;42 Suppl 2:S41-S44.
    PubMed    


  962. WAHEED DE, Bolio A, Kyesi F, Miano CW, et al
    Routine HPV vaccination: Reflection on delivery strategies based on countries' experiences.
    Vaccine. 2024;42 Suppl 2:S37-S40.
    PubMed     Abstract available


  963. KOUASSI KS, Chisupa E, Clarke A, Massenon I, et al
    Pandemic-related resilience in HPV vaccination programmes - Perspectives from selected countries in Africa on what it will take to vaccinate 90 % of girls by 2030.
    Vaccine. 2024;42 Suppl 2:S33-S36.
    PubMed     Abstract available


  964. NJOGU R, Deb Roy A, Bagudu Z, Borda H, et al
    Effective communication by health care workers to promote HPV vaccination: Lessons learned from Kenya, India, and Nigeria.
    Vaccine. 2024;42 Suppl 2:S27-S32.
    PubMed     Abstract available


  965. WAHEED DE, Mumba M, Alfred D, Bogale M, et al
    Identifying key challenges and optimizing approaches for training of health care professionals for HPV vaccination programmes.
    Vaccine. 2024;42 Suppl 2:S22-S26.
    PubMed     Abstract available


  966. STANLEY M, Schuind A, Muralidharan KK, Guillaume D, et al
    Evidence for an HPV one-dose schedule.
    Vaccine. 2024;42 Suppl 2:S16-S21.
    PubMed     Abstract available


  967. BORDA H, Bloem P, Akaba H, Guillaume D, et al
    Status of HPV disease and vaccination programmes in LMICs: Introduction to special issue.
    Vaccine. 2024;42 Suppl 2:S1-S8.
    PubMed     Abstract available


  968. GHARPURE R, Longley AT, Takamiya M, Hidle A, et al
    Typhoid conjugate vaccine perceptions and coverage among children and adults: Findings from a post-campaign coverage survey - Harare, Zimbabwe, 2019.
    Vaccine. 2024 Jul 10:S0264-410X(24)00727-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  969. WEITZMAN ER, Pierce SE, Blakemore LM, Murdock A, et al
    Need for strategic communications and stakeholder engagement to advance acceptability of an overdose preventing vaccine targeting fentanyl.
    Vaccine. 2024 Jul 10:S0264-410X(24)00722-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  970. ZOU M, Lei C, Huang D, Liu L, et al
    Application of plant-derived products as adjuvants for immune activation and vaccine development.
    Vaccine. 2024 Jul 9:S0264-410X(24)00756-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  971. SANCHEZ-GONZALEZ G, Luna-Casas G, Mascarenas C, Macina D, et al
    Corrigendum to "Pertussis in Mexico from 2000 to 2019: A real-world study of incidence, vaccination coverage, and vaccine effectiveness" [Vaccine 41(41) (2023) 6105-6111].
    Vaccine. 2024 Jul 8:S0264-410X(24)00726-6. doi: 10.1016/j.vaccine.2024.
    PubMed    


  972. JITENDER, Vikram Kumar B, Singh S, Verma G, et al
    Mammalian cell expressed recombinant trimeric spike protein is a potent vaccine antigen and confers near-complete protection against SARS-CoV-2 infection in Hamster.
    Vaccine. 2024 Jul 8:S0264-410X(24)00740-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  973. BANG JY, Kim YJ, Seo YJ, Hong SH, et al
    Reduced cell-mediated immune response in hyperglycemic NOD mice following influenza vaccination.
    Vaccine. 2024 Jul 8:S0264-410X(24)00757-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  974. KORCHINSKI I, Marquez C, McClymont E, Av-Gay G, et al
    Maternal-infant transfer of SARS-CoV-2 antibodies following vaccination in pregnancy: A prospective cohort study.
    Vaccine. 2024 Jul 8:S0264-410X(24)00785-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  975. WACHINGER J, Renosa MDC, Endoma V, Landicho-Guevarra J, et al
    Routines, disruptions, revised decisions: A biographical analysis of vaccination trajectories among Filipino caregivers.
    Vaccine. 2024 Jul 6:S0264-410X(24)00736-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  976. ARAUJO-CHAVERON L, Olivier C, Pellissier G, Bouvet E, et al
    Analyzing the 7C psychological antecedents of vaccine acceptance throughout the COVID-19 pandemic among healthcare sector workers in France: A repeated cross-sectional study (CappVac-Cov).
    Vaccine. 2024 Jul 6:S0264-410X(24)00744-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  977. LANIECE DELAUNAY C, Melo A, Maurel M, Mazagatos C, et al
    Corrigendum to "Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: results from the VEBIS primary care test-negative design study, September 2023-January 2024" [Vaccine 42(19) (2024)].
    Vaccine. 2024 Jul 5:S0264-410X(24)00730-8. doi: 10.1016/j.vaccine.2024.
    PubMed    


  978. NOWALK MP, Smith KJ, Raviotta JM, Wateska A, et al
    Cost-effectiveness of recombinant influenza vaccine compared with standard dose influenza vaccine in adults 18-64 years of age.
    Vaccine. 2024 Jul 5:S0264-410X(24)00748-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  979. MESHRAM R, Kolte B, Gacche R
    Reverse vaccinology approach for identification of epitopes from E1 protein as peptide vaccine against HCV: A proof of concept.
    Vaccine. 2024 Jul 5:S0264-410X(24)00747-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  980. KOUTSOUMPLI G, Stasiukonyte N, Hoogeboom BN, Daemen T, et al
    An in vitro CD8 T-cell priming assay enables epitope selection for hepatitis C virus vaccines.
    Vaccine. 2024 Jul 3:S0264-410X(24)00659-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  981. KAFADAR AH, Sabatini S, Jones KA, Dening T, et al
    Categorising interventions to enhance vaccine uptake or reduce vaccine hesitancy in the United Kingdom: A systematic review and meta-analysis.
    Vaccine. 2024 Jul 2:S0264-410X(24)00733-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  982. ZHANG D, Jiang Y, Wang M, Zhao J, et al
    A novel costimulatory molecule gene-modified leukemia cell-derived exosome enhances the anti-leukemia efficacy of DC vaccine in mouse models.
    Vaccine. 2024 Jul 2:S0264-410X(24)00738-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  983. HOULE SKD, Waite NM, Vernon-Wilson E, Dolovich L, et al
    Uptake and outcomes of VaxCheck, an adult life-course vaccination service: A study among community pharmacists.
    Vaccine. 2024 Jul 1:S0264-410X(24)00737-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


    June 2024
  984. GAO H, Zhang S, Chang H, Guo Y, et al
    Generation of a novel attenuated IBDV vaccine strain by mutation of critical amino acids in IBDV VP5.
    Vaccine. 2024 Jun 28:S0264-410X(24)00723-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  985. ROOZEN GVT, Granger A, van Binnendijk RS, den Hartog G, et al
    Intradermal fractional dose vaccination as a method to vaccinate individuals with suspected allergy to mRNA COVID-19 vaccines.
    Vaccine. 2024 Jun 28:S0264-410X(24)00734-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  986. BHELLA S, Wilkin AM, Hueniken K, Vijenthira A, et al
    COVID-19 vaccine immunogenicity and safety surrounding fourth and subsequent vaccine doses in patients with hematologic malignancies.
    Vaccine. 2024 Jun 28:S0264-410X(24)00715-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  987. PLEY C, Kampmann B
    Opportunities and challenges to the development and deployment of vaccines for pregnant women in Germany.
    Vaccine. 2024 Jun 28:S0264-410X(24)00735-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  988. KELLY JA, Walsh JL, Quinn K, Amirkhanian YA, et al
    Factors predicting primary and booster COVID-19 vaccination in a community sample of African American men and women in the United States Midwest.
    Vaccine. 2024 Jun 27:S0264-410X(24)00729-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  989. JIN F, Zhu L, Wang Y, Qin G, et al
    Randomized, blind, controlled phase III clinical trial: Assessing the immunogenicity and safety of freeze-dried human rabies vaccine (vero cell) with a 4-dose regimen (2-1-1) in a 10-60 year-old demographic.
    Vaccine. 2024 Jun 26:S0264-410X(24)00700-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  990. GUTIERREZ MP, Huckaby AB, Yang E, Weaver KL, et al
    Antibody-mediated immunological memory correlates with long-term Lyme veterinary vaccine protection in mice.
    Vaccine. 2024 Jun 26:S0264-410X(24)00725-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  991. COULIBALY D, Douba A, N'Guessan K, N'Gattia AK, et al
    Intent to receive flu vaccine and influenza vaccination coverage among health professionals during 2019, 2020 and 2021 campaigns in Cote d'Ivoire.
    Vaccine. 2024 Jun 25:S0264-410X(24)00717-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  992. YOO YM, Katz MA, Greenberg D, Marcenac P, et al
    Knowledge, attitudes, and practices associated with influenza vaccine uptake among healthcare personnel in Israel during three influenza seasons, 2016-2019.
    Vaccine. 2024 Jun 25:S0264-410X(24)00705-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  993. HUSSEIN I, Mohamud H, Hussein A, Luomala O, et al
    "If the nurse tells me this is a good thing, I trust her completely" - Exploring health system enablers of MMR vaccine uptake in the Finnish Somali community: A mixed method study.
    Vaccine. 2024 Jun 25:S0264-410X(24)00728-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  994. VIANNA CM, Noronha TG, Camacho LAB, Andrade RC, et al
    Duration of post-vaccination immunity to yellow fever in volunteers ten years after a dose-response study - A complementary study.
    Vaccine. 2024 Jun 25:S0264-410X(24)00724-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  995. CHATZILENA A, Hyams C, Challen R, Marlow R, et al
    Winter 2022-23 influenza vaccine effectiveness against influenza-related hospitalised aLRTD: A test-negative, case-control study.
    Vaccine. 2024 Jun 24:S0264-410X(24)00713-8. doi: 10.1016/j.vaccine.2024.
    PubMed    


  996. LE GARS M, Sadoff J, Cardenas V, Heerwegh D, et al
    Safety, reactogenicity, and immunogenicity of Ad26.COV2.S as homologous or heterologous COVID-19 booster vaccination: Results of a randomized, double-blind, phase 2 trial.
    Vaccine. 2024 Jun 24:S0264-410X(24)00401-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  997. LIN M, Deng JZ, Scapin G, Yuan Y, et al
    Quantitation and characterization of serotype 6A activation for pneumococcal conjugate vaccine by cryo-EM and SEC methods.
    Vaccine. 2024 Jun 24:S0264-410X(24)00709-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  998. HELARY A, Botelho-Nevers E, Bonneton M, Khennouf L, et al
    Factors, motivations and barriers associated with eagerness to volunteer in COVID-19 vaccine clinical trials in France: A mixed-method study.
    Vaccine. 2024 Jun 22:S0264-410X(24)00662-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  999. FITZPATRICK T, Yamoah P, Lacuesta G, Sadarangani M, et al
    Revaccination outcomes among adolescents and adults with suspected hypersensitivity reactions following COVID-19 vaccination: A Canadian immunization research network study.
    Vaccine. 2024 Jun 22:S0264-410X(24)00719-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1000. RIMAL RN, Ganjoo R, Jamison A, Parida M, et al
    Social norms, vaccine confidence, and interpersonal communication as predictors of vaccination intentions: Findings from slum areas in Varanasi, India.
    Vaccine. 2024 Jun 21:S0264-410X(24)00666-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1001. POVEDA-URKIXO I, Mena-Bueno S, Ramirez GA, Zabalza-Barangua A, et al
    Brucella melitensis Rev1Deltawzm: Placental pathogenesis studies and safety in pregnant ewes.
    Vaccine. 2024;42:3710-3720.
    PubMed     Abstract available


  1002. MCDERMID P, Abdi I, Mustafa K, Blazek K, et al
    Examining the influence of community leaders and other community actors on immunisation practices in Australia: A national cross-sectional study.
    Vaccine. 2024;42:3647-3654.
    PubMed     Abstract available


  1003. PISCHEL L, Martini BA, Yu N, Cacesse D, et al
    Vaccine effectiveness of 3rd generation mpox vaccines against mpox and disease severity: A systematic review and meta-analysis.
    Vaccine. 2024 Jun 20:S0264-410X(24)00694-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1004. CHU X, Ge S, Zuo Y, Cui J, et al
    Thoughts on the research of African swine fever live-attenuated vaccines.
    Vaccine. 2024 Jun 20:S0264-410X(24)00693-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1005. ZHANG X, Monnat SM
    Watchful, skeptics, and system distrusters: Characteristics associated with different types of COVID-19 vaccine hesitancy among U.S. working-age adults.
    Vaccine. 2024 Jun 19:S0264-410X(24)00721-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1006. CARLSON CJ, Garnier R, Tiu A, Luby SP, et al
    Strategic vaccine stockpiles for regional epidemics of emerging viruses: A geospatial modeling framework.
    Vaccine. 2024 Jun 19:S0264-410X(24)00690-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1007. CARLOS GUILLERMO B, Tomas Alberto O, Julio I
    First vaccine confidence and access index in Argentina: Comparison of results from 2019 to 2022.
    Vaccine. 2024 Jun 19:S0264-410X(24)00711-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1008. AHMED T, Tauheed I, Hoque S, Sarower Bhuyan G, et al
    A phase 3 non-inferiority trial of locally manufactured Meningococcal ACWY vaccine 'Ingovax ACWY' among Bangladeshi adults.
    Vaccine. 2024 Jun 18:S0264-410X(24)00704-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1009. CHICHILI GR, Smulders R, Santos V, Cywin B, et al
    Corrigendum to "Phase 1/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years" [Vaccine 40 (2002) 4190-4198].
    Vaccine. 2024 Jun 18:S0264-410X(24)00650-9. doi: 10.1016/j.vaccine.2024.
    PubMed    


  1010. HOPKINS KL, Lihemo G, Underwood T, Sommers T, et al
    The second annual Vaccination Acceptance Research Network Conference (VARN2023): Shifting the immunization narrative to center equity and community expertise.
    Vaccine. 2024 Jun 18:S0264-410X(24)00655-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1011. CHENG TM, Chen YS, Wei KC, Chang YC, et al
    Assessment of the herpes zoster risk among renal transplant recipients administered the influenza vaccine.
    Vaccine. 2024 Jun 18:S0264-410X(24)00716-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1012. LAEMMLE-RUFF I, Morgan HJ, Harris A, Abruzzo V, et al
    Guillain-Barre syndrome temporally associated with COVID-19 vaccines - Progress over time.
    Vaccine. 2024 Jun 17:S0264-410X(24)00714-X. doi: 10.1016/j.vaccine.2024.
    PubMed    


  1013. YAZDAN PANAH M, Vaheb S, Mokary Y, Afshari-Safavi A, et al
    Comparing the consequences of COVID-19 vaccination between central nervous system (CNS) demyelinating diseases and other neurological disorders.
    Vaccine. 2024 Jun 16:S0264-410X(24)00702-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1014. FERM J, Jaworski DC, Stoll I, Kleinhenz MD, et al
    Genetically modified live vaccine offers protective immunity against wild-type Anaplasma marginale tick-transmission challenge.
    Vaccine. 2024 Jun 15:S0264-410X(24)00710-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1015. DESLAURIERS F, Hoq M, Kaufman J, Enticott J, et al
    Comparison of parent-reported motivators of non-vaccination for children 5-11 years old in Australia and Canada: Results of the iCARE study.
    Vaccine. 2024 Jun 15:S0264-410X(24)00698-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1016. WALTENBURG MA, Kainulainen MH, Whitesell A, Nyakarahuka L, et al
    Knowledge, attitudes, and practices and long-term immune response after rVSVDeltaG-ZEBOV-GP Ebola vaccination in healthcare workers in high-risk districts in Uganda.
    Vaccine. 2024 Jun 15:S0264-410X(24)00658-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1017. GUL C, Gul A, Karakavuk T, Erkunt Alak S, et al
    A novel DNA vaccine encoding the SRS13 protein administered by electroporation confers protection against chronic toxoplasmosis.
    Vaccine. 2024 Jun 15:S0264-410X(24)00706-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1018. JIANG X, Wang J, Li C, Yeoh EK, et al
    Relationship between parental acceptance of the COVID-19 vaccine and attitudes towards measles vaccination for children: A cross-sectional study.
    Vaccine. 2024 Jun 15:S0264-410X(24)00708-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1019. REY-ARES L, Ta A, Freigofaite D, Warren S, et al
    Cost-effectiveness analysis of the pediatric 20-valent pneumococcal conjugate vaccine compared with lower-valent alternatives in Argentina.
    Vaccine. 2024 Jun 14:S0264-410X(24)00670-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1020. TING DK, Rosychuk RJ, Hau JP, Righolt CH, et al
    Leveraging a clinical emergency department dataset to estimate two-dose COVID-19 vaccine effectiveness and duration of protection in Canada.
    Vaccine. 2024 Jun 14:S0264-410X(24)00699-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1021. SONG T, Cao F, Huang X, Wu S, et al
    Augmenting vaccine efficacy: Tailored immune strategy with alum-stabilized Pickering emulsion.
    Vaccine. 2024 Jun 13:S0264-410X(24)00649-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1022. WHITE MC, Osazuwa-Peters OL, Abouelella DK, Barnes JM, et al
    Trends and factors associated with receipt of human papillomavirus (HPV) vaccine in private, public, and alternative settings in the United States.
    Vaccine. 2024 Jun 13:S0264-410X(24)00663-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1023. DAVEY SA, Hampson C, Christodoulaki ME, Gaffiero D, et al
    Investigating the predictors of COVID-19 vaccine decision-making among parents of children aged 5-11 in the UK.
    Vaccine. 2024 Jun 13:S0264-410X(24)00646-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1024. HASSO-AGOPSOWICZ M, Sparrow E, Cameron AM, Sati H, et al
    The role of vaccines in reducing antimicrobial resistance: A review of potential impact of vaccines on AMR and insights across 16 vaccines and pathogens.
    Vaccine. 2024 Jun 13:S0264-410X(24)00676-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1025. CARDOSO N, Eschbaumer M, Capozzo AV
    An IgG1 single-dilution avidity ELISA predicts cross-protection against heterologous foot-and-mouth disease virus challenge after vaccination.
    Vaccine. 2024 Jun 13:S0264-410X(24)00707-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1026. EMILIE HARTVIG RASMUSSEN C, Odgaard Vedel J, Moller Jensen A, Da Silva Borges I, et al
    Implementation of the vaccination program in Guinea-Bissau: Coverage and missed opportunities for BCG at birth.
    Vaccine. 2024 Jun 12:S0264-410X(24)00697-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1027. QUIROGA R, Gastellu S, Fernandez B, Ottaviani R, et al
    The impact of COVID-19 childhood and adolescent vaccination on mortality in Argentina.
    Vaccine. 2024 Jun 12:S0264-410X(24)00665-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1028. CARDENAS V, Le Gars M, Truyers C, Ruiz-Guinazu J, et al
    Safety and immunogenicity of Ad26.COV2.S in adults: A randomised, double-blind, placebo-controlled Phase 2a dose-finding study.
    Vaccine. 2024;42:3536-3546.
    PubMed     Abstract available


  1029. SHERMAN AC, van Haren SD, Borberg E, Swank Z, et al
    Heterologous SARS-CoV-2 booster vaccine for individuals with hematological malignancies after a primary SARS-CoV-2 mRNA vaccine series.
    Vaccine. 2024 Jun 10:S0264-410X(24)00695-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1030. MANANDHAR P, Katz J, Lama TP, Khatry SK, et al
    COVID-19 vaccine hesitancy, trust, and communication in Sarlahi District, Nepal.
    Vaccine. 2024 Jun 10:S0264-410X(24)00661-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1031. HOFFMAN E, Kahan T, Auerbach E, Brody H, et al
    Peer education as a strategy to promote vaccine acceptance: A randomized controlled trial within New York community healthcare practices.
    Vaccine. 2024 Jun 10:S0264-410X(24)00654-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1032. OTSUKI T, Akada S, Anami A, Kosaka K, et al
    Efficacy and safety of bivalent RSVpreF maternal vaccination to prevent RSV illness in Japanese infants: Subset analysis from the pivotal randomized phase 3 MATISSE trial.
    Vaccine. 2024 Jun 8:S0264-410X(24)00668-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1033. BRADY K, Lee A, Bassler J, Young Pierce J, et al
    Human papillomavirus vaccine beliefs and intentions Post-COVID-19 vaccine release among mothers in Alabama.
    Vaccine. 2024 Jun 8:S0264-410X(24)00673-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1034. BADLIS S, Yu H, Klusaritz H, S L Tan A, et al
    Engaging Trusted Messengers to Increase COVID-19 Pediatric Vaccine Uptake in Philadelphia: Lessons from the VaxUpPhillyFamilies program.
    Vaccine. 2024 Jun 8:S0264-410X(24)00664-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1035. SRITIPSUKHO P, Sinlapamongkolkul P, Satdhabudha A, Chaiyakulsil C, et al
    Immunogenicity during 6 months after SARS-CoV-2 infection is significantly different depending on previous COVID-19 vaccine regimens and a booster dose received.
    Vaccine. 2024 Jun 7:S0264-410X(24)00652-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1036. R MUGALI R, Ip H, Zikusooka A, Vong L, et al
    Striving for equitable vaccination coverage: Leveraging rapid coverage and community assessments during the COVID-19 pandemic to reach missed populations in Cambodia.
    Vaccine. 2024 Jun 7:S0264-410X(24)00642-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1037. JAYAWARDANA S, Esquivel M, Oreskovic T, Mossialos E, et al
    Gender differences in COVID-19 preventative measures and vaccination rates in the United States: A longitudinal survey analysis.
    Vaccine. 2024 Jun 7:S0264-410X(24)00671-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1038. DE POUVOURVILLE G, Guyot E, Farge G, Belhassen M, et al
    Human Papillomavirus (HPV) vaccination coverage among French adolescents: A claims data study.
    Vaccine. 2024 Jun 7:S0264-410X(24)00667-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1039. VILLENA R, Izquierdo G, Wilhelm J, Garcia C, et al
    Dynamics of multisystem inflammatory syndrome in children associated to COVID-19 in Chile: Epidemiologic trends during pandemic, before and after children vaccination.
    Vaccine. 2024 Jun 7:S0264-410X(24)00640-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1040. YOUNES S, Nicolai E, Younes N, Pieri M, et al
    Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting.
    Vaccine. 2024 Jun 5:S0264-410X(24)00669-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1041. KANG DW, June Choe Y, Lee JY, Suk IA, et al
    Cost-effectiveness analysis of the 20-valent pneumococcal conjugate vaccine for the pediatric population in South Korea.
    Vaccine. 2024 Jun 5:S0264-410X(24)00616-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1042. LANIECE DELAUNAY C, Melo A, Maurel M, Mazagatos C, et al
    Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023-January 2024.
    Vaccine. 2024 Jun 4:S0264-410X(24)00644-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1043. KAWASUJI H, Morinaga Y, Tani H, Yamada H, et al
    Low pre-infection levels of neutralizing antibody in breakthrough infections after bivalent BA.4-5 vaccine and practical application of dried blood spots.
    Vaccine. 2024 Jun 4:S0264-410X(24)00656-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1044. GOBIN S, Sahakyan G, Kusi Appiah M, Manukyan A, et al
    Costs of in- and outpatient respiratory disease and the seasonal influenza vaccination program in Armenia - 2020-2021.
    Vaccine. 2024 Jun 4:S0264-410X(24)00623-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1045. FENG J, Du Y, Chen L, Su W, et al
    A quadrivalent recombinant influenza Hemagglutinin vaccine induced strong protective immune responses in animal models.
    Vaccine. 2024 Jun 3:S0264-410X(24)00624-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1046. FABIANI M, Mateo-Urdiales A, Sacco C, Fotakis EA, et al
    Effectiveness against severe COVID-19 of a seasonal booster dose of bivalent (original/Omicron BA.4-5) mRNA vaccines in persons aged >/=60 years: Estimates over calendar time and by time since administration during prevalent circulation of different O
    Vaccine. 2024 Jun 3:S0264-410X(24)00653-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1047. QUIAMBAO BP, Payumo RA, Roa C, Borja-Tabora CF, et al
    A phase 2b, Randomized, double blinded comparison of the safety and efficacy of the monoclonal antibody mixture SYN023 and human rabies immune globulin in patients exposed to rabies.
    Vaccine. 2024 Jun 3:S0264-410X(24)00643-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1048. BEJKO D, Ernst C, Vergison A, Stranges S, et al
    High vaccine effectiveness against severe COVID-19 outcomes and population preventable fraction during the Omicron era in Luxembourg: A nationwide retrospective risk factor analysis.
    Vaccine. 2024 Jun 1:S0264-410X(24)00636-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


    May 2024
  1049. KUPEK E
    Avoidable COVID-19-related deaths and hospitalizations in Brazil, 2020-2023.
    Vaccine. 2024;42:3437-3444.
    PubMed     Abstract available


  1050. WOLFSCHMIDT-FIETKAU A, Goertz RS, Goertzen S, Schmid K, et al
    Immunity against vaccine-preventable diseases among pregnant employees in Germany. A situation analysis before the introduction of the Measles Protection Act.
    Vaccine. 2024 May 31:S0264-410X(24)00604-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1051. HE Q, Chen Y, Li Y, Cheng X, et al
    Single immunization of non-adjuvanted recombinant TTFC-mi3 nanoparticle vaccine elicited a rapid and potent protective immunity against tetanus.
    Vaccine. 2024 May 31:S0264-410X(24)00583-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1052. EDOKA I, Silal S, Jamieson L, Meyer-Rath G, et al
    A cost-effectiveness analysis of South Africa's COVID-19 vaccination programme.
    Vaccine. 2024 May 31:S0264-410X(24)00595-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1053. COMER D, Warner NZ, Noone C
    Human PapillomaVirus vaccination in gay and bi men: Predictors, dynamic norms, and connectedness to the LGBT+ community.
    Vaccine. 2024 May 31:S0264-410X(24)00639-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1054. MANSFIELD LN, Kahn BZ, Kokitkar S, Kritikos KI, et al
    HPV vaccine standing orders and communication in primary care: A qualitative study.
    Vaccine. 2024 May 29:S0264-410X(24)00554-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1055. NAKASE T, Brownwright T, Okunromade O, Egwuenu A, et al
    The impact of sub-national heterogeneities in demography and epidemiology on the introduction of rubella vaccination programs in Nigeria.
    Vaccine. 2024 May 28:S0264-410X(24)00589-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1056. LUO H, Ma Y, Bi J, Li Z, et al
    Experimental and molecular dynamics simulation studies on the physical properties of three HBc-VLP derivatives as nanoparticle protein vaccine candidates.
    Vaccine. 2024 May 28:S0264-410X(24)00599-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1057. BATOOL R, Yousafzai MT, Mir F, Muhammad S, et al
    Longevity of serologic responses following a single dose of typhoid conjugate vaccine among children living with HIV in Pakistan: A prospective cohort study.
    Vaccine. 2024 May 28:S0264-410X(24)00625-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1058. BEGUM T, Efstathiou N, Bailey C, Guo P, et al
    Cultural and social attitudes towards COVID-19 vaccination and factors associated with vaccine acceptance in adults across the globe: A systematic review.
    Vaccine. 2024 May 27:S0264-410X(24)00600-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1059. EOM J, Kim Y, Kim D, Lee E, et al
    Cost-benefit analysis of human adenovirus vaccine development in a Korean military setting.
    Vaccine. 2024 May 27:S0264-410X(24)00622-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1060. MENA-BUENO S, Garrido V, Romero F, Zabalza-Barangua A, et al
    Rev1Deltawzm vaccine candidate is safe in young and adult sheep and protects against Brucella ovis infection in rams.
    Vaccine. 2024 May 27:S0264-410X(24)00605-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1061. LUSTIG Y, Barda N, Weiss-Ottolenghi Y, Indenbaum V, et al
    Humoral response superiority of the monovalent XBB.1.5 over the bivalent BA.1 and BA.5 mRNA COVID-19 vaccines.
    Vaccine. 2024 May 27:S0264-410X(24)00635-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1062. VASHIST K, Yankey D, Elam-Evans LD, Mu Y, et al
    Changes in vaccine hesitancy among parents of children aged 6 months - 17 Years, National Immunization Surveys, 2019-2022.
    Vaccine. 2024 May 27:S0264-410X(24)00596-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1063. RENDUCHINTALA K, Arevalo M, Fonseca G, Haver MK, et al
    Vaccination uptake among post-treatment cancer survivors: A multi-vaccine scoping review.
    Vaccine. 2024 May 27:S0264-410X(24)00602-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1064. TREHARNE A, Patel Murthy B, Zell ER, Jones-Jack N, et al
    Impact of the COVID-19 pandemic on routine childhood vaccination in 9 U.S. jurisdictions.
    Vaccine. 2024 May 25:S0264-410X(24)00603-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1065. DOHERTY K, Bonnett L, Agbla SC, Beveridge NER, et al
    The effectiveness of revaccination with pneumococcal polysaccharide vaccine for preventing pneumococcal disease in older adults in England: A population-based cohort study.
    Vaccine. 2024 May 24:S0264-410X(24)00618-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1066. OKOLI GN, Neilson CJ, Grossman Moon A, Kimmel Supron H, et al
    Exploration of individual socioeconomic and health-related characteristics associated with human papillomavirus vaccination initiation and vaccination series completion among adult females: A comprehensive systematic evidence review with meta-analysis
    Vaccine. 2024 May 24:S0264-410X(24)00601-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1067. LYNETTE EJEZIE C, Cuccaro P, Savas LS, Shegog R, et al
    Regional differences in provider recommendation of HPV vaccines among 13-to-17 year old adolescents from 2019 to 2021.
    Vaccine. 2024 May 24:S0264-410X(24)00581-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1068. WU JY, Zhang W, Pu J, Liu Y, et al
    A randomized, double-blind, placebo-controlled phase I clinical trial of rotavirus inactivated vaccine (Vero cell) in a healthy adult population aged 18-49 years to assess safety and preliminary observation of immunogenicity.
    Vaccine. 2024 May 24:S0264-410X(24)00559-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1069. BAK J, Hasan Q, Kissa J, Mere MO, et al
    Deployment of COVID-19 vaccine in the WHO Eastern Mediterranean Region 2021-23: How do we switch to a life course approach?
    Vaccine. 2024 May 24:S0264-410X(24)00560-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1070. MARANTOS T, Kyriazopoulou E, Angelakis E, Kitsos D, et al
    Immunogenicity of a seasonal influenza and a pneumococcal polysaccharide vaccine in multiple sclerosis patients under disease modifying therapies: A single-center prospective study.
    Vaccine. 2024 May 24:S0264-410X(24)00617-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1071. TSAMPALIEROS A, Zemek R, Barrowman N, Langlois MA, et al
    Hybrid immunity after BNT162b2 Covid-19 vaccine administration in children aged 5 to 11 years.
    Vaccine. 2024 May 23:S0264-410X(24)00588-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1072. BENEDICT KPOZEHOUEN E, Raina Macintyre C, Tan TC
    Coverage of influenza, pneumococcal and zoster vaccination and determinants of influenza and pneumococcal vaccination among adults with cardiovascular diseases in community.
    Vaccine. 2024 May 23:S0264-410X(24)00619-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1073. EIBERG MF, Rezahosseini O, Bukan KB, Charlotte Arp B, et al
    Changes in vaccination uptake against pneumococcal disease, influenza, and coronavirus disease 2019 (COVID-19) before and after a Head and Neck cancer diagnosis.
    Vaccine. 2024 May 23:S0264-410X(24)00566-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1074. KANDASAMY R, Gurung M, Shrestha S, Gautam MC, et al
    Decline in pneumococcal vaccine serotype carriage, multiple-serotype carriage, and carriage density in Nepalese children after PCV10 introduction: A pre-post comparison study.
    Vaccine. 2024 May 23:S0264-410X(24)00564-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1075. YEGANEH N, Yin S, Moir O, Danza P, et al
    Effectiveness of JYNNEOS vaccine against symptomatic mpox disease in adult men in Los Angeles County, August 29, 2022 to January 1, 2023.
    Vaccine. 2024 May 23:S0264-410X(24)00594-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1076. CARNALLA M, Stern D, Arantxa Colchero M, Rangel-Moreno K, et al
    Who is getting COVID-19 boosters? A latent class analysis in a nationally representative sample of Mexican adults 60 years and over.
    Vaccine. 2024;42:3273-3276.
    PubMed     Abstract available


  1077. RAMOS-DUARTE VA, Orlowski A, Jaquenod de Giusti C, Corigliano MG, et al
    Safe plant Hsp90 adjuvants elicit an effective immune response against SARS-CoV2-derived RBD antigen.
    Vaccine. 2024;42:3355-3364.
    PubMed     Abstract available


  1078. PROSPER P, Rodriguez Puertas R, Guerin DMA, Branda MM, et al
    Computational method for designing vaccines applied to virus-like particles (VLPs) as epitope carriers.
    Vaccine. 2024 May 22:S0264-410X(24)00584-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1079. ZHOU H, Zhao W, Ma R, Zheng Y, et al
    Mixed methods examination of risk perception on vaccination intentions: The perspective of doctor-patient communication.
    Vaccine. 2024 May 22:S0264-410X(24)00565-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1080. ZHANG WX, Zhang Y, Du J, Shi W, et al
    Effectiveness of momentary intervention on influenza vaccination among the elderly in China: From willingness to action.
    Vaccine. 2024 May 22:S0264-410X(24)00591-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1081. PAN X, Guo X, Shi J
    Design of a novel multiepitope vaccine with CTLA-4 extracellular domain against Mycoplasma pneumoniae: A vaccine-immunoinformatics approach.
    Vaccine. 2024 May 21:S0264-410X(24)00568-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1082. CHIHANA R, Jin Kee J, Moodie Z, Huang Y, et al
    Factors associated with reactogenicity to an investigational HIV vaccine regimen in HIV vaccine trials network 702.
    Vaccine. 2024 May 21:S0264-410X(24)00598-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1083. VAN DER PLAS JL, Haijema BJ, Leenhouts K, Paul Zoeteweij J, et al
    Safety, reactogenicity and immunogenicity of an intranasal seasonal influenza vaccine adjuvanted with gram-positive matrix (GEM) particles (FluGEM): A randomized, double-blind, controlled, ascending dose study in healthy adults and elderly.
    Vaccine. 2024 May 20:S0264-410X(24)00370-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1084. MACHIDA M, Fukushima S, Saitoh A, Inoue S, et al
    Uptake among four indicated vaccines by adults aged 65 years and older in Japan, 2023.
    Vaccine. 2024 May 20:S0264-410X(24)00592-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1085. KARIMI-SHAHRBABAK E, Di Chiara C, Farrar DS, Abu Fadaleh SM, et al
    COVID-19 vaccine acceptance and uptake among caregivers of children aged 5-11?years in Ontario, Canada: A cross-sectional survey.
    Vaccine. 2024 May 20:S0264-410X(24)00553-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1086. GARG R, Liu Q, Van Kessel J, Asavajaru A, et al
    Efficacy of a stable broadly protective subunit vaccine platform against SARS-CoV-2 variants of concern.
    Vaccine. 2024 May 19:S0264-410X(24)00586-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1087. TSUJII A, Takahashi K, Harada H, Kawashima S, et al
    Evaluation of the protective effect of the intranasal vaccines adjuvanted with bacterium-like particles against intestinal infection.
    Vaccine. 2024 May 18:S0264-410X(24)00582-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1088. ANN COSTA CLEMENS S, Weckx L, Milan EP, Smolenov I, et al
    Interchangeability of different COVID-19 vaccine platforms as booster doses: A phase 3 study mimicking real-world practice.
    Vaccine. 2024 May 17:S0264-410X(24)00555-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1089. YANG T, Tong F, Tang L, Li P, et al
    Repeated vaccination does not appear to significantly weaken the protective effect of influenza vaccine in the elderly: A test-negative case-control study in China.
    Vaccine. 2024 May 17:S0264-410X(24)00593-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1090. KIM S, Choi JK, Suh J, Park SH, et al
    The epidemiologic and economic impact of varicella and herpes zoster vaccination in South Korea: A mathematical modelling study.
    Vaccine. 2024 May 17:S0264-410X(24)00562-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1091. GRIFFIN I, Berry I, Navarra T, Priyamvada L, et al
    Serologic responses to the MVA-based JYNNEOS mpox vaccine in a cohort of participants from the District of Columbia (D.C.).
    Vaccine. 2024 May 17:S0264-410X(24)00563-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1092. GARCIA-VICENTE EJ, Rey-Casero I, Martin M, Perez A, et al
    Oral supplementation with postbiotics modulates the immune response produced by myxomatosis vaccination in wild rabbits.
    Vaccine. 2024 May 16:S0264-410X(24)00585-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1093. URAGUCHI K, Matsumoto N, Mitsuhashi T, Takao S, et al
    Pediatric otitis media in Japan: A nationwide longitudinal study of the pre- and post-pneumococcal conjugate vaccine eras born in 2001 and 2010.
    Vaccine. 2024 May 16:S0264-410X(24)00567-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1094. NG'OMBE H, Bosomprah S, Phiri B, Muchimba M, et al
    Comparative analysis of cholera serum vibriocidal antibodies from Convalescent and vaccinated adults in Zambia.
    Vaccine. 2024 May 16:S0264-410X(24)00587-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1095. URQUIDI C, Sepulveda-Penaloza A, Valenzuela MT, Ponce A, et al
    Vaccine effectiveness in reducing COVID-19-related hospitalization after a risk-age-based mass vaccination program in a Chilean municipality: A comparison of observational study designs.
    Vaccine. 2024 May 14:S0264-410X(24)00538-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1096. MIRANDA-LOPEZ A, Gonzalez-Ortega O, Govea-Alonso DO, Betancourt-Mendiola L, et al
    Rational design and production of a chimeric antigen targeting Zika virus that induces neutralizing antibodies in mice.
    Vaccine. 2024 May 14:S0264-410X(24)00518-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1097. MUANGNOICHAROEN S, Wiangcharoen R, Lawpoolsri S, Nanthapisal S, et al
    Heterologous Ad26.COV2.S booster after primary BBIBP-CorV vaccination against SARS-CoV-2 infection: 1-year follow-up of a phase 1/2 open-label trial.
    Vaccine. 2024 May 13:S0264-410X(24)00556-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1098. KARIM S, Rehana Siddiqui A, Karim N, Pradhan NA, et al
    Role of rotavirus vaccine in reducing diarrheal episodes in infants visiting private primary health care clinics in Karachi, Pakistan: A mixed-methods study.
    Vaccine. 2024 May 13:S0264-410X(24)00558-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1099. EJNAR HANSEN M, David Pickering S
    The role of religion and COVID-19 vaccine uptake in England.
    Vaccine. 2024;42:3215-3219.
    PubMed     Abstract available


  1100. MUTTUCUMARU R, Lau CL, Leeb A, Mills DJ, et al
    Post-marketing surveillance of 10,392 herpes zoster vaccines doses in Australia.
    Vaccine. 2024;42:3166-3171.
    PubMed     Abstract available


  1101. LIU F, Li Z, Wang H, Cao Y, et al
    Effectiveness of the varicella vaccine in the real world, a matched case-control study.
    Vaccine. 2024 May 10:S0264-410X(24)00552-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1102. DINH THIEM V, Van Anh PT, Van Men C, Hung DT, et al
    A SARS-CoV-2 recombinant spike protein vaccine (S-268019-b) for COVID-19 prevention during the Omicron-dominant period: A phase 3, randomised, placebo-controlled clinical trial.
    Vaccine. 2024 May 10:S0264-410X(24)00523-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1103. MALTEZOU HC, Gamaletsou MN, Giannouchos TV, Koukou DM, et al
    Effectiveness of COVID-19 booster vaccination, morbidity and absenteeism among healthcare personnel during the 2022-2023 season dominated by Omicron BA.5 and BA.2 subvariants.
    Vaccine. 2024 May 9:S0264-410X(24)00522-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1104. SHANI M, Hermesh I, Feldhamer I, Reges O, et al
    The association between BNT162b2 vaccinations and incidence of immune-mediated comorbidities.
    Vaccine. 2024 May 9:S0264-410X(24)00536-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1105. LEE KY, Song KH, Lee KH, Baek JY, et al
    Persistent differences in the immunogenicity of the two COVID-19 primary vaccines series, modulated by booster mRNA vaccination and breakthrough infection.
    Vaccine. 2024 May 9:S0264-410X(24)00539-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1106. KIM DH, Lee SH, Kim J, Lee J, et al
    Efficacy of live and inactivated recombinant Newcastle disease virus vaccines expressing clade 2.3.4.4b H5 hemagglutinin against H5N1 highly pathogenic avian influenza in SPF chickens, Broilers, and domestic ducks.
    Vaccine. 2024 May 8:S0264-410X(24)00527-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1107. LAURA SORIANO PEREZ M, Montironi I, Alejandro Funes J, Margineda C, et al
    Nanogel-Mediated antigen delivery: Biocompatibility, immunogenicity, and potential for tailored vaccine design across species.
    Vaccine. 2024 May 7:S0264-410X(24)00525-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1108. BASKOL ELIK D, Yildirim C, Akyol Seyhan D, Aytac Erdem H, et al
    Evaluation of antibody responses in healthcare workers before & after meningococcal vaccine and determination of meningococcal carriage rates.
    Vaccine. 2024 May 7:S0264-410X(24)00540-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1109. TIPPINS A, Acevedo JC, Palomeque FS, Coy KC, et al
    Strategies to strengthen COVID-19 vaccine uptake and improve vaccine equity in U.S. Territories and Freely Associated States during the first six months of vaccine rollout.
    Vaccine. 2024 May 7:S0264-410X(24)00541-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1110. DIONNE M, Etienne D, Witteman HO, Sauvageau C, et al
    Impact of interventions to improve HPV vaccination acceptance and uptake in school-based programs: Findings of a pilot project in Quebec.
    Vaccine. 2024 May 6:S0264-410X(24)00528-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1111. CAO A, Ueta M, Uchibori M, Murakami M, et al
    Trust in governments, public health institutions, and other information sources as determinants of COVID-19 vaccine uptake behavior in Japan.
    Vaccine. 2024 May 6:S0264-410X(24)00520-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1112. SONG H, Waheed Abdullah S, Yin S, Dong H, et al
    Virus-like particle-based multipathogen vaccine of FMD and SVA elicits balanced and broad protective efficacy in mice and pigs.
    Vaccine. 2024 May 6:S0264-410X(24)00530-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1113. SOE P, Wong H, Naus M, Muller MP, et al
    mRNA COVID-19 vaccine safety among older adults from the Canadian National Vaccine Safety Network.
    Vaccine. 2024 May 6:S0264-410X(24)00535-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1114. JEARANAIWITAYAKUL T, Sunintaboon P, Kittiayuwat A, Limthongkul J, et al
    Intranasal immunization with the bivalent SARS-CoV-2 vaccine effectively protects mice from nasal infection and completely inhibits disease development.
    Vaccine. 2024 May 6:S0264-410X(24)00519-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1115. KOLAKOWSKA A, Marshall E, Krastinova E, Cros A, et al
    Insufficient vaccine coverage and vaccine hesitancy in people living with HIV: A prospective study in outpatient clinics in the Paris region.
    Vaccine. 2024 May 6:S0264-410X(24)00516-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1116. KIM J, Chang J
    Cross-protective efficacy and safety of an adenovirus-based universal influenza vaccine expressing nucleoprotein, hemagglutinin, and the ectodomain of matrix protein 2.
    Vaccine. 2024 May 6:S0264-410X(24)00481-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1117. LI H, Li Q, Hao Z, Zhang L, et al
    A recombinant IL-1beta vaccine attenuates bleomycin-induced pulmonary fibrosis in mice.
    Vaccine. 2024 May 6:S0264-410X(24)00531-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1118. CROWE CL, Dreyfus J, Lanes S, Chung H, et al
    Variation in incidence rates of outcomes relevant to vaccine safety monitoring in a US commercially insured population by case identification algorithm.
    Vaccine. 2024 May 6:S0264-410X(24)00534-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1119. MAJE BELLO A, Chaimongkolnukul K, Poomputsa K, Mekvichitsaeng P, et al
    Immunogenicity and immunodominant linear B-cell epitopes of a new DNA-based tetravalent vaccine against four major enteroviruses causing hand, foot, and mouth disease.
    Vaccine. 2024 May 4:S0264-410X(24)00526-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1120. ANDREJKO KL, Gierke R, Rowlands JV, Rosen JB, et al
    Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease among children in the United States between 2010 and 2019: An indirect cohort study.
    Vaccine. 2024 May 3:S0264-410X(24)00499-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1121. ADINUGROHO I, Stafford T, Bentall RP
    The correlation between conspiracy mentality and vaccine intentions is moderated by social events: Evidence from longitudinal data during COVID-19 pandemic in the UK.
    Vaccine. 2024 May 3:S0264-410X(24)00510-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1122. CHRISTOU-ERGOS M, Bleicher K, Leask J
    Factors associated with vaccination intention and uptake over time in a sample of older Australians.
    Vaccine. 2024 May 3:S0264-410X(24)00508-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1123. ESPARZA J
    Introduction of the smallpox vaccine in Napoleonic France, as recorded in contemporary medals.
    Vaccine. 2024 May 3:S0264-410X(24)00503-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1124. SHI XC, Gruber JF, Ondari M, Lloyd PC, et al
    Assessment of potential adverse events following the 2022-2023 seasonal influenza vaccines among U.S. adults aged 65 years and older.
    Vaccine. 2024 May 3:S0264-410X(24)00478-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1125. MAUREL M, Mazagatos C, Goerlitz L, Oroszi B, et al
    Exploring the effect of clinical case definitions on influenza vaccine effectiveness estimation at primary care level: Results from the end-of-season 2022-23 VEBIS multicentre study in Europe.
    Vaccine. 2024 May 3:S0264-410X(24)00497-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1126. SEFAT KMSR, Kumar M, Kehl S, Kulkarni R, et al
    An intranasal nanoparticle vaccine elicits protective immunity against Mycobacterium tuberculosis.
    Vaccine. 2024 May 3:S0264-410X(24)00482-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1127. BENEDICT KPOZEHOUEN E, Macintyre CR, Tan TC
    Determinants of uptake of influenza, zoster and pneumococcal vaccines in patients with cardiovascular diseases.
    Vaccine. 2024 May 3:S0264-410X(24)00445-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1128. BAGLIVO F, De Angelis L, Magri M, De Nicola I, et al
    The impact of COVID-19 vaccination campaign on pediatric vaccine uptake based on parents' attitudes towards mandatory and recommended vaccination in Southern Italy.
    Vaccine. 2024 May 3:S0264-410X(24)00513-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1129. MERTENS JE, Rigby CA, Bardelli M, Quinkert D, et al
    Evaluation of the precision of the Plasmodium knowlesi growth inhibition assay for Plasmodium vivax Duffy-binding protein-based malaria vaccine development.
    Vaccine. 2024 May 3:S0264-410X(24)00514-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1130. MARINTHE G, Brown G, Cristea M, Kutlaca M, et al
    Predicting vaccination hesitancy: The role of basic needs satisfaction and institutional trust.
    Vaccine. 2024 May 3:S0264-410X(24)00507-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1131. HU H, Ma F, Gong L, Wang Y, et al
    Immunogenicity and safety of a recombinant Omicron BA.4/5-Delta COVID-19 vaccine ZF2202-A in Chinese adults.
    Vaccine. 2024 May 3:S0264-410X(24)00495-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1132. LAMBACH P, Silal S, Sbarra AN, Koh M, et al
    Report from the World Health Organization's immunization and vaccines-related implementation research advisory committee (IVIR-AC) meeting, virtual gathering, 26 February-1 March 2024.
    Vaccine. 2024 May 3:S0264-410X(24)00494-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1133. ANGAITKAR P, Ram Janghel R, Prasad Sahu T
    An MCDM approach for Reverse vaccinology model to predict bacterial protective antigens.
    Vaccine. 2024 May 3:S0264-410X(24)00517-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1134. DHALARIA P, Kumar P, Verma A, Priyadarshini P, et al
    Exploring landscape of measles vaccination coverage: A step towards measles elimination goal in India.
    Vaccine. 2024 May 3:S0264-410X(24)00511-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1135. EHRLICH KB, Lyle SM, Corallo KL, Lavner JA, et al
    Changes in depressive symptoms and antibody production following influenza vaccination in adolescents and adults.
    Vaccine. 2024 May 2:S0264-410X(24)00505-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1136. MASTROLEO I
    Use of experimental vaccines is ethically permissible during public health emergencies.
    Vaccine. 2024 May 1:S0264-410X(24)00504-8. doi: 10.1016/j.vaccine.2024.
    PubMed    


    April 2024
  1137. LV M, Du J, Xie MZ, Zhou Y, et al
    Protective effect of PCV13 against all-cause hospitalized pneumonia in children in Beijing, China: real-world evidence.
    Vaccine. 2024;42:3091-3098.
    PubMed     Abstract available


  1138. WANG Z, Wang M, Wang F, Luo Y, et al
    Dendritic cell targeting peptide plus Salmonella FliCd flagellin fused outer membrane protein H (OmpH) demonstrated increased efficacy against infections caused by different Pasteurella multocida serogroups in mouse models.
    Vaccine. 2024;42:3075-3083.
    PubMed     Abstract available


  1139. MAGALI P, Sophie M, Arnaud B, Pol L, et al
    Retrospective study on the health and economic burden of hospitalized patients due to pneumonia and invasive pneumococcal infections in Belgium settings.
    Vaccine. 2024;42:3018-3023.
    PubMed     Abstract available


  1140. GRANT LR, Hanquet G, Sepulveda-Pachon IT, Theilacker C, et al
    Effects of PCV10 and PCV13 on pneumococcal serotype 6C disease, carriage, and antimicrobial resistance.
    Vaccine. 2024;42:2983-2993.
    PubMed     Abstract available


  1141. JI W, Zhou H, Li J, Britto CD, et al
    Distributions of candidate vaccine Targets, virulence Factors, and resistance features of invasive group B Streptococcus using Whole-Genome Sequencing: A Multicenter, population-based surveillance study.
    Vaccine. 2024 Apr 30:S0264-410X(24)00498-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1142. FLEARY SA, Shahn Z, Teasdale CA
    Effects of parental childhood cultural health environment on children's influenza and COVID-19 vaccination status.
    Vaccine. 2024 Apr 29:S0264-410X(24)00515-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1143. NIESSEN FA, Bruijning-Verhagen PCJL, Bonten MJM, Knol MJ, et al
    Vaccine effectiveness against COVID-19 related hospital admission in the Netherlands by medical risk condition: A test-negative case-control study.
    Vaccine. 2024 Apr 29:S0264-410X(24)00432-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1144. GUDOORU K, Nguyen K, Le K, Sarabu V, et al
    Collective good and individual choice: Perceptions on COVID-19 vaccine mandate among COVID-19 vaccinated individuals.
    Vaccine. 2024 Apr 27:S0264-410X(24)00479-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1145. DORJEE K, Namdon T, Topgyal S, Gyatso U, et al
    Association between Covishield vaccine and menstrual disturbance. Findings from a cross-sectional study among participants of Zero TB cohort in India.
    Vaccine. 2024 Apr 27:S0264-410X(24)00500-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1146. PIASECKI AM, Hall DM, Zajac J, Miller SA, et al
    A programmatic update on COVID-19 vaccination in rural communities in the United States.
    Vaccine. 2024 Apr 25:S0264-410X(24)00469-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1147. LUO G, Zeng Y, Sheng R, Zhang Z, et al
    Wa-VP4* as a candidate rotavirus vaccine induced homologous and heterologous virus neutralizing antibody responses in mice, pigs, and cynomolgus monkeys.
    Vaccine. 2024 Apr 25:S0264-410X(24)00483-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1148. XIE Z, Stallings-Smith S, Patel S, Case S, et al
    COVID-19 booster vaccine uptake and reduced risks for long-COVID: A cross-sectional study of a U.S. adult population.
    Vaccine. 2024 Apr 25:S0264-410X(24)00509-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1149. LYTRAS T, Athanasiadou M, Demetriou A, Stylianou D, et al
    Authors' reply: Excess mortality in Cyprus during the COVID-19 vaccination campaign.
    Vaccine. 2024 Apr 25:S0264-410X(24)00506-1. doi: 10.1016/j.vaccine.2024.
    PubMed    


  1150. FUJITA DM, da Silva Nali LH, da Costa RR, de Andrade Junior HF, et al
    Low vaccine coverage and varicella outbreaks in Brazil - 2019-2022.
    Vaccine. 2024 Apr 24:S0264-410X(24)00435-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1151. SELLIES AJ, Knol MJ, de Melker HE, Bruijning-Verhagen PCJL, et al
    Non-specific effects of the inactivated influenza vaccine. A test-negative study: The inactivated influenza vaccine and SARS-CoV-2 infections.
    Vaccine. 2024 Apr 23:S0264-410X(24)00468-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1152. SWITALSKI J, Miazga W, Wnuk K, Tatara T, et al
    Analyzing the dynamics of meningococcal vaccinations initiatives by local government units in Poland (2017-2021) - Scope, challenges and recommendations.
    Vaccine. 2024 Apr 22:S0264-410X(24)00472-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1153. SONG S, Madewell ZJ, Liu M, Miao Y, et al
    A systematic review and meta-analysis on the effectiveness of bivalent mRNA booster vaccines against Omicron variants.
    Vaccine. 2024 Apr 22:S0264-410X(24)00476-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1154. MUSA S, Merdrignac L, Skocibusic S, Nedic R, et al
    BBIBP-CorV vaccine effectiveness against COVID-19 in patients aged 60 years and older during the Delta-dominant period in the Federation of Bosnia and Herzegovina, a test-negative case-control study.
    Vaccine. 2024 Apr 20:S0264-410X(24)00471-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1155. WANG Y, Xu F, Yuan C, Zhang Y, et al
    Comparison of immune effects of porcine circovirus type 2d (PCV2d) capsid protein expressed by Escherichia coli and baculovirus-insect cells.
    Vaccine. 2024;42:2848-2857.
    PubMed     Abstract available


  1156. MOHANTY S, Done N, Liu Q, Song Y, et al
    Incidence of pneumococcal disease in children
    Vaccine. 2024;42:2758-2769.
    PubMed     Abstract available


  1157. LIEVRE G, Sicsic J, Galmiche S, Charmet T, et al
    Are the 7C psychological antecedents associated with COVID-19 vaccine behaviours beyond intentions? A cross-sectional study on at-least-one-dose and up-to-date vaccination status, and uptake speed among adults in France.
    Vaccine. 2024 Apr 19:S0264-410X(24)00438-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1158. INGRAO F, Ngabirano E, Rauw F, Dauphin G, et al
    Immunogenicity and protective efficacy of a multivalent herpesvirus vectored vaccine against H9N2 low pathogenic avian influenza in chicken.
    Vaccine. 2024 Apr 18:S0264-410X(24)00452-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1159. WON H, Kim JA, Jeong NY, Choi NK, et al
    Safety of concomitant administration of 23-valent polysaccharide pneumococcal vaccine and influenza vaccine among the elderly.
    Vaccine. 2024 Apr 18:S0264-410X(24)00400-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1160. RICKE IJ, Spaulding AB, Rajtar NN, Benton EM, et al
    Predictors of willingness to receive updated 2023-2024 COVID-19 booster vaccines among a convenience sample in Minnesota.
    Vaccine. 2024 Apr 18:S0264-410X(24)00480-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1161. ORANGZEB S, Desalegn A, Trinh NTH, Zhao J, et al
    COVID-19 vaccine uptake among children and adolescents in Norway: A comprehensive registry-based cohort study of over 800,000 individuals.
    Vaccine. 2024 Apr 18:S0264-410X(24)00464-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1162. GAJEWSKA M, Lewtak K, Gorynski P, Piotrowicz M, et al
    Effect of the PCV 10 vaccination on community-acquired pneumonia hospitalisations after four years of its introduction into the Polish National Immunisation Programme: Follow-up study.
    Vaccine. 2024 Apr 18:S0264-410X(24)00433-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1163. TRINITE B, Durr E, Pons-Grifols A, O'Donnell G, et al
    VLPs generated by the fusion of RSV-F or hMPV-F glycoprotein to HIV-Gag show improved immunogenicity and neutralizing response in mice.
    Vaccine. 2024 Apr 18:S0264-410X(24)00473-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1164. BEITARI S, Yi S, Sharma S, Yung R, et al
    Exploring COVID-19 vaccine uptake and hesitancy among vulnerable populations in inner city Vancouver, Canada: Insights into characteristics and clinical outcomes.
    Vaccine. 2024 Apr 17:S0264-410X(24)00477-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1165. MUTSAERTS EAML, van Cranenbroek B, Madhi SA, Simonetti E, et al
    Impact of nutritional status on vaccine-induced immunity in children living in South Africa: Investigating the B-cell repertoire and metabolic hormones.
    Vaccine. 2024 Apr 17:S0264-410X(24)00448-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1166. MATUR RV, Thuluva S, Gunneri S, Yerroju V, et al
    Immunogenicity and safety of a 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14) administered to 6-8 weeks old healthy Indian Infants: A single blind, randomized, active-controlled, Phase-III study.
    Vaccine. 2024 Apr 17:S0264-410X(24)00362-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1167. VAN DER POL S, Zeevat F, Postma MJ, Boersma C, et al
    Cost-effectiveness of high-dose influenza vaccination in the Netherlands: Incorporating the impact on both respiratory and cardiovascular hospitalizations.
    Vaccine. 2024 Apr 17:S0264-410X(24)00465-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1168. JI Y, Sui X, Miao W, Wang C, et al
    Erratum to "Immunogenicity of an adenovirus-vectored bivalent vaccine against wild type SARS-CoV-2 and Omicron variants in a murine model" [Vaccine 42(6) (2024) 1292-1299].
    Vaccine. 2024 Apr 16:S0264-410X(24)00386-4. doi: 10.1016/j.vaccine.2024.
    PubMed    


  1169. PEREIRA ET, Iasulaitis S, Greco BC
    Analysis of causal relations between vaccine hesitancy for COVID-19 vaccines and ideological orientations in Brazil.
    Vaccine. 2024 Apr 16:S0264-410X(24)00436-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1170. GEE J, Shimabukuro TT, Su JR, Shay D, et al
    Overview of U.S. COVID-19 vaccine safety surveillance systems.
    Vaccine. 2024 Apr 16:S0264-410X(24)00224-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1171. LEE N, Hong Y, Kirkpatrick CE, Hu S, et al
    COVID-19 vaccination communication: Effects of vaccine conspiracy beliefs and message framing among black and white participants.
    Vaccine. 2024 Apr 16:S0264-410X(24)00402-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1172. DEAL A, Crawshaw AF, Salloum M, Hayward SE, et al
    Understanding the views of adult migrants around catch-up vaccination for missed routine immunisations to define strategies to improve coverage: A UK in-depth interview study.
    Vaccine. 2024 Apr 16:S0264-410X(24)00406-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1173. SHEFFER R, Bucris E, Amitai Z, Indenbaum V, et al
    Measles outbreak associated with a preschool setting among partially vaccinated children in the Tel Aviv District, Israel, October 2023.
    Vaccine. 2024 Apr 15:S0264-410X(24)00427-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1174. MELNIKOW J, Padovani A, Zhang J, Miller M, et al
    Patient concerns and physician strategies for addressing COVID-19 vaccine hesitancy.
    Vaccine. 2024 Apr 15:S0264-410X(24)00437-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1175. WONG IOL, Wong C, Mak N, Dai A, et al
    Assessment of the impact of the vaccine pass policy on COVID-19 vaccine hesitancy and uptake among Chinese adults in Hong Kong.
    Vaccine. 2024 Apr 15:S0264-410X(24)00449-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1176. DAVIS BM, Blake I, Panicker G, Meites E, et al
    Immunogenicity of quadrivalent human papillomavirus vaccine among Alaska Native children aged 9-14 years at 5 years after vaccination.
    Vaccine. 2024 Apr 15:S0264-410X(24)00447-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1177. YAGI A, Ueda Y, Kimura T
    HPV Vaccine Issues in Japan: A review of our attempts to promote the HPV vaccine and to provide effective evaluation of the problem through social-medical and behavioral-economic perspectives.
    Vaccine. 2024 Apr 13:S0264-410X(24)00407-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1178. SUKIK L, Chemaitelly H, Ayoub HH, Coyle P, et al
    Effectiveness of two and three doses of COVID-19 mRNA vaccines against infection, symptoms, and severity in the pre-omicron era: A time-dependent gradient.
    Vaccine. 2024 Apr 13:S0264-410X(24)00440-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1179. BAKER J, Aliabadi N, Munjal I, Jiang Q, et al
    Equivalent immunogenicity across three RSVpreF vaccine lots in healthy adults 18-49 years of age: Results of a randomized phase 3 study.
    Vaccine. 2024 Apr 13:S0264-410X(24)00387-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1180. NASKAR S, Harsukhbhai Chandpa H, Agarwal S, Meena J, et al
    Super epitope dengue vaccine instigated serotype independent immune protection in-silico.
    Vaccine. 2024 Apr 13:S0264-410X(24)00423-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1181. YONEKAWA M, Watanabe T, Kogawara O, Yoshii C, et al
    Phase 3 immunogenicity and safety study of a tick-borne encephalitis vaccine in healthy Japanese participants 1 year of age and older.
    Vaccine. 2024 Apr 12:S0264-410X(24)00388-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1182. LEE JS, Choi H, Shin SH, Hwang MJ, et al
    Characterization of Brighton Collaboration criteria for myocarditis and pericarditis following COVID-19 vaccine in Korean adolescents.
    Vaccine. 2024 Apr 11:S0264-410X(24)00446-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1183. NOLAN MB, Chrenka E, Walker P, Steiner A, et al
    COVID-19 vaccine uptake among non-US-born populations in the United States, 2020-2022.
    Vaccine. 2024 Apr 11:S0264-410X(24)00443-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1184. KAINTH MK, Sembajwe GN, Ahn H, Qian M, et al
    Despite mandated primary series, health care personnel still hesitant about COVID-19 vaccine and immunizing children.
    Vaccine. 2024 Apr 11:S0264-410X(24)00442-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1185. AHERN S, Browne J, Murphy A, Teljeur C, et al
    An economic evaluation and incremental analysis of the cost effectiveness of three universal childhood varicella vaccination strategies for Ireland.
    Vaccine. 2024 Apr 11:S0264-410X(24)00441-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1186. OWUSU-EDUSEI K, Favre-Bulle A, Tsoumani E, Mutschler T, et al
    Evaluating the health and economic outcomes of a PCV15 vaccination program for adults aged 65 years-and-above in Switzerland.
    Vaccine. 2024 Apr 11:S0264-410X(24)00431-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1187. PITTS PJ, Poland GA
    Addressing vaccine hesitancy: Learning from the successes and failures of the COVID-19 pandemic.
    Vaccine. 2024 Apr 10:S0264-410X(24)00396-7. doi: 10.1016/j.vaccine.2024.
    PubMed    


  1188. HUSETH-ZOSEL AL, Fuller H, Hicks A, Carson PJ, et al
    Reliance on sources of immunization information and vaccine uptake among older adults in a rural state: The mediating role of trust.
    Vaccine. 2024 Apr 10:S0264-410X(24)00444-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1189. BLAKE JM, Thompson J, HogenEsch H, Ekenstedt KJ, et al
    Heritability and genome-wide association study of vaccine-induced immune response in Beagles: A pilot study.
    Vaccine. 2024 Apr 10:S0264-410X(24)00398-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1190. THAI H, Audet EC, Koestner R
    Motivation for COVID-19 Vaccination: Applying a Self-Determination Theory Perspective to a Global Health Crisis.
    Vaccine. 2024 Apr 9:S0264-410X(24)00439-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1191. AKMATOVA R, Ebama MS, Temirbekov S, Alymkulova V, et al
    A comparative analysis of knowledge, attitude, and practice (KAP) towards influenza and influenza vaccination among healthcare workers in Kyrgyzstan prior to and during the COVID-19 pandemic.
    Vaccine. 2024 Apr 9:S0264-410X(24)00420-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1192. EL BUSHRA HE, Haroun AAA, Dauod Altaf M, Gardiwal H, et al
    Early use of oral cholera vaccines as a prime control measure during outbreaks: Necessary but not sufficient.
    Vaccine. 2024 Apr 8:S0264-410X(24)00332-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1193. KONERU A, Wells K, Amanda Carnes C, Drumhiller K, et al
    A survey of state and local practices encouraging pediatric COVID-19 vaccination of children ages 6 months through 11 years.
    Vaccine. 2024 Apr 8:S0264-410X(24)00369-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1194. WONODI C, Crowcroft N, Bose AS, Oteri J, et al
    Country ownership as a guiding principle for IA2030: A case study of the measles and rubella elimination programs in Nepal and Nigeria.
    Vaccine. 2024;42 Suppl 1:S107-S117.
    PubMed     Abstract available


  1195. PATEL MK, Scobie HM, Serhan F, Dahl B, et al
    A global comprehensive vaccine-preventable disease surveillance strategy for the immunization Agenda 2030.
    Vaccine. 2024;42 Suppl 1.
    PubMed     Abstract available


  1196. CERNUSCHI T, Malvolti S, Hall S, Debruyne L, et al
    The quest for more effective vaccine markets - Opportunities, challenges, and what has changed with the SARS-CoV-2 pandemic.
    Vaccine. 2024;42 Suppl 1:S64-S72.
    PubMed     Abstract available


  1197. ARCHER H, McCoy SI, Sears D, Kwan A, et al
    Indirect vaccine effectiveness in an outbreak of Alpha B.1.1.7 variant in a California state Prison, May 2021.
    Vaccine. 2024 Apr 6:S0264-410X(24)00368-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1198. CUMMINGS JF, Polhemus ME, Kester KE, Ockenhouse CF, et al
    A phase IIa, randomized, double-blind, safety, immunogenicity and efficacy trial of Plasmodium falciparum vaccine antigens merozoite surface protein 1 and RTS,S formulated with AS02 adjuvant in healthy, malaria-naive adults.
    Vaccine. 2024 Apr 6:S0264-410X(24)00389-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1199. CHONG CY, Kam KQ, Zhang J, Bertoletti A, et al
    Immunogenicity and safety of Sinovac-CoronaVac booster vaccinations in 12-17- year-olds with clinically significant reactions from Pfizer-BNT162b2 vaccination.
    Vaccine. 2024 Apr 6:S0264-410X(24)00425-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1200. BINTE HOSSAIN F, Muscatello D, Jayasinghe S, Jonnagaddala J, et al
    Uptake of pneumococcal vaccines in older Australian adults before and after universal public funding of PCV13.
    Vaccine. 2024 Apr 6:S0264-410X(24)00426-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1201. CHARD AN, Machingaidze C, Loayza S, Gharpure R, et al
    Estimating averted illnesses from influenza vaccination for children and pregnant women - El Salvador, Panama, and Peru, 2011-2018.
    Vaccine. 2024 Apr 6:S0264-410X(24)00419-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1202. SCHULTZE A, Martin I, Messina D, Bots S, et al
    A comparison of four self-controlled study designs in an analysis of COVID-19 vaccines and myocarditis using five European databases.
    Vaccine. 2024 Apr 5:S0264-410X(24)00330-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1203. STEFANIZZI P, Moscara L, Palmieri C, Martinelli A, et al
    Safety profile of recombinant adjuvanted anti-herpes zoster vaccine (RZV) in high-risk groups: Data from active surveillance program. Puglia (Italy), 2021-23.
    Vaccine. 2024 Apr 5:S0264-410X(24)00311-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1204. NYBRU GLEDITSCH R, Skogset Ofitserova T, Aubrey White R, Karoline Raberg Kjollesdal M, et al
    Vaccine coverage among children born to immigrant parents in Norway, 2000-2020.
    Vaccine. 2024 Apr 5:S0264-410X(24)00395-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1205. NAKANO T, Hasegawa M, Endo M, Matsuda K, et al
    Immunogenicity and safety of adsorbed diphtheria-purified pertussis-tetanus-inactivated polio (Sabin strain)-Haemophilus type b conjugate combined vaccine (DPT-IPV-Hib) in healthy Japanese Infants >/= 2 and < 43 months of Age: A phase III, multicenter
    Vaccine. 2024 Apr 5:S0264-410X(24)00394-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1206. BAUM HE, Thirard R, Halliday A, Baos S, et al
    Detection of SARS-CoV-2-specific mucosal antibodies in saliva following concomitant COVID-19 and influenza vaccination in the ComFluCOV trial.
    Vaccine. 2024 Apr 4:S0264-410X(24)00367-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1207. ALTAWALBEH SM, Wateska AR, Nowalk MP, Lin CJ, et al
    Cost-effectiveness of an in-development adult-formulated 21-valent pneumococcal conjugate vaccine in US adults aged 50 years or older.
    Vaccine. 2024 Apr 4:S0264-410X(24)00404-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1208. HEISLER-MACKINNON JA, Queen T, Yi Kong W, Kennedy KL, et al
    Identifying effective vaccine champions: Findings from a national survey of primary care professionals.
    Vaccine. 2024 Apr 3:S0264-410X(24)00403-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1209. NURDIN A, Movieta Nency Y, Maddeppungeng M, Sekartini R, et al
    Immunogenicity and safety of SARS-CoV-2 recombinant protein subunit vaccine (IndoVac) adjuvanted with alum and CpG 1018 in Indonesian adults: A phase 3, randomized, active-controlled, multicenter trial.
    Vaccine. 2024 Apr 3:S0264-410X(24)00399-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1210. TEMBO G, Mayuni M, Kamng'ona R, Chimgoneko L, et al
    Poor association between 13-valent pneumococcal conjugate vaccine-induced serum and mucosal antibody responses with experimental Streptococcus pneumoniae serotype 6B colonisation.
    Vaccine. 2024 Apr 2:S0264-410X(24)00360-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1211. WU CY, Kao SE, Tseng YC, Hou JT, et al
    Pilot-scale production of a highly efficacious and stable monoglycosylated influenza split virus vaccine.
    Vaccine. 2024;42:2220-2228.
    PubMed     Abstract available


  1212. LIU J, Qi Q, Liu Y, Ni P, et al
    A paired measles-rubella catch-up campaign in Sichuan China to stop an outbreak and strengthen local immunization programs.
    Vaccine. 2024;42:2155-2160.
    PubMed     Abstract available


  1213. SU L, Zhou X, Peng W, Luo J, et al
    Investigation on the correlation factors of positive Streptococcus pneumoniae antibody and IgG antibody level of Streptococcus pneumoniae in the elderly over 60 years old in Shenzhen.
    Vaccine. 2024;42:2448-2454.
    PubMed     Abstract available


  1214. HUBER A, Kovacs E, Horvath A, Sahin-Toth J, et al
    Prevalence, serogroup distribution and risk factors of Neisseria meningitidis carriage in high school and university students in Hungary.
    Vaccine. 2024;42:2271-2277.
    PubMed     Abstract available


  1215. KIMBUGWE G, Vatrinet R, Mwanga JA, Kakuru R, et al
    Perceptions, attitudes, and willingness of healthcare and frontline workers to participate in an Ebola vaccine trial in Uganda.
    Vaccine. 2024 Apr 1:S0264-410X(24)00358-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


    March 2024
  1216. GONG JD, Barnboym E, O'Mara M, Gurevich N, et al
    Self-reported determinants of COVID-19 vaccine acceptance among persons with and without autoimmune disease.
    Vaccine. 2024 Mar 30:S0264-410X(24)00373-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1217. MALTEZOU HC, Kontogianni S, Michailidou E, Vergadi E, et al
    Effectiveness of COVID-19 vaccination against school absenteeism in children and adolescents hospitalized with COVID-19.
    Vaccine. 2024 Mar 30:S0264-410X(24)00397-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1218. PADENIYA TN, Hui BB, Wood JG, Regan DG, et al
    Review of mathematical models of Neisseria gonorrhoeae vaccine impact: Implications for vaccine development.
    Vaccine. 2024 Mar 30:S0264-410X(24)00380-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1219. HUF SW, Grailey K, Crespo RF, Woldmann L, et al
    Testing the impact of differing behavioural science informed text message content in COVID-19 vaccination invitations on vaccine uptake: A randomised clinical trial.
    Vaccine. 2024 Mar 28:S0264-410X(24)00365-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1220. FUKUDA Y, Suzuki T, Iwata KI, Haruta K, et al
    Nanopore sequencing in distinguishing between wild-type and vaccine strains of Varicella-Zoster virus.
    Vaccine. 2024 Mar 27:S0264-410X(24)00333-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1221. BRUUN N, Laursen MF, Carmelo R, Christensen E, et al
    Novel nucleotide-packaging vaccine delivers antigen and poly(I:C) to dendritic cells and generate a potent antibody response in vivo.
    Vaccine. 2024 Mar 26:S0264-410X(24)00364-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1222. PARISI A, Nunez O, Lopez-Perea N, Masa-Calles J, et al
    Reduced pertussis disease severity in infants following the introduction of pertussis vaccination of pregnant women in Spain, 2015-2019.
    Vaccine. 2024 Mar 25:S0264-410X(24)00315-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1223. WEYANT C, Hooda Y, Munira SJ, Lo NC, et al
    Cost-effectiveness and public health impact of typhoid conjugate vaccine introduction strategies in Bangladesh.
    Vaccine. 2024 Mar 25:S0264-410X(24)00322-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1224. DALEY MF, Reifler LM, Shoup JA, Glanz JM, et al
    Influenza vaccination accuracy among adults: Self-report compared with electronic health record data.
    Vaccine. 2024 Mar 25:S0264-410X(24)00339-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1225. BIEGUS J, Szenborn L, Zymlinski R, Zakliczynski M, et al
    The early safety profile of simultaneous vaccination against influenza and Respiratory Syncytial Virus (RSV) in patients with high-risk heart failure.
    Vaccine. 2024 Mar 25:S0264-410X(24)00366-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1226. VOLKMANN AM, Goldin S, McMurren B, Gapare C, et al
    Leveraging seasonal influenza health worker vaccination programmes for COVID-19 vaccine Introduction: A global qualitative analysis.
    Vaccine. 2024 Mar 25:S0264-410X(23)01490-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1227. DAHL BA, Tritter B, Butryn D, Dahlke M, et al
    Global VAX: A U.S. contribution to global COVID-19 vaccination efforts, 2021-2023.
    Vaccine. 2024 Mar 23:S0264-410X(24)00359-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1228. PONNE S, Kumar R, Vanmathi SM, Brilhante RSN, et al
    Reverse engineering protection: A comprehensive survey of reverse vaccinology-based vaccines targeting viral pathogens.
    Vaccine. 2024 Mar 23:S0264-410X(24)00265-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1229. MORGAN G, Casalino S, Chowdhary S, Frangione E, et al
    COVID-19 vaccine reactogenicity among participants enrolled in the GENCOV study.
    Vaccine. 2024 Mar 22:S0264-410X(24)00317-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1230. STUREBORG R, Nichols J, Dhingra B, Yang J, et al
    Development and validation of VaxConcerns: A taxonomy of vaccine concerns and misinformation with Crowdsource-Viability.
    Vaccine. 2024 Mar 22:S0264-410X(24)00255-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1231. CONDIE J, Northstone K, Major-Smith D, Halstead I, et al
    Exploring associations between the Big Five personality traits and cognitive ability with COVID-19 vaccination hesitancy and uptake among mothers and offspring in a UK prospective cohort study.
    Vaccine. 2024 Mar 22:S0264-410X(24)00305-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1232. COMES JDG, Doets K, Zegers T, Kessler M, et al
    Evaluation of bird-adapted self-amplifying mRNA vaccine formulations in chickens.
    Vaccine. 2024 Mar 22:S0264-410X(24)00319-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1233. PRICE O, Dietze P, Maher L, Dore GJ, et al
    High COVID-19 vaccine uptake following initial hesitancy among people in Australia who inject drugs.
    Vaccine. 2024 Mar 21:S0264-410X(24)00337-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1234. HIRTH J, Ostovar-Kermani T, Gutierrez JA, Thompson EL, et al
    Effect of age at initiation of the human papillomavirus vaccine on the association between race/ethnicity and completion of the vaccine series.
    Vaccine. 2024 Mar 21:S0264-410X(24)00336-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1235. ZHANG Y, Wang Y, Li G, Zhao X, et al
    A randomized, blind, parallel controlled phase I clinical trial to evaluate the safety and preliminary immunogenicity of 23-valent pneumococcal polysaccharide vaccine in healthy people aged 2 years and older.
    Vaccine. 2024 Mar 21:S0264-410X(24)00331-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1236. KLUWER B, Gleditsch R, Rydland KM, Mamelund SE, et al
    Higher educational attainment associated with higher confidence in influenza vaccination in Norway.
    Vaccine. 2024 Mar 21:S0264-410X(24)00338-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1237. ZHAO Z, Meng Q, Sun TZ, Zhu B, et al
    Mannose modified targeted immersion vaccine delivery system improves protective immunity against Infectious spleen and kidney necrosis virus in mandarin fish (Siniperca chuatsi).
    Vaccine. 2024 Mar 21:S0264-410X(24)00335-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1238. MOFFETT KW, Seserman K, Margolis KA, Kranzler EC, et al
    Differences in social media use by COVID-19 vaccination status.
    Vaccine. 2024 Mar 20:S0264-410X(24)00318-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1239. SASI A, Dandotiya J, Kaushal J, Ganguly S, et al
    Humoral and cellular immunity to SARS-CoV-2 following vaccination with non-mRNA vaccines in adolescent/young adults with cancer: A prospective cohort study.
    Vaccine. 2024 Mar 20:S0264-410X(24)00329-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1240. BROOKS SP, Sidhu K, Cooper E, Michelle Driedger S, et al
    The influence of health service interactions and local policies on vaccination decision-making in immigrant women: A multi-site Canadian qualitative study.
    Vaccine. 2024 Mar 20:S0264-410X(24)00299-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1241. CRISTINA MARTINI RODRIGUES C, Caroline Ribeiro Sales A, Marli Christovam Sartori A, de Souza Azevedo A, et al
    Yellow fever neutralizing antibody seroprevalence proportion and titers in previously vaccinated adults with chronic kidney disease.
    Vaccine. 2024 Mar 20:S0264-410X(24)00316-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1242. ARTIGAS-JERONIMO S, Villar M, Estrada-Pena A, Alberdi P, et al
    Subolesin knockdown in tick cells provides insights into vaccine protective mechanisms.
    Vaccine. 2024 Mar 19:S0264-410X(24)00278-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1243. CHENG Y, Shen R, Liu F, Li Y, et al
    Humoral and cellular immune responses induced by serogroup W135 meningococcal conjugate and polysaccharide vaccines.
    Vaccine. 2024 Mar 19:S0264-410X(24)00326-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1244. KRASILNIKOV I, Isaev A, Djonovic M, Ivanov A, et al
    Transformative vaccination: A pentavalent shield against COVID-19 and influenza with betulin-based adjuvant for enhanced immunity.
    Vaccine. 2024 Mar 19:S0264-410X(23)01421-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1245. GEHRT L, Englund H, Laake I, Nieminen H, et al
    Is vaccination against measles, mumps, and rubella associated with reduced rates of antibiotic treatments among children below the age of 2 years? Nationwide register-based study from Denmark, Finland, Norway, and Sweden.
    Vaccine. 2024 Mar 19:S0264-410X(24)00313-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1246. ANWARI P, Burnett E, Chavers TP, Samsor A, et al
    Post-marketing surveillance of intussusception after Rotarix administration in Afghanistan, 2018-2022.
    Vaccine. 2024;42:2059-2064.
    PubMed     Abstract available


  1247. LLOYD PC, Lufkin B, Moll K, Ogilvie RP, et al
    Incidence rates of thrombosis with thrombocytopenia syndrome (TTS) among adults in United States commercial and Medicare claims databases, 2017-2020.
    Vaccine. 2024;42:2004-2010.
    PubMed     Abstract available


  1248. SOVIK WLM, Madsen AMR, Aaby P, Nielsen S, et al
    The association between BCG scars and self-reported chronic diseases: A cross-sectional observational study within an RCT of Danish health care workers.
    Vaccine. 2024;42:1966-1972.
    PubMed     Abstract available


  1249. KWON KW, Choi HG, Choi HH, Choi E, et al
    Immunogenicity and protective efficacy of RipA, a peptidoglycan hydrolase, against Mycobacterium tuberculosis Beijing outbreak strains.
    Vaccine. 2024;42:1941-1952.
    PubMed     Abstract available


  1250. HILL-BATORSKI L, Bowen R, Bielefeldt-Ohmann H, Moser MJ, et al
    Mucosal immunization with dual influenza/COVID-19 single-replication virus vector protects hamsters from SARS-CoV-2 challenge.
    Vaccine. 2024 Mar 19:S0264-410X(24)00327-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1251. SANCHEZ-MARTINEZ ZV, Alpuche-Lazcano SP, Stuible M, Durocher Y, et al
    CHO cells for virus-like particle and subunit vaccine manufacturing.
    Vaccine. 2024 Mar 18:S0264-410X(24)00321-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1252. WU J, Jiang L, Shao Q, Liu J, et al
    Comparison of the safety and efficacy of the wild-type and lpxL/lpxM mutant inactivated vaccine against the avian pathogenic Escherichia coli O1, O2, and O78 challenge.
    Vaccine. 2024 Mar 18:S0264-410X(24)00325-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1253. MEDENI V, Altiner OT, Medeni I
    Measles vaccination coverage and immunization status of nurses: An interventional study in Turkiye.
    Vaccine. 2024 Mar 18:S0264-410X(24)00324-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1254. DANGOR Z, Benson N, Berkley JA, Bielicki J, et al
    Vaccine value profile for Klebsiella pneumoniae.
    Vaccine. 2024 Mar 18:S0264-410X(24)00248-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1255. OPMEER L, Gazzoli I, Ballmann M, Willemsen M, et al
    High throughput AS LNA qPCR method for the detection of a specific mutation in poliovirus vaccine strains.
    Vaccine. 2024 Mar 18:S0264-410X(24)00130-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1256. CAMPAGNA R, Dominelli F, Zingaropoli MA, Ciurluini F, et al
    COVID-19 vaccination in cancer patients: Immune responses one year after the third dose.
    Vaccine. 2024 Mar 17:S0264-410X(24)00304-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1257. FIERRO C, Weidenthaler H, Vidojkovic S, Schmidt D, et al
    Safety and immunogenicity of a novel trivalent recombinant MVA-based equine encephalitis virus vaccine: A Phase 1 clinical trial.
    Vaccine. 2024 Mar 16:S0264-410X(24)00296-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1258. HARTMEIER PR, Ostrowski SM, Busch EE, Empey KM, et al
    Lymphatic distribution considerations for subunit vaccine design and development.
    Vaccine. 2024 Mar 16:S0264-410X(24)00320-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1259. FIX J, Christopher Mast T, Smith K, Baker N, et al
    Benefit-risk assessment for the Novavax COVID-19 vaccine (NVX-CoV2373).
    Vaccine. 2024 Mar 16:S0264-410X(24)00323-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1260. COTTON SA, Subramanian A, Hughes TD, Huang Y, et al
    The effect of SARS-COV-2 variant on non-respiratory features and mortality among vaccinated and non-fully vaccinated patients.
    Vaccine. 2024 Mar 14:S0264-410X(24)00195-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1261. JUNEAU C, Fall E, Bros J, Le Duc-Banaszuk AS, et al
    Do boys have the same intentions to get the HPV vaccine as girls? Knowledge, attitudes, and intentions in France.
    Vaccine. 2024 Mar 14:S0264-410X(24)00256-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1262. CAMERON DB, Grage L, Van Wyck R, Edwards A, et al
    Identifying trusted local sources and predicting behavior change pathways according to COVID-19 vaccination status: Results of a 2022 statewide survey of Alaskan adults.
    Vaccine. 2024 Mar 14:S0264-410X(24)00314-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1263. MACKENZIE GA, Hossain I, Salaudeen R, Badji H, et al
    Impact of pneumococcal conjugate vaccination on pneumococcal nasopharyngeal carriage in the Gambia: Population-based cross-sectional surveys.
    Vaccine. 2024 Mar 14:S0264-410X(24)00225-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1264. EL SALIBI N, Abdulrahim S, El Haddad M, Abi Zeid B, et al
    Predicting intention to vaccinate against COVID-19 in older Syrian refugees in Lebanon: Findings from a multi-wave study.
    Vaccine. 2024 Mar 13:S0264-410X(24)00213-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1265. MCCOSKER LK, Ware RS, Seale H, Hooshmand D, et al
    The effect of a financial incentive on COVID-19 vaccination uptake, and predictors of uptake, in people experiencing homelessness: A randomized controlled trial.
    Vaccine. 2024 Mar 13:S0264-410X(24)00307-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1266. SAKAUE T, Sugawara T, Mukasa K, Nohara M, et al
    Varicella outbreak at nursery school under routine immunization in Japan in 2017 and 2018 and vaccine effectiveness.
    Vaccine. 2024 Mar 12:S0264-410X(24)00250-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1267. CHEUNG DH, Chen S, Fang Y, Sun F, et al
    Influences of mpox disease perceptions, sources and contents of information exposure on mpox vaccine uptake among gay, bisexual, and other men who have sex with men in Hong Kong, China.
    Vaccine. 2024 Mar 12:S0264-410X(24)00259-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1268. SHERMAN SM, Allerton-Price C, Lingley-Heath N, Lai J, et al
    UK healthcare professionals' attitudes towards the introduction of varicella vaccine into the routine childhood vaccination schedule and their preferences for administration.
    Vaccine. 2024 Mar 12:S0264-410X(24)00274-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1269. RUSS S, Myers C, Licherdell E, Bowden A, et al
    Sociodemographic and Occupational Characteristics Associated with Early and Continued COVID-19 Vaccine Uptake Among Healthcare Personnel: Monroe County, NY.
    Vaccine. 2024 Mar 12:S0264-410X(24)00306-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1270. MERDRIGNAC L, Ait El Belghiti F, Pandolfi E, Acosta L, et al
    Effectiveness of one and two doses of acellular pertussis vaccines against laboratory-confirmed pertussis requiring hospitalisation in infants: Results of the PERTINENT sentinel surveillance system in six EU/EEA countries, December 2015 - December 201
    Vaccine. 2024 Mar 11:S0264-410X(24)00272-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1271. SHIJIA YAN A, Jay Sehgal N
    Partisan divide and Racial/Ethnic disparities in COVID-19 vaccine hesitancy among Parents/Guardians and vaccine uptake among children in the U.S.
    Vaccine. 2024 Mar 11:S0264-410X(24)00309-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1272. SENPUKU K, Kataoka-Nakamura C, Kunishima Y, Hirai T, et al
    An inactivated whole-virion vaccine for Enterovirus D68 adjuvanted with CpG ODN or AddaVax elicits potent protective immunity in mice.
    Vaccine. 2024 Mar 11:S0264-410X(24)00303-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1273. MORO PL, Carlock G, Fifadara N, Habenicht T, et al
    Safety monitoring of bivalent mRNA COVID-19 vaccine among pregnant persons in the vaccine adverse event reporting System - United States, September 1, 2022 - March 31, 2023.
    Vaccine. 2024 Mar 9:S0264-410X(24)00262-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1274. HARRELL JE, Roy CJ, Gunn JS, McLachlan JB, et al
    Current vaccine strategies and novel approaches to combatting Francisella infection.
    Vaccine. 2024 Mar 8:S0264-410X(24)00264-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1275. SU YW, Qiu YZ, Wang YH, Xu Y, et al
    Safety and immunogenicity of heterologous boosting with a bivalent SARS-CoV-2 mRNA vaccine (XBB.1.5/BQ.1) in Chinese participants aged 18 years or more: A randomised, double-blinded, active-controlled phase 1 trial.
    Vaccine. 2024 Mar 8:S0264-410X(24)00277-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1276. LUISI M, Geana MV, Pei J
    Pandemic antecedents - Exploring predictivity and relationships between COVID-19 vaccine uptake and influenza, shingles, and HPV vaccination.
    Vaccine. 2024 Mar 8:S0264-410X(24)00275-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1277. BROUSSEAU N, Angers-Goulet ME, Bastien R, Ye L, et al
    Vaccination during pregnancy and modulation of IgG response to pertussis vaccines in infants: The impact of different vaccine formulations.
    Vaccine. 2024 Mar 8:S0264-410X(24)00300-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1278. ST-LOUIS P, Martin C, Khatri V, Bourgault S, et al
    Intranasal delivery of a self-adjuvanted nanovaccine composed of the curli filaments and the highly conserved M2e epitope confers protection against influenza a virus in mice.
    Vaccine. 2024 Mar 8:S0264-410X(24)00222-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1279. GHASEMIFAR S, Chabak O, Piri-Gharaghie T, Doosti A, et al
    PIRES2-EGFP/CTB-UreI vaccination activated a mixed Th1/Th2/Th17 immune system defense towards Helicobacter pylori infection in the BALB/c mice model.
    Vaccine. 2024 Mar 7:S0264-410X(24)00209-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available



  1280. Expression of Concern: "Cross-protection against H7N9 influenza strains using a live-attenuated H7N3 virus vaccine" [Vaccine [33/1], 1 January 2015, Pages 108-116].
    Vaccine. 2024;42:1851.
    PubMed    



  1281. Expression of Concern: "Human COBRA 2 vaccine contains two major epitopes that are responsible for eliciting neutralizing antibody responses against heterologous clades of viruses" [Vaccine Volume 38, Issue 4, 22 January 2020, Pages 830-839].
    Vaccine. 2024;42:1850.
    PubMed    


  1282. DE WAELE A, Hendrickx G, Valckx S, Dominguez A, et al
    The Vaccine Training Barometer: Assessing healthcare providers' confidence to answer vaccine-related questions and their training needs.
    Vaccine. 2024 Mar 7:S0264-410X(24)00254-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1283. SIREK G, Ulysse S, Jacques Toussaint M, Nosamiefan C, et al
    A community-engaged approach to translate a Vaccine Hesitancy Scale into Haitian Creole.
    Vaccine. 2024 Mar 7:S0264-410X(24)00257-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1284. GILBERT PB, Fong Y, Hejazi NS, Kenny A, et al
    Four statistical frameworks for assessing an immune correlate of protection (surrogate endpoint) from a randomized, controlled, vaccine efficacy trial.
    Vaccine. 2024 Mar 7:S0264-410X(24)00247-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1285. MALDONADO I, Rodriguez Nino N, Valencia CF, Ortiz D, et al
    Evaluation of the safety profile of the quadrivalent vaccine against human papillomavirus in the risk of developing autoimmune, neurological, and hematological diseases in adolescent women in Colombia.
    Vaccine. 2024 Mar 7:S0264-410X(24)00263-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1286. ZIBOLENOVA J, Malobicka E, Ulbrichtova R, Novak M, et al
    Probability of exposure to the wild measles virus in adult population - Estimation from seroepidemiology and historical data.
    Vaccine. 2024;42:1648-1655.
    PubMed     Abstract available


  1287. HYAMS C, Lahuerta M, Theilacker C, King J, et al
    Surveillance of pneumococcal serotypes in adults hospitalised with acute lower respiratory tract infection in Bristol, UK.
    Vaccine. 2024;42:1599-1607.
    PubMed     Abstract available


  1288. MENG L, Harris L, Shaw L, Lymon H, et al
    Social and demographic factors associated with receipt of a COVID-19 vaccine initial booster dose and with interval between primary series completion and initial booster dose uptake among persons aged >/= 12 years, United States, August 2021-October 2
    Vaccine. 2024 Mar 6:S0264-410X(24)00271-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1289. KARRAS J, Harrison M, Steffens M, Abdi I, et al
    "COVID is a huge jigsaw puzzle that I am trying to make sense of myself": Exploring the perceptions towards the COVID-19 vaccine communication strategy in Australia amongst unvaccinated Australian adults.
    Vaccine. 2024 Mar 6:S0264-410X(24)00276-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1290. WONG WHS, Leung DL, Yip KM, So HK, et al
    Effectiveness of inactivated COVID-19 vaccine CoronaVac in children aged less than 3 years old during Omicron wave in Hong Kong.
    Vaccine. 2024 Mar 6:S0264-410X(24)00226-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1291. RAETHKE M, van Hunsel F, Luxi N, Lieber T, et al
    Frequency and timing of adverse reactions to COVID-19 vaccines; A multi-country cohort event monitoring study.
    Vaccine. 2024 Mar 6:S0264-410X(24)00273-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1292. CHEN D, Cowling BJ, Ainslie KEC, Lin Y, et al
    Association of COVID-19 vaccination with duration of hospitalization in older adults in Hong Kong.
    Vaccine. 2024 Mar 5:S0264-410X(24)00252-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1293. MARQUES RF, Gimenez AM, Caballero O, Simpson A, et al
    Non-clinical toxicity and immunogenicity evaluation of a Plasmodium vivax malaria vaccine using Poly-ICLC (Hiltonol(R)) as adjuvant.
    Vaccine. 2024 Mar 5:S0264-410X(24)00229-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1294. BEAVIS AC, Dienger-Stambaugh K, Briggs K, Chen Z, et al
    A J Paramyxovirus-vectored HIV vaccine induces humoral and cellular responses in mice.
    Vaccine. 2024 Mar 4:S0264-410X(24)00227-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1295. DUAN X, Zhang L, Ding L, Zhang C, et al
    Effectiveness of enterovirus A71 vaccine against pediatric HFMD and disease profile of post-vaccination infection.
    Vaccine. 2024 Mar 2:S0264-410X(24)00172-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1296. ZAMAN K, Schuind AE, Adjei S, Antony K, et al
    Safety and immunogenicity of Innovax bivalent human papillomavirus vaccine in girls 9-14 years of age: Interim analysis from a phase 3 clinical trial.
    Vaccine. 2024 Mar 1:S0264-410X(24)00251-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1297. YASHAR-GERSHMAN SG, Rosenberg AT, Sawhney M, Fernanda Machicao M, et al
    Developing a novel screening tool to address pediatric COVID-19 vaccine hesitancy at point of care.
    Vaccine. 2024 Mar 1:S0264-410X(24)00228-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


    February 2024
  1298. YADEGARYNIA D, Keyvanfar A, Keyvani H, Tehrani S, et al
    Immunogenicity and safety of a quadrivalent recombinant influenza vaccine manufactured in Iran (FluGuard) in volunteers aged 18-60 years: A double-blind, non-inferiority, randomized controlled trial.
    Vaccine. 2024 Feb 29:S0264-410X(24)00249-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1299. KOHLI M, Maschio M, Lee A, Igarashi A, et al
    Projections of the incidence of COVID-19 in Japan and the potential impact of a Fall 2023 COVID-19 vaccine.
    Vaccine. 2024 Feb 29:S0264-410X(24)00117-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1300. CHATHAM-STEPHENS K, Carter RJ, Duggar C, Woodworth KR, et al
    An overview of the COVID-19 pediatric vaccine program - The U.S. experience vaccinating children ages 6 months through 17 years.
    Vaccine. 2024 Feb 29:S0264-410X(24)00166-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1301. LEVIN MJ, Ginde AA, Schmid DS, Lang N, et al
    Effect of high dose vitamin D supplementation on subsequent immune responses to administration of the live herpes zoster vaccine to long-term care residents.
    Vaccine. 2024 Feb 28:S0264-410X(24)00214-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1302. MARINDA E, Mathentamo Q, Coulson N, Parker S, et al
    Impact evaluation of a youth led intervention to increase COVID-19 vaccine uptake in Kwazulu-Natal, South Africa.
    Vaccine. 2024 Feb 28:S0264-410X(24)00211-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1303. OMAR ALI S, Dessart C, Parikh R
    Co-administration of the adjuvanted recombinant zoster vaccine with other adult vaccines: An overview.
    Vaccine. 2024 Feb 28:S0264-410X(24)00194-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1304. GUO J, Chen X, Guo Y, Liu M, et al
    Real-world effectiveness of seasonal influenza vaccination and age as effect modifier: A systematic review, meta-analysis and meta-regression of test-negative design studies.
    Vaccine. 2024 Feb 28:S0264-410X(24)00218-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1305. ZHOU W, Guo X, Lu J, Lu X, et al
    Parental willingness to accept and pay human papillomavirus vaccine for boys aged 9-14 in a metropolis area of China: Evidence for developing a vaccination strategy.
    Vaccine. 2024 Feb 28:S0264-410X(24)00253-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1306. JACKSON S, Kabir Z, Comiskey C
    Retrospective cohort study exploring the impact of universal Tuberculosis (TB) vaccination cessation on the epidemiology of paediatric TB in Ireland, 2011-2021.
    Vaccine. 2024 Feb 28:S0264-410X(24)00220-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1307. JABBAR F, Kadhim KA, Alhilfi RA, Chitheer A, et al
    Intensification of integrated immunization services to recover routine vaccination coverage and bring COVID-19 vaccine to the population of Iraq in 2022.
    Vaccine. 2024 Feb 27:S0264-410X(24)00197-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1308. TANAKA M, Okubo R, Hoshi SL, Kondo M, et al
    Cost-effectiveness analysis of pertussis booster vaccination for adolescents in Japan.
    Vaccine. 2024 Feb 27:S0264-410X(24)00199-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1309. GIDENGIL C, Scherer AM, Parker AM, Gedlinske A, et al
    Lyme disease vaccine attitudes and intentions among parents of children aged 5-18 years in the United States.
    Vaccine. 2024 Feb 27:S0264-410X(24)00105-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1310. YANG XY, Liu T, Jiang SC, Zhang ZW, et al
    Antibodies against SARS-CoV-2 non-structural protein 3 cross-react with human muscle cells and neuroglial cells.
    Vaccine. 2024;42:1259-1267.
    PubMed     Abstract available


  1311. MUNDO ORTIZ A, Nasri B
    Socio-demographic determinants of COVID-19 vaccine uptake in Ontario: Exploring differences across the Health Region model.
    Vaccine. 2024 Feb 26:S0264-410X(24)00204-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1312. KEGELE LIGNANI L, de Vasconcellos Carvalhaes de Oliveira R, Matos Dos Santos E, Antonio Bastos Camacho L, et al
    Neutralizing antibody titers against D8 genotype and persistence of measles humoral and cell-mediated immunity eight years after the first dose of measles, mumps, and rubella vaccine in Brazilian children.
    Vaccine. 2024 Feb 26:S0264-410X(24)00219-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1313. TOLENTINO JUNIOR DS, Vasconcelos Marques MS, de Oliveira RC
    Rabies vaccination of the Maxakali indigenous population.
    Vaccine. 2024 Feb 26:S0264-410X(23)01542-6. doi: 10.1016/j.vaccine.2023.
    PubMed    


  1314. KRISTINSDOTTIR I, Haraldsson A, Thors V
    Influenza vaccination in pregnant women in Iceland 2010-2020 and the burden of influenza in pregnant women and their infants.
    Vaccine. 2024 Feb 26:S0264-410X(24)00205-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1315. NEWALL AT, Nazareno AL, Muscatello DJ, Boettiger D, et al
    The association between influenza vaccination uptake and influenza and pneumonia-associated deaths in the United States.
    Vaccine. 2024 Feb 24:S0264-410X(24)00113-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1316. BIJUKCHHE SM, Gurung M, Pokhrel B, Shakya M, et al
    Immune responses to typhoid conjugate vaccine in a two dose schedule among Nepalese children <2 years of age.
    Vaccine. 2024 Feb 22:S0264-410X(24)00156-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1317. MURPHY C, Kwan MYW, Chan ELY, Wong JSC, et al
    Influenza vaccine effectiveness against hospitalizations associated with influenza A(H3N2) in Hong Kong children aged 9 months to 17 years, June-November 2023.
    Vaccine. 2024 Feb 22:S0264-410X(24)00215-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1318. SHETTY AN, Morgan HJ, Phuong LK, Mallard J, et al
    Audiovestibular adverse events following COVID-19 vaccinations.
    Vaccine. 2024 Feb 22:S0264-410X(24)00210-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1319. KOCHHAR S, Assis DN, Mack C, Izurieta HS, et al
    Autoimmune hepatitis: Brighton Collaboration case definition and guidelines for data collection, analysis, and presentation of immunisation safety data.
    Vaccine. 2024 Feb 16:S0264-410X(24)00021-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  1320. DREYFUS J, Munnangi S, Bengtsson C, Correia B, et al
    Background incidence rates of health outcomes in populations at risk for Lyme disease using US administrative claims data.
    Vaccine. 2024;42:1094-1107.
    PubMed     Abstract available


  1321. PREVOT-MONSACRE P, Hamaide-Defrocourt F, Guyonvarch O, Masse S, et al
    What is the relevancy of a surveillance of mumps without a systematic laboratory confirmation in highly immunized populations? Epidemiology of suspected and biologically confirmed mumps cases seen in general practice in France between 2014 and 2020.
    Vaccine. 2024;42:1065-1070.
    PubMed     Abstract available


    November 2023
  1322. ZURCHER SJ, Signorell A, Lechot-Huser A, Aebi C, et al
    Childhood vaccination coverage and regional differences in Swiss birth cohorts 2012-2021: Are we on track?
    Vaccine. 2023;41:7226-7233.
    PubMed     Abstract available


  1323. FLANDES X, Hansen CA, Palani S, Abbas K, et al
    Vaccine value profile for Chikungunya.
    Vaccine. 2023 Nov 7:S0264-410X(23)00915-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1324. HOTEZ PJ, Bottazzi ME, Kaye PM, Lee BY, et al
    Neglected tropical disease vaccines: hookworm, leishmaniasis, and schistosomiasis.
    Vaccine. 2023;41 Suppl 2.
    PubMed    


  1325. UGHASORO MD, Nnakenyi I, Echendu N, Akpeh JO, et al
    Neutralizing anti-polio antibody titre in newborn babies in post-polio eradication period in Nigeria.
    Vaccine. 2023;41:6820-6823.
    PubMed     Abstract available


  1326. DO LAH, Le NTN, Mahmud S, Mulholland K, et al
    Impact and cost-effectiveness of strategies to prevent respiratory syncytial virus (RSV) disease in Vietnam: A modelling study.
    Vaccine. 2023;41:6782-6790.
    PubMed     Abstract available


    October 2023
  1327. CORSTEN C, Vang ZM, Gold I, Goldenberg MJ, et al
    Understanding COVID-19 vaccine hesitancy in Canada.
    Vaccine. 2023 Oct 27:S0264-410X(23)01260-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1328. LI J, Shi LW, Li K, Huang LR, et al
    Comparison of the safety and persistence of immunogenicity of bivalent HPV16/18 vaccine in healthy 9-14-year-old and 18-26-year-old Chinese females: A randomized, double-blind, non-inferiority clinical trial.
    Vaccine. 2023;41:7212-9.
    PubMed     Abstract available


  1329. MULLER T, Wallace RM, Freuling CM
    Rabies importation in dogs and reduction of waiting period - The fear for scientifically justified changes.
    Vaccine. 2023 Oct 20:S0264-410X(23)01043-5. doi: 10.1016/j.vaccine.2023.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Vaccines is free of charge.